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  i 
ABSTRACT 
 
CTLA-4 is an important inhibitor of T cell immune responses. The location of CTLA-4 in intracellular 
vesicles is the most dominating aspect of its biology, yet the significance of this at the functional level 
remains to be completely understood. I have therefore investigated the role of the CTLA-4 cytoplasmic 
domain in the intracellular trafficking of the receptor with particular emphasis on sorting signals encoded 
within this domain. 
 
We found that CTLA-4 was located in punctate intracellular vesicles in transfected cells, activated T 
cells and in regulatory T cells. CTLA-4 internalisation from the cell surface was clathrin dependent and 
was driven by the YVKM motif encoded within the cytoplasmic domain. Post-internalisation CTLA-4 co-
localised with markers of late endosomes. Since the degradation process may serve as one of the 
mechanisms to regulate CTLA-4 expression we investigated this further and found that ubiquitination of 
intracellular lysine residues targets CTLA-4 to lysosomes. The ability of CTLA-4 to recycle was 
dependent on the YVKM motif and subtle changes in this motif reduced recycling efficiency. Moreover, 
in the absence of lysine residues CTLA-4 recycling was enhanced. CTLA-4 transendocytosis was 
conserved through evolution but the exact sorting signals required for this function remain to be 
identified. Overall this thesis emphasises the importance of the CTLA-4 cytoplasmic domain in 
regulating its intracellular trafficking. 
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1.0 INTRODUCTION 
 
1.1 Introduction to immune regulation 
The immune system is made up of a variety of effector cells and molecules that protect the body from 
infectious agents and the damage they cause, and from other harmful substances (Delves and Roitt, 
2000a; Murphy, 2008). The immune system fulfills four tasks to protect an individual against disease. 
The first task is immunological recognition. The key players to detect the infection are the white blood 
cells (WBCs) of the innate immune system, which provide an immediate response, and the lymphocytes 
of the adaptive immune system. The second task is to control the infection, and if at all possible 
eliminate it. This involves immune effector functions such as the complement system, antibodies (Abs), 
lymphocytes, and other WBCs. The third task is self-regulation. The immune response must be kept 
under control so as to prevent any damage to the body, as a failure to regulate contributes to conditions 
such as autoimmune disease and allergy (Murphy, 2008). The fourth task is to provide the individual 
with protection against disease caused by the same pathogen. The ability of the adaptive immune 
system to generate immunological memory allows an individual to make an immediate and stronger 
response after re-exposure to the same infectious agent (Murphy, 2008). In the following sections I will 
consider the major aspects of the adaptive immune system as it pertains to T cell regulation, which is 
the topic of this thesis. 
 
1.1.1 T lymphocyte development  
T lymphocytes, also known as T cells, develop from a common progenitor in the bone marrow and 
migrate through the blood to the thymus (Schwarz and Bhandoola, 2006). The thymus provides a 
 2 
specialised and organised microenvironment for mature T cell development (Gray et al., 2005). Most 
steps in T cell development take place in the thymic cortex, whereas the medulla mainly contains 
mature T cells. T cell receptors (TCR) are encoded by TCR genes assembled by somatic recombination 
(Murphy, 2008). The TCR is composed of two disulphide-linked polypeptide chains, an α-chain and a 
β-chain (figure 1.1) (Jones and Zhuang, 2007). At the CD4 and CD8 double-negative (DN) stage, TCR 
gene rearrangement gives rise to αβ or γδ progenitors. A small proportion of the αβ CD4 and CD8 
DN thymocytes expand to give a large number of CD4 and CD8 double positive (DP) thymocytes. Each 
of these thymocytes undergoes somatic recombination of the TCR genes generating a broad repertoire 
of distinct αβ TCRs with random specificity (Chien et al., 1984). DP cells undergo selection for their 
ability to recognise self-peptides in association with self-major histocompatibility complex (MHC) 
molecules. If successful, the cells are rescued from programmed cell death and mature into single 
positive (SP) CD4 or CD8 cells (Goodnow et al., 2005; Murphy, 2008).  
 
1.1.2 Antigen presentation to T cells 
T cells encounter and respond to antigen (Ag) in the peripheral lymphoid organs – the lymph nodes, 
spleen, and the mucosal lymphoid tissues. Lymphocyte recirculation through these tissues ensures 
contact with pathogen Ags. The TCR recognises Ag in the form of a processed foreign peptide bound to 
a self-MHC molecule on the surface of antigen-presenting cells (APCs) such as dendritic cells (DCs) 
(Inaba et al., 1983), B cells (Chen and Jensen, 2008) and macrophages (Davis et al., 1998). There are 
two different classes of MHC: MHC class I that activate CD8+ T cells, and MHC class II that activate 
CD4+ T cells. MHC class I molecules present peptides derived from proteins synthesised in the cell 
cytoplasm and display fragments of viral proteins. MHC class II molecules present peptides derived 
from phagocytosed proteins and display fragments of Ags engulfed by professional APCs such as DCs. 
 3 
  
 
 
 
 
 
 
 
 
Figure 1.1 The TCR/CD3/ζ complex. The TCR complex consists of the TCR-α and -β chains, ζ-
chain accessory molecule and the CD3 signal transduction complex. The α and β chain each contain 
two ITAM (immunoreceptor tyrosine-based activation motif) domains. The CD3 T cell co-receptor 
consists of four chains, a CD3γ chain, a CD3δ chain and two CD3ε chains. Taken from (de Felipe, 
2004). 
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1.1.3 Two signal model of T cell activation 
T cells require two signals for optimal activation (figure 1.2). Signal one is provided by the TCR binding 
to peptide-MHC complexes presented on the surface of APCs. Since the TCR has a short cytoplasmic 
domain it lacks the signalling motifs required to activate downstream signalling pathways, which 
ultimately lead to T cell activation (Delves and Roitt, 2000b). In order to achieve this, the TCR 
associates with the CD3 co-receptor (Clevers et al., 1988). This association leads to the activation of 
the transcription factors AP-1 (Baier-Bitterlich et al., 1996), Nuclear factor of activated T cells (NF-AT) 
(Shaw et al., 1988) and Nuclear factor Kappa B (NF-κB) (Schwartz, 1992). Importantly this results in the 
production of cytokines of which interleukin-2 (IL-2) is required to initiate and maintain T cell proliferation. 
Signal two is best known as the co-stimulatory signal. This signal is just as important as signal one, and 
is provided by the cell surface co-stimulatory CD28 receptor binding to CD80 or CD86 ligands on the 
surface of APCs. CD28 co-stimulation increases IL-2 production, leads to T cell proliferation and 
prevents cell apoptosis. The importance of CD28 co-stimulation is highlighted by the phenotype of 
CD28 knockout mice. Such mice have decreased sensitivity to antigen, reduced IL-2 production and are 
unable to maintain T cell proliferation (Shahinian et al., 1993). A different outcome however can result if 
the T cell only receives signal one in the absence of signal two. In such circumstances T cells become 
unresponsive (anergic) or can undergo apoptosis (Schwartz, 1996). The ligation of co-stimulatory 
receptors alone also fails to result in T cell activation since signal two is dependent on signal one.  
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Figure 1.2 The two signal model of T cell activation. (A) The TCR recognises Ag in the form of a 
peptide-MHC complex presented on the surface of APCs (signal 1). T cells require a second signal 
provided by co-stimulatory receptors (CoRs) and ligands (CoLs). Both signals are required for efficient T 
cell activation, proliferation, differentiation and cytokine production. (B) In the absence of co-stimulation, 
T cells become anergic or undergo apoptosis. (C) In the absence of TCR ligation T cells fail to respond.  
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1.1.4 Central tolerance 
The immune system must distinguish between self-reactive and non-reactive lymphocytes to generate a 
state of self-tolerance (Murphy, 2008; Xing and Hogquist, 2012). T cell tolerance is important, not only 
because T cells recognising self-Ag can cause enormous damage of healthy tissue, but T cell tolerance 
has an impact on B cell tolerance, as B cells require T cell help in Ab responses (Xing and Hogquist, 
2012). Thus, a failure or breakdown of T cell tolerance can result in autoimmune disease. T cell 
tolerance begins in the thymus once a T cell progenitor forms and expresses a TCR. This is referred to 
as “central tolerance’. Ultimately, the fate of the thymocyte is determined by the affinity of the TCR for 
self-peptide:self-MHC complexes. Thymocytes that do not recognise self-peptide:self-MHC complexes 
die by neglect, thymocytes with a weak affinity TCR undergo positive selection and those with a high 
affinity TCR undergo negative selection (Laufer, 2008; Murphy, 2008; Xing and Hogquist, 2012).  
 
1.1.5 Peripheral tolerance: Role of Regulatory T cells (Tregs) 
Since the thymus does not express all self-Ags required to eliminate self-reactive T cells, additional 
tolerance mechanisms exist in the periphery. This is referred to as “peripheral tolerance”. Anergy and 
deletion have long been recognised as the primary mechanisms used in the periphery to eliminate self-
reactive T and B cells. However evidence is now emerging that the thymic CD4+ CD25+ Tregs play an 
important role in maintaining self-tolerance. Tregs are characterised by the expression of CD4, CD25, 
the transcription factor Forkhead box P3 (FOXP3) and by the constitutive expression of cytotoxic T 
lymphocyte antigen-4 (CTLA-4). 
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Thymic Tregs encode TCRs that recognise self-peptides and studies suggest that recognition of self is 
central to their role in preventing other T cells from attacking self (Toda and Piccirillo, 2006). Such ideas 
stem from observations that autoimmunity can result if nude mice, which lack T cells, are given 
CD4+CD25- T cells without a CD25+ regulatory population (Sakaguchi et al., 2007). Moreover, a 
mutation in the Treg transcription factor FOXP3 causes the disease scurfy in mice. Such mice have 
pathology suggestive of poor CD4+ T cell regulation where CD4+ cells are over-proliferative and cause 
multi-organ infiltration again highlighting the central role Tregs play in preventing autoimmune disease. 
A similar phenotype is also seen in humans with Immunodysregulation, Polyendocrinopathy, and 
Enteropathy X-linked (IPEX) syndrome, a disease resulting from mutations in the FOXP3 gene. The 
importance of the CTLA-4 receptor in preventing autoimmune disease is illustrated in mice genetically 
deficient in CTLA-4. Such mice develop a lymphoproliferative disease, where T cells accumulate in 
peripheral lymphoid organs and the mice die 3-5 weeks after birth (Tivol et al., 1995; Waterhouse et al., 
1995). In humans, type 1 diabetes, Grave’s disease and celiac disease are a few of many autoimmune 
diseases associated with CTLA-4 deficiency (Ueda et al., 2003). 
 
1.1.5.1 Role of Immunosuppressive Cytokines 
The role of the immunosuppressive cytokines, IL-10 and transforming growth factor-β (TGF-β) in Treg-
mediated suppression in the periphery remains to be completely understood. The importance of IL-10 in 
Treg mediated suppression has been shown using inflammatory disease models, where severe 
combined immunodeficiency (SCID) mice developed inflammatory bowel disease after transfer of 
CD4+CD25−CD45RBhigh T cells. However the co-transfer of CD4+CD25+ or CD4+CD45RBlow T cells 
prevented disease development. Moreover when the mice were injected with a neutralising anti-IL-10 
receptor monoclonal Ab they developed inflammatory bowel disease (Annacker et al., 2003). In this 
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situation, IL-10 production by Tregs compensated for the lack of IL-10 production by the 
CD4+CD25−CD45RBhigh T cells in order to regulate immune homeostasis, an effect that was abolished 
by the anti-IL-10 receptor monoclonal Ab. 
 
Mice deficient in TGF-β1 develop T cell mediated autoimmune disease within a few weeks of birth (Li et 
al., 2006), similar to that observed in CTLA-4 knockout mice. Tregs produce copious amounts of both 
membrane-bound and soluble TGF-β. The importance of this cytokine in Treg mediated suppression 
has been demonstrated in human T cells where by blocking TGF-β suppression T cell proliferation was 
partially abrogated (Levings et al., 2002). However, data presented by other groups failed to 
demonstrate a role for TGF-β in Treg mediated suppression (Godfrey et al., 2005; Oberle et al., 2007), 
suggesting that a combination of suppression mechanisms may operate at one time, which could be 
influenced by factors such as the site of the immune response and the activation status of the Treg 
(Schmidt et al., 2012). 
 
1.2 The B7-1/B7-2-CD28/CTLA-4 pathway 
CD28 and CTLA-4 are glycoproteins that belong to the immunoglobulin superfamily (IgSF) (Sharpe and 
Freeman, 2002). Both are expressed on T cells and are important in shaping immune responses. CD28 
and CTLA-4 share 30% homology at the amino acid level and use a conserved MYPPPY motif located 
in the extracellular domain to interact with CD80 (B7-1) and CD86 (B7-2) expressed on the surface of 
APCs (Sharpe and Freeman, 2002, Peggs et al., 2008). However the two molecules differ in terms of 
their function. While CD28 is important in promoting T cell responses, CTLA-4 acts as an inhibitor 
(Carreno and Collins, 2002; Peggs et al., 2008; Sansom and Walker, 2006; Sharpe and Freeman, 2002).  
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CD28 and CTLA-4 expression on T cells is highly distinct (Malmstrom et al., 2005; Murphy, 2008). While 
CD28 is constitutively expressed on the plasma membrane of both naïve and activated T cells, (Gross 
et al., 1990), CTLA-4 expression is induced after TCR signaling (Lindsten et al., 1993). CTLA-4 
expression can be detected after 6hours of TCR engagement and levels peak around 36hours. 
Moreover, both CD28 and IL-2 can further upregulate CTLA-4 levels. Staining for CTLA-4 expression 
reveals that it is predominantly located in intracellular vesicles and it is trafficked from these 
compartments to the cell surface upon TCR activation. As such, CTLA-4 expression at the cell surface 
appears to be dependent on the strength of the TCR signal as opposed to resulting from new protein 
synthesis. This situation provides the best mechanism to balance both stimulatory and inhibitory signals, 
where although CD28 binding to ligand stimulates T cell activation, once activated the T cells upregulate 
CTLA-4, which acts to inhibit T cell activation.  
 
1.2.1 Other B7 and CD28 family co-stimulatory systems 
Although the B7-1/B7-2-CD28/CTLA-4 represents the best and most recognised co-stimulatory pathway 
new members of the B7-CD28 family have been discovered. These include the CD28 family members 
ICOS (inducible T cell co-stimulator), PD-1 (programmed death-1) and B and T lymphocyte attenuator 
(BTLA) that interact with their respective B7 ligands ICOS-L (B7-H2), PD-L1 (B7-H1), PD-L2 (B7-DC), 
B7-H3 and B7-H4 (Carreno et al., 2005). The receptors have been found on leukocytes whilst both 
hematopoietic and non-hematopoietic cells express the ligands. Studies in knockout mice have been 
key in identifying whether these receptor-ligand pairs regulate T cell activation and whether they have a 
stimulatory or inhibitory effect. In the absence of these molecules, mice develop autoimmune disease or 
an immunosuppressive disorder. The importance of these receptor-ligand pairs on the basis of their 
function and requirement is ongoing but there are differences between their expression patterns when 
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compared to the B7-1/B7-2-CD28/CTLA-4 (Carreno et al., 2005). For instance ICOS is upregulated 
rapidly after T cell activation suggesting that co-stimulation is provided to activated T cells and not to 
naïve T cells. Thus, these differences may allow for finer tuning of T cell activation.  
 
1.2.2 Interactions between CD28, CTLA-4 and their ligands 
CD28 and CTLA-4 are homodimers; however whereas CD28 has a single ligand-binding site, CTLA-4 
has two. Crystallisation studies of CTLA-4 reveal that the ligand-binding site is distal to the 
homodimerisation domain of CTLA-4 and CD80/CD86 (Alegre et al., 2001; Schwartz et al., 2001; 
Stamper et al., 2001). The binding of a CTLA-4 dimer to a CD80 or CD86 dimer creates a stable zipper-
like structure (Schwartz et al., 2001; Stamper et al., 2001). Structural studies suggest that CD80 is a 
homodimer whereas CD86 is monomeric (Collins et al., 2002; Sansom and Walker, 2006). This 
complexity supports a model where the different receptor-ligand interactions may generate a difference 
in the balance of co-stimulatory and inhibitory actions (Sansom and Walker, 2006). So although CD80 is 
a potent co-stimulator of CD28, the increased affinity of CTLA-4 for CD80 suppresses its stimulatory 
capacity; while CD86 is a poor CD28 co-stimulator, the decreased affinity of CTLA-4 for CD86 only 
weakly impairs its co-stimulatory capacity. Therefore, in situations where CTLA-4 is present, CD86 may 
function as a better co-stimulator than CD80 (Sansom and Walker, 2006). 
 
The view that CD80 and CD86 have overlapping functions (Borriello et al., 1997; McAdam et al., 1998) 
has been challenged in recent years using mice deficient in either CD80 or CD86, with suggestions that 
both molecules differ in affinity, valency and in the structural organisation of receptor-ligand interactions 
(Collins et al., 2002; Ikemizu et al., 2000). Compared to CD28, CTLA-4 has a 20- to 100-fold higher 
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affinity for CD80 and CD86 (Collins et al., 2002; Sansom and Walker, 2006); yet both receptors have a 
higher affinity for CD80 compared to CD86 (figure 1.3) (Borriello et al., 1997). The significance of this 
finding is not known but may have implications at the functional level. The 10-fold higher affinity of CD28 
for CD80 could imply this interaction makes CD80 a more effective co-stimulator of CD28 function.  
 
1.2.3 Blocking CD28-B7 pathway: CTLA-4 Ig 
For the treatment of autoimmune disease, it has long been anticipated that by blocking the CD28-B7 
pathway T cells that respond to self-Ags could be selectively targeted without affecting resting T cells. 
The fact that CTLA-4 has a higher affinity for both CD80 and CD86 has allowed investigators to take 
advantage of this mechanism and block CD28 signalling. To this end, the fusion protein CTLA-4 Ig, 
which consists of the CTLA-4 extracellular domain fused to the constant region of IgG (immunoglobulin 
G), was developed and ultimately this fusion protein blocks CD28-B7 interactions (Linsley et al., 1991). 
In mice CTLA-4 Ig has been shown to facilitate organ transplantation, block T cell responses and inhibit 
the differentiation of B cells into plasma cells (Lenschow et al., 1992; Lin et al., 1993; Milich et al., 1994). 
Moreover in models of autoimmune disease, treatment with CTLA-4 Ig has been shown to prevent the 
production of autoantibodies and to reduce the severity of lupus nephritis.  
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Figure 1.3 Interactions between co-stimulatory receptors and their ligands. CD28, CTLA-4 and 
CD80 are dimers, whilst CD86 is a monomer. Both receptors interact with both ligands and so four 
interactions are possible. The interactions vary according to affinity. Interactions between CD28 and 
either CD80 or CD86 are weaker than those for CTLA-4 and either ligand. The monovalent solution 
dissociation constant (Kd) for each interaction, as reported by Collins et al., (2002), is shown.  
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With the encouraging results from animal models of autoimmune disease, attention has now been 
directed at using CTLA-4 Ig for treating patients with autoimmune disease. The drug Abatacept consists 
of the CTLA-4 extracellular domain and the Fc fragment of human IgG1 (Davis et al., 2007). The drug 
has been shown to improve the signs and symptoms of rheumatoid arthritis (RA) at different stages of 
disease ranging from early stage RA to refractory disease (Genovese et al., 2005; Kremer et al., 2005). 
Moreover Abatacept has been used successfully in the treatment of patients with juvenile idiopathic 
arthritis and in patients with systemic lupus erythematosus (Merrill et al., 2010; Ruperto et al., 2008). 
Another human CTLA-4 Ig in phaseI/II clinical trials is Belatacept (LEA29Y). Although a difference of 
two amino acids distinguishes Belatacept from Abatacept, this difference allows Belatacept to bind B7 
molecules with a higher avidity (Larsen et al., 2005). As such Belatacept has a greater inhibitory effect 
on T cell activation. The preliminary efficacy of Belatacept in RA treatment has been shown in phaseI/II 
clinical trials (Watanabe and Nakajima, 2012).  
 
1.3 CTLA-4 function 
The concept of CTLA-4 actively inhibiting T cell activation is widely accepted. However, the 
mechanisms and circumstances under which CTLA-4 inhibition becomes dominant remain to be 
identified. CTLA-4 function has long been defined as the delivery of an inhibitory signal into cells. 
However, a number of studies now dispute the existence of this model and have proposed alternative 
models of CTLA-4 function that could have cell-intrinsic or cell-extrinsic effects on T cells. Walker & 
Sansom (2011) have reviewed these proposed functions and it is now becoming clear that in fact CTLA-
4 exerts its effects through other cells (cell-extrinsic) (Walker and Sansom, 2011).  
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1.3.1 Ligand Competition 
The preferential affinity of CD80 and CD86 for CTLA-4 compared with CD28 provides the basis for the 
first model of ligand competition (figure 1.4A). It can be argued that in situations where ligand 
expression is limited and CTLA-4 is highly expressed, the ligands will preferentially bind to CTLA-4 
(Sansom and Walker, 2006). The lack of CD28 signalling results in depriving T cells of essential co-
stimulatory signals and results in decreased responses. Moreover, the administration of CTLA-4 Ig 
blocks T cell activation and furthermore transgenic mice with high surface CTLA-4 expression do not 
respond to Ag stimulation (Saito and Yamasaki, 2003). Taken together, these results support the 
concept that high surface CTLA-4 expression may outcompete CD28 to bind ligands. However, this 
could be due to increased negative signalling by CTLA-4 but further support for the ligand competition 
model comes from transgenic CTLA-4 knockout mice that express CTLA-4 without a cytoplasmic tail 
(Masteller et al., 2000). Although these mice were long lived and did not encounter multi-organ 
infiltration, they accumulated large numbers of activated T cells, and eventually suffered from 
lymphadenopathy. These results suggest that ligand competition could contribute to the inhibitory 
effects of CTLA-4, and the cytoplasmic domain may also confer inhibitory function. 
 
1.3.2 Inhibitory signalling 
The second model of CTLA-4 function suggests that CTLA-4 delivers a cell-intrinsic negative signal, 
acting either at the level of the TCR or by directly antagonising CD28 signalling (figure 1.4B). This 
possibility is supported by several studies in which Abs to CTLA-4 inhibit IL-2 production and T cell 
proliferation (Krummel and Allison, 1995; Walunas et al., 1996). A number of signalling models have 
been proposed that account for the inhibitory actions of CTLA-4. Amongst these include the recruitment 
of phosphatases to the TCR, and the reduction of lipid raft formation. Studies have also shown that 
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CTLA-4 has the potential to remove TCR signalling components, such as TCRξ, from lipid rafts, while 
other studies propose that CTLA-4 acts to reduce ZAP70 (Zeta-chain associated protein kinase 70) 
microcluster formation thereby reducing the phosphorylation of TCR substrates (Chikuma et al., 2003; 
Darlington et al., 2002; Martin et al., 2001).  
 
The observation that negative signalling by CTLA-4 can occur in the absence of ligand binding has 
raised the possibility that this level of signalling might be a constitutive event regulated by CTLA-4 
expression levels and not by a ligand-generated signal (Chikuma et al., 2005). However, the functional 
events that occur in the absence of the cytoplasmic domain do not appear to be explained by this 
negative signalling model. Moreover CTLA-4 mediated inhibition of T cell proliferation during primary T 
cell responses has been consistently difficult to demonstrate, particularly using natural ligands 
(Chambers et al., 1998). 
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Figure 1.4 Cell-intrinsic models of CTLA-4 function. (A) Representation of the ligand competition 
model. CTLA-4 has a higher affinity for both CD80 and CD86 and so can outcompete CD28 for binding 
the ligands. (B) Representation of the model where CTLA-4 delivers an inhibitory signal. CTLA-4 can 
impair lipid raft formation following its co-ligation with the TCR and can therefore raise the threshold for 
TCR signalling. Additionally, CTLA-4 could impair TCR signalling by reducing ZAP70 microcluster 
formation. Taken from (Walker and Sansom, 2011). 
A B 
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1.3.3 Indoleamine 2,3-dioxygenase (IDO) and tryptophan metabolism 
A third model of CTLA-4 function has been the suggested ability of CTLA-4 to induce the expression of 
the enzyme IDO on DCs by initiating a reverse signal. In this model CTLA-4 functions in a cell-extrinsic 
manner and indirectly inhibits T cell activation (figure 1.5A) (Gough et al., 2005; Munn et al., 1999). IDO 
is the rate-limiting enzyme that catalyses the breakdown of the essential amino acid tryptophan required 
for T cell proliferation. In doing so, IDO suppresses T cell mediated immunity.  
 
Numerous studies have now indicated that the immune tolerance resulting from the interaction between 
co-stimulatory ligands on DCs and CTLA-4 on T cells is mediated by IDO (Grohmann et al., 2002; 
Mellor et al., 2004; Munn et al., 2004). CTLA-4 is an important receptor expressed on Tregs and IDO 
has been identified to have an important downstream effector role in CTLA-4-mediated immune 
tolerance (Boasso et al., 2005). In fact IDO induction was suggested to be a potential function of CTLA-
4 Ig, where CTLA-4 Ig stimulates the upregulation of IDO activity in APCs as opposed to acting as a 
blockade of CD80 and CD86 function (Orabona et al., 2005). Support for this idea was provided in a 
study where the IDO inhibitor 1-methyltryptophan (1MT) prevented the long-term survival of pancreatic 
islet allografts that was induced by CTLA-4 Ig (Grohmann et al., 2002). Likewise Tregs, which 
constitutively express CTLA-4, have been shown to upregulate the activity of IDO in DCs via a CTLA-4-
dependent mechanism (Oderup et al., 2006). However if IDO induction is the primary function of CTLA-
4, why does the phenotype of IDO deficient mice differ from the phenotype of CTLA-4 deficient mice? 
Since CTLA-4 plays an important role in regulating peripheral T cell tolerance, CTLA-4 knockout mice 
die within a couple of weeks of birth from fatal lymphoproliferation (Waterhouse et al., 1995), yet IDO-
knockout mice have not been observed to show signs of spontaneous autoimmune disease (Mellor and 
Munn, 2004). These observations therefore suggest that IDO is not an absolute requirement for 
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homeostatic maintenance of central or peripheral tolerance to self-Ags. Furthermore, CD80 or CD86 
Abs are reported to drive IDO production so a further question that remains to be answered is how the 
DC integrates the opposing signal from CTLA-4 Ig? 
 
1.3.4 Regulatory T cells 
A further proposed model of CTLA-4 function is for CTLA-4 to inhibit T cell activation through Tregs. In 
mice and humans, Tregs constitute 2-10% of peripheral CD4+ T cells (Sakaguchi, 2000). The 
importance of CTLA-4 in Tregs has been demonstrated in studies where CTLA-4 blockade inhibits the 
regulatory function of Tregs. Moreover, Bachmann et al., (1999) demonstrated the ability of CTLA-4 
expressing cells to regulate disease caused by CTLA-4 negative cells by generating chimeric animals, 
which were reconstituted with bone marrow from CTLA-4 knockout and CTLA-4 wild-type (WT) mice 
(Bachmann et al., 1999). Cross-linking CTLA-4 with Abs has been shown to drive the production of the 
inhibitory cytokine TGF-β in CD4+ T cells. This results in an inhibition of T cell proliferation and IL-2 
production. In doing so, the TGF-β production by the CTLA-4 positive cell compensates for the lack of 
TGF-β production by the CTLA-4 negative cell and therefore prevents disease development (figure 
1.5B) (Chen et al., 1998). Moreover, adoptive transfer experiments have revealed that WT cells are less 
responsive to antigenic stimulation than CTLA-4 deficient cells, thus demonstrating a cell-autonomous 
mechanism of CTLA-4 inhibition (Egen et al., 2002). These experiments reveal the ability of CTLA-4 to 
regulate not only the cell in which it is expressed on, but also to regulate bystander cells.      
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Figure 1.5 Cell-extrinsic models of CTLA-4 function. (A) CTLA-4 induces the production of IDO, the 
tryptophan metabolising enzyme, by APCs. IDO catalyses the breakdown of tryptophan, an essential 
amino acid required for T cell proliferation. (B) CTLA-4 in Tregs stimulates the production of the 
inhibitory cytokine TGF-β, which acts to inhibit T cell proliferation and IL-2 production. Taken from 
(Walker and Sansom, 2011). 
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1.3.5 Transendocytosis 
Treg suppression in vitro can proceed in the absence of accessory cells. However, in vivo Treg 
suppression operates via an APC. In lymph nodes, it has been shown that a Treg can alter the ability of 
a DC bound to Ag to form stable contacts with T cells (Tadokoro et al., 2006; Tang et al., 2006). 
Furthermore, Tregs have been demonstrated to impair the stimulatory capacity of human DCs in vitro 
(Misra et al., 2004). This raises the possibility for the existence of a model where the expression of 
CTLA-4 by Tregs can function to modify APCs. In both mouse and human systems, there is evidence 
for Tregs to downregulate CD80 and CD86, to inhibit the upregulation of ligand during APC maturation, 
and to downregulate ligands on mature DCs (Onishi et al., 2008; Wing et al., 2008).  
 
Our lab has now identified a further model of CTLA-4 function where CTLA-4 in activated T cells and in 
Tregs, alters APC phenotype by removing ligand from the APC and thus suppresses T cell responses 
(figure 1.6) (Qureshi et al., 2011). This phenomenon is called transendocytosis. In this case, CTLA-4 
traffics to the plasma membrane, and binds and rips it ligand from the surface of the APC. CTLA-4 then 
internalises the ligand and targets it for degradation in lysosomes. Such a model clears up some 
unexplained features of the CD28/CTLA-4 system. Firstly, this model could explain why CD28 and 
CTLA-4 share ligands, as without this CD28 stimulation cannot be inhibited by CTLA-4. Secondly, this 
model requires CTLA-4 to be internalised from the plasma membrane, which currently is seen as the 
most dominating aspect of CTLA-4 biology.  
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Figure 1.6 CTLA-4 captures ligands and alters APC phenotype. CTLA-4 binds its ligand and 
internalises the entire molecule from the surface of the APC. This reduces the amount of ligand 
available to bind CD28 and therefore CTLA-4 inhibits T cell activation in a cell-extrinsic manner. Taken 
from (Walker and Sansom, 2011).  
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1.4 The evolutionary biology of CTLA-4 
The genetic and molecular similarities between CD28 and CTLA-4 suggest the evolution of CTLA-4 is a 
duplication event of an ancient co-stimulatory gene (Bernard et al., 2007; Teft et al., 2006). Interestingly 
the CD28 and CTLA-4 receptor have been reported in fish, amphibians and birds. The conservation of 
the ligand-binding site (L/MYPPPY) in the CTLA-4 extracellular domain suggests the CTLA-4 ligand 
competition model dates back to teleost fish. The amino acid sequence of CTLA-4 in mammalian 
species shows an increasing degree of conservation from the extracellular domain to the cytoplasmic 
domain. In fact the 100% conservation in the mammalian CTLA-4 cytoplasmic domain suggests there is 
a selective pressure to conserve the functional mechanisms mediated through this region (Teft et al., 
2006). This is also true for the conserved cysteine residue located in the extracellular domain required 
for CTLA-4 dimerisation. The cysteine residue forms a covalent bond between individual CTLA-4 chains 
(Teft et al., 2006).  
 
The CTLA-4 cytoplasmic domain varies considerably in non-mammals (figure 1.7). As a lab we have 
shown that the specialised intracellular trafficking itinerary of CTLA-4 is key for its ability to remove 
ligand from APCs and to target the ligand for degradation in lysosomes (Qureshi et al., 2011). This 
raises questions as to whether this feature of CTLA-4 has developed through evolution. Importantly, the 
YVKM motif required for CTLA-4 internalisation is absent in fish. However trout CTLA-4 does encode 
YxxF motif further downstream the cytoplasmic domain, which is also found in several fish species 
including salmon (Bernard et al., 2007; Walker and Sansom, 2011). Although the significance of this 
motif in fish CTLA-4 remains to be identified, this motif could represent the initial emergence of CTLA-4 
endocytosis. 
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Figure 1.7 Evolution of CTLA-4 molecules. The CTLA-4 cytoplasmic domain is conserved amongst 
mammalian species suggesting there is selective pressure to maintain this region. Importantly the 
YVKM motif required for internalisation (red) is not evident until after birds. Trout CTLA-4 lacks this 
conserved endocytic motif but does possess a YxxF motif (green) the significance of which remains to 
be determined. Adapted from (Bernard et al., 2007). 
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1.5 Receptor Protein Trafficking 
1.5.1 Endocytic Pathways 
There are different types of endocytic pathways, which vary according to the size of the endocytic 
vesicle, the mechanism of vesicle formation and the nature of the cargo (Conner and Schmid, 2003; 
Wing et al., 2008). Endocytosis is divided into two categories: phagocytosis and pinocytosis. 
Phagocytosis takes place in specialised mammalian cells. Pinocytosis, however, takes place in all cells 
by four basic mechanisms: macropinocytosis, clathrin-mediated endocytosis, caveolae-mediated 
endocytosis, and clathrin- and caveolae-independent endocytosis (Conner and Schmid, 2003). 
 
1.5.2 Phagocytosis 
Phagocytosis is an active and regulated process. In mammals phagocytosis takes place in specialised 
cells such as neutrophils, macrophages and monocytes (Aderem and Underhill, 1999). The main 
function of this process is to clear cell debris, apoptotic cells and microorganisms and involves cell 
surface receptors and signalling cascades (Doherty and McMahon, 2009; Nichols and Lippincott-
Schwartz, 2001). For example, in macrophages Abs bound to surface Ags are recognised by the 
surface Fc receptor. This activates a signalling cascade, which in turn activates cell division cycle 42 
(CDC42) and Rac. This process triggers the assembly of actin and cell surface extensions (Hall and 
Nobes, 2000). These extensions then facilitate the engulfment of the Ab-coated pathogen into a 
phagosome. The bacteria are then destroyed once the cell’s inflammatory responses are activated and 
finally an immune response is elicited once the regurgitated bacterial peptides are presented on the 
macrophage surface.  
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1.5.3 Macropinocytosis 
Pinocytosis involves the internalisation of large volumes of extracellular fluid. The efficiency of 
endocytosis is often greater when solutes bind non-specifically to the cell membrane. In certain cells, 
growth factor stimulation or other types of stimulation induces membrane ruffling, which is accompanied 
by macropinocytosis (Swanson and Watts, 1995). Similar to phagocytosis the Rho-family GTPases are 
activated by signalling cascades, which triggers actin assembly and membrane protrusions. However, 
unlike phagocytosis the protrusions fuse with the plasma membrane and generate large endocytic 
vesicles called macropinosomes, which move into the cytosol (Doherty and McMahon, 2009; Nichols 
and Lippincott-Schwartz, 2001). 
 
1.5.4 Caveolin-mediated endocytosis 
Caveolae is one of the most common clathrin-independent pathways studied (Le Roy and Wrana, 2005). 
They are small flask-shaped invaginations and their appearance, function and composition are cell-type 
dependent. For long, caveolae have been suggested to be involved in internalisation and cell signalling 
(Pelkmans and Helenius, 2002). The internalisation of caveolae is triggered by a signalling cascade, 
which results in the tyrosine phosphorylation of caveolae constituents by Src kinases (Li et al., 1996). 
The process seems to require dynamin and actin rearrangement, since the overexpression of dominant-
negative dynamin or the disruption of actin assembly can block caveolin-mediated endocytosis 
(Pelkmans and Helenius, 2002). Recent studies have shown that caveolae are important in the 
internalisation of non-enveloped viruses such as Simian virus 40, bacterial toxins such as cholera toxin, 
extracellular ligands such as albumin, and membrane components such as glycosphingolipids 
(Pelkmans and Helenius, 2002; van der Aa et al., 2007). 
 
 26 
1.5.5 Clathrin- and caveolin-independent endocytosis 
A number of lipids, toxins, viruses and proteins can be internalised into cells via non-clathrin mediated 
pathways (Sandvig and van Deurs, 2002). Lipid rafts, like caveolae, are cholesterol-rich microdomains 
that diffuse freely on the cell surface (Anderson and Jacobson, 2002; Edidin, 2001). Whilst dynamin is 
not an absolute requirement for this pathway, cholesterol plays a crucial role in cargo internalisation. For 
example glycophosphatidylinositol (GPI)-anchored proteins are internalised by a raft-dependent 
pinocytic route, which is dynamin-independent but dependent on CDC42 (Mayor and Pagano, 2007; 
Sabharanjak et al., 2002). By contrast on lymphocytes the IL-2 receptor, which is associated with lipid 
microdomains, is internalised in a clathrin- and caveolin-independent way (Lamaze et al., 2001). While 
dominant-negative dynamin mutants inhibit the internalisation of IL-2 receptors, dominant-negative 
mutants of Epidermal growth factor receptor substrate 15 (Eps15), which is an AP-2 binding partner and 
inhibits clathrin-mediated endocytosis, fails to inhibit IL-2 receptor internalisation. How clathrin- and 
caveolae-independent endocytosis is regulated is not clear. Nevertheless, the existence of such 
pathways could suggest they mediate unique functions in the cell, which vary according to which cargo 
is being transported, where it is being transported to and how entry into these compartments is 
regulated. For example tetanus toxins, which are internalised via the clathrin pathway, require 
cholesterol-dependent clustering to facilitate their internalisation by clathrin (Deinhardt et al., 2006). 
 
1.5.6 Clathrin-mediated endocytosis 
In mammalians cells, clathrin-mediated endocytosis is the major mechanism used to regulate cell 
surface traffic (Brodsky et al., 2001; Kibbey et al., 1998). A number of receptors including transferrin 
receptor (TfR), epidermal growth factor receptor (EGFR) and low-density lipoprotein (LDL) use clathrin-
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mediated endocytosis to internalise ligand (Clague and Hammond, 2006). Receptors become 
concentrated in clathrin-coated pits, which bind to the clathrin adaptor protein 2 (AP-2) directly or 
indirectly via sorting motifs encoded in the cytoplasmic domain of the receptor (figure 1.8). Clathrin is 
then recruited to the plasma membrane by binding to AP-2 (Kirchhausen et al., 1997). When many 
clathrin triskelions interact at the membrane they form a polyhedral lattice, which pulls the membrane 
into a bud. Changes in membrane curvature, resulting from localised changes in phospholipid 
composition, facilitate this membrane invagination. A protein that is thought to play an important role in 
altering the membrane curvature is Endophylin (Verstreken et al., 2002). The completion of the inward 
budding of the membrane is then followed by fission of the forming vesicle resulting from the 
interactions between AP-2 and the GTPase dynamin (Wang et al., 1995).  
 
Following on from the invagination and pinching off of the coated pits, the vesicles are released into the 
cytoplasm, and deliver their cargo to a tubovesicular compartment known as the early or sorting 
endosome (Sorkin, 2000). From here the receptors can either be recycled back to the plasma 
membrane or they can be targeted for lysosomal degradation. Vesicles containing receptors destined 
for lysosomes bud from the limiting membrane into the lumen of multivesicular bodies (MVBs) (Madshus 
and Stang, 2009), whilst the recycling components are removed in recycling vesicles, and are sorted 
from lysosomally targeted components. Thus, the number of receptors at the cell surface is a balance 
between the rate of internalisation and the rate of replacement (recycling and new synthesis) (Goh and 
Sorkin, 2013).  
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Figure 1.8 Clathrin-mediated endocytosis. Proteins that internalise by the clathrin (orange) and 
dynamin (pink circle) pathway are sorted in early endosomes. Rab5 is the marker for early endosomes. 
The conversion of Rab5 and Rab7 marks the point when early endosomes are converted into late 
endosomes. In most cases, there is an intermediate organelle that mediates cargo transfer called MVBs. 
Fusion of MVBs with the plasma membrane allows protein and lipids, which are sorted in the 
intraluminal vesicles (blue circles) of MVBs, to be released into the extracellular space as exosomes. 
Proteins targeted for degradation are sorted from late endosomes to lysosomes. Rab4 mediates 
recycling of proteins and lipids directly from early endosomes to the plasma membrane. Other proteins 
are recycled to the plasma membrane via recycling endosomes mediated by Rab11. Rab9 is associated 
with the transfer of cargo from late endosomes to the Golgi complex. Intracellular organelles can also be 
distinguished by Phosphoinositide phosphates such as phosphatidylinositol-4,5-bisphosphate 
(PtdIns(3,5)P2) and phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3) (coloured arcs on 
endosomes). Taken from (Rajendran et al., 2010).  
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1.5.6.1 Clathrin and AP Complexes 
Clathrin and AP complexes are the two fundamental building blocks of the clathrin coat. The clathrin 
protein was first discovered in 1975 (Pearse, 1976) and forms a triskelion shape, which is composed of 
three heavy chains and three light chains. The AP complex family in mammals has six members 
(Robinson, 2004), however, two of these members, AP-5 and AP-6, have only been recently identified 
(Hirst et al., 2011; Ohno, 2006b). AP-1 and AP-2 were the first two complexes to be discovered and 
these complexes are important in the sorting of cargo into clathrin-coated vesicles (CCVs) (Robinson, 
2004). AP-3 and AP-4 on the other hand can function in the absence of clathrin (Boehm and Bonifacino, 
2001). The AP complexes are heterotetramers that consist of two large subunits and two small subunits, 
for AP-1 γ, β1, μ1 and σ1; for AP-2 α, β2, μ2 and σ2; for AP-3 δ, β3, μ3 and σ3 and for AP-4 ε, β4, 
μ4 and σ4 (Owen et al., 2004).  
 
The AP complexes have specialised functions in distinct transport pathways. AP-1 is important in 
trafficking cargo between early endosomes, the trans-Golgi network (TGN) and the plasma membrane. 
However the direction of transport remains to be determined (Owen et al., 2004; Traub, 2005). AP-2 is 
important in clathrin-dependent endocytosis where it facilitates CCV formation from the plasma 
membrane, which eventually fuse with early endosomes (Owen et al., 2004; Traub, 2005). AP-3 is 
important in trafficking cargo from early endosomes to late endosomes and/or lysosomes (Owen et al., 
2004). AP-4 is important in the delivery of lysosomal proteins from the TGN to lysosomes (Ohno, 
2006a) and has recently been identified to have a role in the transport of the amyloid precursor protein 
from the TGN to endosomes (Burgos et al., 2010).  
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1.5.7 Sequences of Receptor Internalisation 
1.5.7.1 YXXΦ motif  
A number of short-linear sequences important for clathrin-dependent internalisation have been identified 
using models where critical amino acid residues important for internalisation have been deleted or 
substituted in the cytoplasmic domain of the receptor (Kozik et al., 2010; Pandey, 2009). The first and 
most common internalisation signal is the bulky tyrosine-based hydrophobic YXXΦ motif (Kozik et al., 
2010; Le Roy and Wrana, 2005; Traub, 2003). This motif contains the critical tyrosine residue that binds 
directly to µ2 subunit in AP-2 and drives clathrin-dependent endocytosis. The use of the tyrosine-based 
motif is not restricted to internalisation and in fact roles have been identified in other sorting events such 
as targeting of receptors from the endosome to lysosomes (Pandey, 2009). Further studies have 
revealed that the location of the tyrosine residue in the cytoplasmic domain of receptors is critical to the 
movement of the receptor into coated pits (Lazarovits and Roth, 1988). For example the influenza virus 
hemagglutinin does not move into coated pits but when a key cysteine residue was substituted to 
tyrosine, the receptor moved into coated pits (Lazarovits and Roth, 1988). Importantly the distance of 
the tyrosine residue from the transmembrane domain was a key factor in this movement.  
 
1.5.7.2 Dileucine motif  
The second internalisation signal is the dileucine motif DxxxLL that interacts with the β1 subunit of AP-1 
(Owen and Evans, 1998). Dileucine based motifs were discovered using chimeras of Tac antigen and 
the cytoplasmic domain of CD3-γ and δ (Letourneur and Klausner, 1992). The study revealed that both 
CD3 chains contained a dileucine motif that was responsible for internalisation. Moreover the dileucine 
motif played an important role in the lysosomal targeting of the chimeras. Both tyrosine-based and 
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dileucine based signals have been implicated in the internalisation of a variety of receptors including 
neurotransmitter receptors such as N-methyl-D-aspartate (NMDA) receptors, GPCRs (G-protein 
coupled receptors), TfR and EGFR. Importantly, there is no preference as to which motif is used to drive 
receptor internalisation. For example whilst the subunit NR2B requires YXXΦ motif for internalisation, 
NR2A shows some dependency on a dileucine based signal for internalisation and can internalise in the 
absence of YXXΦ motif (Lavezzari et al., 2004).  
 
1.5.7.3 FXNPXY motif 
The third internalisation signal is the FXNPXY motif that interacts with the phosphotyrosine-binding 
domains of the ‘alternative adaptors’ such as ARH, Dab1, Dab2 and Numb (Kozik et al., 2010). In fact a 
NPXY motif has been identified to be important in driving the rapid internalisation of the LDL receptor. 
By generating a range of truncated LDL receptor mutants, Chen et al., 1990 demonstrated that LDL 
receptor internalisation is markedly reduced when N, P or Y are substituted to alanine and this reduces 
the clustering of the receptor into coated pits (Chen et al., 1990). The occurrence of this motif in tyrosine 
kinase-linked receptors such as EGFR and insulin receptor family is far more frequent than to be 
present by chance alone suggesting it has some underlying importance. However in the case of EGFR, 
a role for this motif in ligand-dependent internalisation has been ruled out by deletion experiments 
(Glenney et al., 1988), but a role in ligand-independent internalisation may be possible (Chen et al., 
1990).  
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1.5.8 Endosomal sorting of receptors 
There are three types of endosomes: early endosomes, late endosomes and recycling endosomes 
(Mellman, 1996). Each endosome is specialised to perform distinct functions and markers such as Rabs 
can distinguish them (Stenmark, 2009). Cargo internalised from the cell surface first reaches early 
endosomes. Early endosomes are sorting organelles that are located in the periphery of the cell and 
consist of a tubular-vesicular network (Huotari and Helenius, 2011). The mildly acidic pH of the lumen 
facilitates ligand dissociation from receptors as is well described for EGFR and TfR. This process then 
enables the receptor to recycle back to the cell surface via tubules or the receptor can be targeted for 
degradation (Mellman, 1996; Mukherjee et al., 1997). Markers that distinguish early endosomes are 
EEA1 (Early Endosome Antigen 1), transferrin and TfR, Rab5A and Rab4. Late endosomes are 
spherical and consist of luminal vesicles but can be distinguished by the lack of tubules. They are acidic 
(pH 5.5) and receive material prior to degradation in lysosomes (Huotari and Helenius, 2011). This 
includes material from the TGN in the biosynthetic pathway and internalised material from early 
endosomes in the endocytic pathway. Markers including LAMP1 (Lysosomal associated membrane 
protein 1), Rab7, Rab9 and mannose-6-phosphate receptor are used to distinguish late endosomes 
from early endosomes (Russell et al., 2006). Recycling endosomes consist of a tubular network and are 
concentrated mainly at the microtubule organising centre (MTOC). Rab11 is the main marker of 
recycling endosomes (Ullrich et al., 1996). The final compartment of the endocytic pathway is the 
lysosomes. The primary function of lysosomes is to break down cellular waste into simple compounds 
that can be used as new cell-building material once the compounds are returned to the cytoplasm 
(Luzio et al., 2000). Lysosomes consist of large vacuoles that contain electron dense material. 
Lysosomes are acidic (pH 4.8) and contain active lysosomal hydrolases and lysosomal membrane 
proteins (Gruenberg and Maxfield, 1995; Luzio et al., 2000). The lack of mannose 6-phosphate receptor 
distinguishes lysosomes from late endosomes.  
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1.5.9 Degradation of trafficking receptors 
Cell surface proteins have different rates of degradation, ranging from minutes to days, but any changes 
in their stability can form the underlying basis for certain forms of cancer and disease (Hare and Taylor, 
1991; Vendruscolo et al., 2003). Different reasons could account for why certain receptors are degraded 
more rapidly than others (Cooper, 2000). Most regulatory proteins such as transcription factors are 
degraded rapidly so as to allow their levels to change rapidly in response to external factors. Other 
proteins however are degraded rapidly in response to specific signals or if the protein is damaged, thus 
providing an additional regulatory mechanism of intracellular enzyme activity (Cooper, 2000). For many 
signalling receptors lysosomal targeting is used as a mechanism to downregulate the receptor and 
switch off the signal (Sorkin and von Zastrow, 2009). 
 
Cell surface expressed proteins, in most cases, must internalise to undergo degradation since their 
proteolysis is dependent on trafficking through endosomes and lysosomes (Cooper, 2000). The 
receptors most often encode sorting motifs, which facilitate their transport to lysosomal compartments 
(Sorkin and von Zastrow, 2009). The susceptibility for their selective removal from the membrane 
results from a structural feature of the protein that controls its protease sensitivity, diffusion rate or some 
other physical characteristic (Hare and Taylor, 1991). A recycling protein, on the other hand, is either 
degraded more frequently, or since a greater proportion of their life span is spent inside the cell, they 
show a greater likelihood to interact with lysosomes or intracellular proteolytic enzymes (Hare and 
Taylor, 1991). Support for the latter is provided in studies using surface-labeling methodologies. These 
reveal that a protein recycling frequently between the cell surface and endosomes has a rapid 
degradation rate (t½ 2-20h), when compared to other surface glycoproteins (t½ >50) (Baumann and 
Doyle, 1978; Chu and Doyle, 1985).  
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1.5.10 Ubiquitin-Proteasome Pathway 
Destruction is a major cellular regulatory pathway that controls protein half-life. There are two major 
destruction pathways in cells: the first is the collection of proteolytic enzymes within the lysosome, and 
the second is the multi-catalytic proteolytic core of the ubiquitin-proteasome pathway (Urbanowski and 
Piper, 2001). Proteins targeted for degradation are marked by the covalent attachment of multiple 
ubiquitin molecules. This provides a signal for the 26S proteasome. The process is divided into two 
steps: the first step is a specific recognition system that uses the ubiquitin conjugation cascade, and the 
second is the destruction process mediated by the proteasome (proteolytic) core (Myung et al., 2001).   
 
1.5.11 Ubiquitin Conjugation Cascade 
Ubiquitination is the process where protein receptors undergo post-translational modification through 
the attachment of ubiquitin proteins to intracellular lysine residues. Most commonly, a carboxypeptide 
bond is formed between the carboxylic acid group of the glycine 76 residue in ubiquitin and the amino 
group of the lysine residue. The ubiquitin conjugation cascade uses three different sets of enzymes to 
link ubiquitin to the protein substrate (figure 1.9). These are the ubiquitin activating enzymes (E1), 
ubiquitin-conjugating enzymes (E2) and ubiquitin ligases (E3). The unique degradation signal of a 
substrate protein is recognised by a different combination of E2 or E3 or both. This confers specificity 
for the ubiquitination of protein substrates (Huang et al., 2004a; Huang et al., 2004b).  
 
There are three types of ubiquitin modifications: monoubiquitination where a single ubiquitin is attached 
to a lysine residue, multi-ubiquitination where single ubiquitin proteins are attached to several lysine 
residues and polyubiquitination where chains of ubiquitin proteins are formed on a single lysine residue 
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(Sadowski and Sarcevic, 2010). Importantly, ubiquitin contains seven lysine residues and all of these 
can serve as targets for ubiquitination. Depending on the type of modification, different cellular 
processes are affected, from membrane trafficking and endocytosis to protein degradation. Several 
receptor proteins use ubiquitination modification as their targeting signal to lysosomes including EGFR 
and PAR2 (Protease-activated receptor 2) (Berlin et al., 2010; Jacob et al., 2005). To date proteomics 
have been used to identify the lysine residues that serve as targets for ubiquitin attachment in a protein 
receptor and in identifying the E3 ubiquitin ligase. For most receptors including GPCRs and EGFR such 
a technique has been useful in understanding the post-endocytic sorting of the receptors to lysosomes 
(Marotti et al., 2002; Miranda and Sorkin, 2007).  Moreover, deubiquitination of a receptor provides a 
further level of regulation where ubiquitinated receptors can escape degradation and undergo recycling. 
This has been well described for EGFR that is deubiquitinated by ubiquitin-specific protease 8 (USP8) 
and in doing so this ultimately helps regulate EGFR signalling (Berlin et al., 2010). 
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Figure 1.9 Ubiquitin Conjugation Cascade. E1 activates ubiquitin, a reaction that involves the 
hydrolysis of ATP. Following activation, ubiquitin is transferred to E2. E2, by itself or in cooperation with 
E3, shuttles ubiquitin to a protein substrate and is attached to internal lysine residues. Following the 
mono-ubiquitination of the protein substrate, a polyubiquitin chain can be formed through the same 
ubiquitination conjugation cascade (Huang et al., 2004b). Taken from (Huang et al., 2004b). 
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1.5.12 Endosomal sorting complex required for transport (ESCRT) complex 
Receptors destined for lysosomal degradation are ubiquitinated and are subsequently sorted into MVBs 
by members of the ESCRT complex (Vardhana et al., 2010; Wollert and Hurley, 2010). Localisation of 
internalised receptors to MVBs was shown 30 years ago by Haigler et al., (1979) who monitored the 
post-internalisation fate of the EGF:receptor complex in human cells, using EGFR:ferritin conjugates 
that bind to cell surface EGFR. Within minutes stimulated EGFR was shown to localise to MVBs, and 
contents were degraded in lysosomes. In fact, it has been identified that this is the same pathway used 
in yeast to downregulate cell surface receptors and transporters (Babst et al., 2002; Katzmann et al., 
2001).  
 
The hallmark of MVBs is the presence of intraluminal vesicles (ILVs) that are formed by inward budding 
of the endosomal limiting membrane (Haigler et al., 1979; Piper and Luzio, 2001). There are five 
ESCRT complexes 0, I, II, III and the AAA-ATPase vacuolar protein sorting 4 (VpS4) complex (Schmidt 
and Teis, 2012). The complexes function to co-ordinate receptor sorting to ILVs of MVBs as is well 
described for EGFR (Katzmann et al., 2002). The ESCRT-0 component Hepatocyte growth-factor 
regulated tyrosine kinase substrate (Hrs) binds ubiquitinated cargo using a ubiquitin interaction motif 
and concentrates the cargo at the perimeter of the membrane (Razi and Futter, 2006; Wollert and 
Hurley, 2010). Hrs then recruits the ubiquitin-binding subunit of ESCRT-I, Tumor susceptibility gene 101 
(TSG101), which recognises ubiquitinated cargo through an ubiquitin E3 variant domain. ESCRT-I in co-
operation with ESCRT-II regulates ILV formation and the sorting of ubiquitinated cargo in ILVs. The 
depletion of TSG101 inhibits MVB formation and subsequent sorting of protein receptors into MVBs, 
thus highlighting the important role played by TSG101 in this process (Bache et al., 2006; Doyotte et al., 
2005). ESCRT-III is then recruited to deubiquitinate the ubiquitinated cargo. The VpS4 complex then 
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catalyzes membrane scission releasing the ESCRT III subunits, which are recycled to allow another 
round of MVB formation (Wollert et al., 2009). 
 
1.5.13 Recycling of trafficking receptors 
Recycling pathways are used as a mechanism to regulate the transport of essential molecules to 
organelles, which are required for their function, and to maintain the lipid and protein composition of 
other organelles. There are two types of recycling pathways: fast recycling and slow recycling (Grant 
and Donaldson, 2009; Sheff et al., 1999). The fast recycling route has been well described for the TfR 
and is associated with receptor recycling back to the plasma membrane from early endosomes. The 
slow recycling route, on the other hand, follows an indirect path through recycling endosomes. 
 
Rab11 is the key regulator of recycling endosomes (Green et al., 1997). Rab proteins exist in two states 
the active form, which is bound to GTP (guanosine triphosphate) and the inactive form, which is bound 
to GDP (guanosine diphosphate) (Seabra and Wasmeier, 2004). Thus the activity of Rab proteins is 
regulated by the phosphorylation status of the bound GDP by GDP/GTP exchange factor (GEF). In fact, 
overexpression of WT or mutant rab11 proteins can modulate the traffic through recycling endosomes 
(Ren et al., 1998; Ullrich et al., 1996). Studies of the TfR demonstrated that overexpression of the 
dominant-negative rab11S25N, which is unable to bind GTP, slowed down the recycling of trafficking 
receptors from early endosomes to the cell surface and further inhibited the delivery of transferrin to 
recycling endosomes (Ren et al., 1998). Moreover, overexpression of the constitutively active Rab11 
rab11Q70L resulted in transferrin accumulation in recycling endosomes. Rab11 has been implicated in 
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the recycling of many trafficking receptors including EGFR (Chi et al., 2011) and a number of GPCRs 
(Drake et al., 2006).  
 
Previously it has been documented that Rab4 is important for the recycling of the TfR from early 
endosomes but recent studies have questioned the precise role of Rab4 in this process. Studies have 
shown that fast recycling is inhibited when a dominant-negative Rab4 is expressed whilst other studies 
have shown an increase in fast recycling when short-interfering RNA is used to knockdown Rab4 
(Deneka et al., 2003; Yudowski et al., 2009). Rab35 on the other hand is now emerging as an important 
regulator of rapid recycling in particular for the mammalian TfR (Kouranti et al., 2006). Rab35 has been 
shown to localise to early endosomes and to the plasma membrane. Depletion of Rab35 or the 
overexpression of an inhibitor of Rab35 (EP164C) has been shown to impair the formation of the 
immunological synapse and TfR recycling (Patino-Lopez et al., 2008). 
 
1.6 CTLA-4 receptor trafficking 
1.6.1 CTLA-4 Internalisation 
The phosphorylation status of the YVKM motif in the CTLA-4 cytoplasmic domain has long been 
established as the regulator of its function. Tyrosine phosphorylation has been suggested to stabilise 
the cell surface expression of CTLA-4 following T cell stimulation (Bradshaw et al., 1997; Chuang et al., 
1997). In fact, such a mechanism overcomes the issue of how the highly endocytic CTLA-4 receptor 
interacts with cell surface ligands on APCs. When the tyrosine residue is phosphorylated, this blocks the 
interaction of the YVKM with the clathrin adaptor AP-2 thereby preventing CTLA-4 endocytosis. A 
question recently addressed by our lab was whether CTLA-4 endocytosis is inhibited in T cells following 
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stimulation. We found that T cell stimulation does increase CTLA-4 trafficking to the plasma membrane, 
which is in agreement with previous studies (Egen and Allison, 2002; Linsley et al., 1996). However, the 
ratio of surface to internalised CTLA-4 demonstrated that the amount of CTLA-4 at the T cell surface at 
any given time remains the same (Qureshi et al., 2012), suggesting the receptor is not stabilised at the 
cell surface. 
 
The importance of tyrosine 201 for CTLA-4 internalisation was initially demonstrated using mutational 
analysis (Leung et al., 1995), and in later studies, an interaction between the cytoplasmic tail of CTLA-4 
and the medium subunit (µ2) AP-2 clathrin-adaptor complex was determined (Chuang et al., 1997; 
Shiratori et al., 1997). Using immunoprecipitation and cells transfected with HA-tagged µ2 and GST-
tagged CTLA-4, it was confirmed the tyrosine 201 residue within the YVKM motif was important for this 
interaction (Chuang et al., 1997; Zhang and Allison, 1997). The importance of clathrin-mediated 
endocytosis was further verified by incubating cells in potassium-depleted medium that has been shown 
to block assembly of CCVs (Chuang et al., 1997). CTLA-4 internalisation was indeed inhibited 
suggesting clathrin is required in CTLA-4 endocytosis.  
 
Our lab has further shown that CTLA-4 internalisation is dynamin-dependent. Using confocal 
microscopy, we found that CTLA-4 internalisation was inhibited when CTLA-4-transfected chinese 
hamster ovary (CHO) cells were incubated with the dynamin inhibitor dynasore (Qureshi et al., 2012). 
Post-internalisation CTLA-4 has also been shown to co-localise with markers of early endosomes and 
with TfR (Mead et al., 2005). Although the post-internalisation fate of CTLA-4 is poorly understood, as a 
lab we have shown that CTLA-4 can recycle back to the plasma membrane or is targeted for 
degradation in lysosomes (figure 1.10). 
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Figure 1.10 CTLA-4 intracellular trafficking. CTLA-4 is exported to the plasma membrane from the 
golgi in an ARF1- and phospholipase D-dependent manner. CTLA-4 internalises into clathrin-coated pits 
via the association of the YVKM motif located in the cytoplasmic domain and the clathrin adaptor AP-2. 
Scission of the vesicle is mediated by the GTPase dyanmin. Once internalised CTLA-4 has been found 
to co-localise with EEA-1 a marker of early endosomes. From here, CTLA-4 has been shown to co-
localise with Rab11 a marker of recycling endosomes, which suggests the receptor recycles back to the 
plasma membrane. CTLA-4 has also been shown to co-localise with LAMP1, which suggests the 
receptor is targeted for degradation in lysosomes. Prior to entry into lysosomes CTLA-4 has been 
identified in late endosomes or MVBs. ARF1, ADP-ribosylation factor 1; LAMP1, Lysosomal-associated 
membrane protein 1). 
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 1.6.2 CTLA-4 degradation 
Several groups have reported that CTLA-4 is degraded in lysosomal compartments and that this could 
serve as a potential mechanism by which a T cell could regulate the expression of CTLA-4. Co-
localisation of CTLA-4 with lysosomal markers has been variable and in fact we also observed little co-
localisation of CTLA-4 with Lysosomal-associated membrane protein 1 (LAMP1) in primary T cells 
(Qureshi et al., 2012). This data rules out the possibility that CTLA-4 is stored in secretory lysosomes as 
if this was the case substantial co-localisation of CTLA-4 with lysosomal markers should be observed at 
steady state. In a study where T cells were treated with Cycloheximide (CHX), the half-life of CTLA-4 
protein turnover was revealed to be approximately 2 hours (Egen and Allison, 2002). Moreover, total 
CTLA-4 expression was increased following treatment with Ammonium chloride (NH4Cl), an inhibitor of 
lysosomal degradation, further suggesting that lysosomes are used to degrade CTLA-4 and are not 
being used as a storage compartment. For transendocytosis function, we have demonstrated using 
lysosomal inhibitors that CTLA-4 targets the ligand for degradation in lysosomes thus providing a 
purpose for this trafficking pathway (Qureshi et al., 2011).  
 
The mechanism required for CTLA-4 targeting to lysosomes remains to be identified. Most trafficking 
receptors use ubiquitin as a sorting signal to be trafficked to lysosomes. In fact, in T cells the TCR is 
downregulated after ligand binding and the internalised receptor is trafficked to lysosomes for 
degradation (Valitutti et al., 1997). It has been suggested that ubiquitination of the TCR could serve as 
the signal regulating its targeting to lysosomes a process performed by the most likely candidate E3 
ligase Casitas B-cell lymphoma-b (Cbl-b) (Naramura et al., 2002). Recently, Vardhana et al., (2010) 
have demonstrated that in TCR downregulation the recognition of ubiquitin by TSG101 is essential for 
central supramolecular activation cluster (cSMAC) formation and function, the site identified to be 
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concentrated in MVB markers. A model is therefore proposed that ESCRT-I sorts the TCR into MVB-like 
structures within the cSMAC and targets the TCR for degradation. This is suggested to be dependent 
upon strong agonist engagement with the TCR (Vardhana et al., 2010). Thus, it is interesting to 
speculate whether CTLA-4 uses a similar pathway to be targeted for lysosomal degradation.  
 
1.6.3 CTLA-4 recycling 
The well-characterised TfR, which also internalises by clathrin-mediated endocytosis, can recycle 
constitutively back to the cell surface. In both murine splenocytes and activated human T cell blasts, 
CTLA-4 has been found to co-localise with TfR (Chuang et al., 1997; Leung et al., 1995), and thus this 
led to the hypothesis that following internalisation, CTLA-4 could recycle back to the plasma membrane 
(Chuang et al., 1997; Leung et al., 1995). As a lab, we have confirmed these findings by providing direct 
evidence of CTLA-4 co-localising with the recycling marker Rab11 (Qureshi et al., 2012). Although this 
data provides further understanding to CTLA-4 intracellular trafficking, it does not explain why the 
CTLA-4 receptor needs to recycle. Moreover, the motifs encoded in the CTLA-4 cytoplasmic domain 
that could possibly mediate such intracellular sorting remain to be identified.   
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1.7 Aims and Objectives 
The foregoing introduction highlights the role of CTLA-4 as a potent negative regulator of T cell immune 
responses. The location of CTLA-4 in intracellular vesicles is the most dominating aspect of its biology, 
yet the significance of this at the functional level remains to be understood. The models of CTLA-4 
function to date include a competition model, the delivery of a cell-intrinsic negative signal, IDO 
production in DCs, and inhibition of T cell responses via Tregs. However, these models assume CTLA-4 
is arrested at the plasma membrane, and fail to take the constitutive internalisation of the receptor into 
account. In our lab, we have identified an unusual biological feature of CTLA-4 that could potentially 
explain some features of the CD28/CTLA-4 system. This phenomenon is called transendocytosis, 
where CTLA-4 in Tregs and activated T cells may modify the phenotype of APCs by removing ligand 
and targeting it for degradation. Central to the understanding of CTLA-4 function is an appreciation of 
how the expression and function of this protein has adapted through evolution. Therefore, an awareness 
of the intracellular trafficking pathways used by CTLA-4 and an understanding of how these trafficking 
events are regulated is essential.  
 
To date, majority of the studies have emphasised that the internalisation of CTLA-4 occurs via the 
clathrin-dependent pathway. This requires the association of the YVKM motif encoded in the CTLA-4 
cytoplasmic domain with the clathrin adaptor AP-2. However, mutations of the tyrosine residue in this 
motif can still facilitate CTLA-4 internalisation but at a slower rate suggesting other residues in the 
cytoplasmic tail may contribute to inclusion into clathrin pits. Moreover, the fate of the CTLA-4 receptor 
post-internalisation is poorly understood. As a lab we have shown that CTLA-4 is recycled and 
degraded but the intracellular trafficking pathways and sorting motifs required for such trafficking remain 
to be identified.  
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Therefore the aim of this project was to investigate the role of the CTLA-4 cytoplasmic domain in 
the intracellular trafficking of the receptor. My main objectives were as follows: 
1. To investigate the steady state localisation of CTLA-4 in CTLA-4 transfected cells and in T cells. 
2. To generate CTLA-4 chimeras and address whether CTLA-4 intracellular trafficking is 
conserved through evolution. 
3. To use site-directed mutagenesis to address role of the CTLA-4 cytoplasmic domain in 
regulating CTLA-4 recycling and degradation. 
4. To use site-directed mutagenesis to address the role of the CTLA-4 cytoplasmic domain in 
transendocytosis of ligand and to understand whether CTLA-4 function has changed through 
evolution. 
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2.0 MATERIALS AND METHODS 
 
2.1 General Methods  
All tissue culture work was carried out under sterile conditions in Class II laminar flow hoods. Vented 
75m2 tissue culture flasks, 6-well, 24-well flat bottom, 96-well round bottom and 96-well flat bottom 
tissue culture plates were purchased from Sarstedt. Cell lines were incubated at 37°C, 95% humidity, 
5% CO2 in a MCO-17A1C Sanyo CO2 incubator. Following passage, cells were transferred into 30ml 
sterile universal tubes (Sterillin).  Cells were counted using a haemocytometer (Neubauer B.S 748; 
Fison Scientific equipments). 
 
For flow cytometric analysis on the FACSCalibur flow cytometer (BD Biosciences – Oxford, UK) cells 
were placed in non-sterile 12x75mm, 5ml round bottom polystyrene tubes (Falcon). For flow cytometric 
analysis on the Dako Cyan flow cytometer, cells were placed in non-sterile 12x75mm, 5ml round bottom 
polypropylene tubes (Falcon). For cell sorting, cells were placed in sterile 12x75mm, 5ml round bottom 
polypropylene tubes with snap caps (Falcon). Using a sterile 0.22µm filter (Millex), samples were 
filtered prior to sorting. For confocal analysis, glass slides and cover slips were purchased from VWR 
International. 
 
 47 
2.1.1 Antibodies and reagents 
Table lists antibodies used for flow cytometry, confocal microscopy and western blotting. 
Specificity Clone Dilution Source 
Primary Antibodies    
CTLA-4-PE BN13 1:100* BD Biosciences 
Mouse IgG2a, κ G155-178 1:100* BD Biosciences 
Unlabelled anti-CTLA-4  11G1 0.3mg/ml Dr J. Allison 
Ticililmumab  1µg/ml Pfizer 
Unlabelled anti-CTLA-4 Az1172/272 1:100 AstraZeneca 
C-19 Polyclonal 0.5µg/ml Santa Cruz 
Ub (P4D1) Monoclonal 1µg/ml Santa Cruz 
CD80-PE L307.4 1:100* BD Biosciences 
CD86-PE 2331 1:100* BD Biosciences 
Secondary Antibodies    
AlexaFluor Donkey anti-mouse 488 - 1:500 Invitrogen 
AlexaFluor Donkey anti-mouse 555 - 1:500 Invitrogen 
AlexaFluor Donkey anti-mouse 647 - 1:200 Invitrogen 
AlexaFluor Donkey anti-human 488 - 1:500 Invitrogen 
AlexaFluor Donkey anti-human 565 - 1:500 Invitrogen 
Polyclonal Goat anti-Mouse 
Immunoglobulins/HRP 
- 1:7500 Dako 
Polyclonal Rabbit anti-Goat 
Immunoglobulins/HRP 
- 1:7500 Dako 
IRDye 800CW Goat anti-Mouse IgG - 1:10000 LI-COR 
Table 2.1 List of antibodies used in flow cytometry, confocal microscopy and western blotting. 
* BD Biosciences do not give concentration of Abs they sell as test format. Abs were titrated to find the 
best concentration required for a volume of 100µl.  
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The following reagents were purchased from Invitrogen: Dulbecco's Modified Eagle Medium 
(DMEM); Roswell Park Memorial Institute (RPMI); Trypsin-EDTA (ethylenediamine tetraacetic acid); 
Dimethyl sulphoxide (DMSO); PureLinkTM HiPure Plasmid Filter Purification Kit; PureLink HiPure 
Precipitator Module; Tris-EDTA (TE) buffer; 100% Methanol; Penicillin and Streptomycin; Geneticin 
Selective Antibiotic (G418); Protein-G-Sepharose beads; Tranferrin from human serum, AlexaFluor 633 
conjugate; Wheat Germ Agglutinin (WGA) - tetramethylrhodamine conjugate; Sybr safe DNA gel stain 
(10,000 concentration); pcDNATM3.3 TOPO Mammalian Expression Vector; One Shot TOP10 
Chemically Competent E.coli; CellTrace Violet; Neon Transfection System; CD3/CD28 T Cell Expander 
Dynabeads. Prestained Protein Marker, Broad Range (7-175 kDa); BglII and SacII restriction enzymes; 
1kb DNA ladder and 6X loading dye were purchased from New England Biosciences (NEB). QIAprep 
Spin Miniprep Kit was purchased from QIAGEN. The following reagents were purchased from Sigma: 
Hepes; Ampicillin; Select Agar; Sodium-Dodecyl-Sulphate (SDS); L-glutamine; Saponin; 
Paraformaldehyde (PFA); N,N,N′,N′-Tetramethylethylenediamine (TEMED); poly-L-lysine; Sodium 
azide; Ethanol; Protease Cocktail Inhibitor; MG132; Ammonium chloride (NH4Cl). Fetal Bovine Serum 
(FBS) was purchased from Harlan Sera-Lab Ltd, UK. QuikChange Lightning Site-Directed Mutagenesis 
kit was purchased from Agilent Technologies. The following reagents were purchased from Thermo 
Fisher Scientific: Pierce Cell Surface Protein Isolation Kit; Pierce Spin Columns (Snap Cap); Precise 
Protein Gels 8-16% and 4-20%, 12-well; Pierce ECL (enhanced chemiluminescence) Western Blotting 
Substrate. The following reagents were purchased from Geneflow: Electroblotting Buffer Tris-glycine 
(10X); TAE buffer (50X); Protein Loading Buffer (2X); Protogel Resolving Buffer (4X); Protogel Stacking 
Buffer; ProtoGel 30%. The following reagents were purchased from Fisher Scientific: Tween20; Tris 
Base; Ethylenediaminetetraacetic acid (EDTA); Triton; Ammonium persulphate (APS). Immobilon-FL 
Polyvinylidene Fluoride (PVDF) was purchased from Millipore. Pfu DNA polymerase (recomb.) 100 units 
was purchased from Fermentas. X-gal/IPTG solution was purchased from Bioline. Amersham Hybond 
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ECL Nitrocellulose membrane was purchased from GE Healthcare Life Sciences. Amaxa Cell Line 
Nucleofector Solution Kit T was purchased from Lonza. Circlegrow was purchased from Q-biogene. 
Phosphate buffered saline (PBS) tablets were purchased from Oxoid. Cycloheximide (CHX) was 
purchased from Calbiochem. Bafilomycin A1 (BafA) was purchased from Tocris Biosciences. 
Unmodified oligonucleotide DNA primers were synthesised by Eurofins MWG and purified by High purity 
salt free (HPSF) purification. Unmodified oligonucleotide DNA primers required for QuikChange 
Lightning Site-Directed Mutagenesis were purified by High-performance liquid chromatography (HPLC).  
 
2.2 Cell culture 
2.2.1 Culture and passage of cell lines 
Adherent chinese hamster ovary (CHO) transfectants were cultured in glutamine free DMEM medium 
supplemented with 2mM L-glutamine, 10% FBS and 1% penicillin and streptomycin. Cells were grown 
in vented 75cm2 sterile tissue culture flasks as a monolayer culture and upon confluence were 
passaged every 2-3 days. To passage the cells, those in suspension were aspirated using glass 
Pasteur pipettes (Appleton Woods) and the flasks washed once in 10ml sterile PBS. Adherent cells 
were removed by incubation with 2ml Trypsin-EDTA for 5minutes at 37°C. Trypsin was inactivated with 
the addition of 8ml fresh medium. Up to 80% of the cell suspension was removed from the flask and 
fresh medium added to a total of 20ml. 
 
Jurkat T cells were cultured in RPMI medium supplemented with 2mM L-glutamine, 10% FBS and 1% 
penicillin and streptomycin. Cells were grown in vented 75m2 sterile tissue culture flasks. 
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2.2.2 Cryogenic preservation and storage of cell lines 
To maintain a permanent stock, transfected CHO cells were stored in liquid nitrogen. Following cell 
passage, 5ml of the cell suspension was washed at 490 g for 5minutes to pellet the cells and re-
suspended in 500µl 80% FBS in DMEM volume/volume (v/v) followed by 500µl 20% DMSO in DMEM 
(v/v). The cell suspension was transferred into cryotube vials and incubated at -80°C for 24hours before 
indefinite storage in liquid nitrogen. 
 
2.2.3 Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
Leukocyte reduction system cones (LC) were provided by the Birmingham National Blood Service and 
used to isolate primary cells from PBMC. The Ficoll-Paque PLUS method of density gradient 
centrifugation was used for PBMC isolation.  
 
LCs were diluted in PBS at a ratio of 1:4. 25ml of the diluted cell suspension was layered over 15ml 
Ficoll-Paque PLUS in a 50ml Falcon tube. The cell suspension was centrifuged at 1060 g without brake 
for 25minutes. The upper layer was aspirated and the mononuclear cell layer was transferred to a new 
50ml Falcon tube using a Pasteur pipette. The cell suspension was made up to 50ml using PBS and 
centrifuged at 1060 g with brake for 10minutes. The supernatant was aspirated and the cells were 
washed in 50ml PBS at 260 g for 5minutes. This was followed by two washes in MACS® buffer (2mM 
EDTA, 0.5% Bovine Serum Albumin (BSA) in PBS). The cells were counted after each wash and the 
number of washes adjusted according to the efficiency of platelet removal.  
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2.2.3.1 Isolation of CD4+ T cells using EASYSEPTM Human CD4+ T cell Enrichment 
Kit    
CD4+ T cells were isolated from PBMCs using the EASYSEPTM Human CD4+ T cell enrichment kit by 
negative selection. The cocktail contains Tetrametric Antibody Complexes that recognise CD8, CD14, 
CD16, CD19, CD20, CD36, CD56, CD66b, CD123, TCRγ/δ, glycophorin A and dextran-coated 
magnetic particles.  
 
PBMCs were resuspended in MACS buffer at a concentration of 100x106/ml in a 15ml Falcon tube. 
CD4+ T cell enrichment cocktail was added to the cells at a concentration of 50µl/ml and the mixture 
was incubated at room temperature for 10minutes. EasySepTM magnetic particles were vortexed to 
ensure the aggregates were in a uniform suspension and added to the cells at a concentration of 
100µl/ml. The tube was inverted to ensure the cells and particles were mixed well and incubated at 
room temperature for 5minutes. The total volume in the tube was adjusted to 9ml using MACS® buffer 
and the tube was placed into an EasySepTM magnet with the cap removed. After 5minute incubation, the 
magnet and tube were inverted for 2-3 seconds to pour off the negative selected cells into a fresh 15ml 
Falcon tube. To increase purity the magnetic removal step was repeated and the negative selected cells 
were finally transferred to a 30ml universal tube. The cells were counted, centrifuged at 490 g for 
5minutes and resuspended at a concentration of 100x106/ml in MACS® buffer.  
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2.2.3.2 Isolation of CD4+ CD25+ Tregs 
CD4+ T cells isolated as described in section 2.2.3.1 were resuspended in MACS buffer at a 
concentration of 1x108/ml in a 15ml Falcon tube. The Tetrametric Antibody Complexes recognises non-
CD4+ T cells, CD127high, CD49d+ cells and dextran-coated magnetic particles.  
 
EasySepTM Human CD4+CD127lowCD49d- Regulatory T Cell Enrichment cocktail was added at a 
concentration of 50µl/ml and the mixture was incubated for 10minutes at room temperature. EasySepTM 
D2 Magnetic particles were vortexed to ensure the aggregates were in a uniform suspension and added 
to the cells at a concentration of 100µl/ml. The tube was inverted to ensure the cells and particles were 
mixed well and incubated at room temperature for 5minutes. The total volume in the tube was adjusted 
to 7ml using MACS® buffer and the tube was placed into an EasySepTM magnet with the cap removed. 
After 5minute incubation, the magnet and tube were inverted for 2-3 seconds to pour off the negative 
selected cells into a fresh 15ml Falcon tube. 70µl EasySepTM Dextran Selection Cocktail was added to 
the cells and the mixture was incubated at room temperature for 10minutes. EasySepTM D2 Magnetic 
particles were vortexed and 70µl of the particles were added to the mixture. The tube was inverted to 
ensure the cells and particles were mixed well and the mixture was incubated at room temperature for 
5minutes. The tube was placed into an EasySepTM magnet with the cap removed. After 5minute 
incubation, the magnet and tube were inverted for 2-3 seconds to remove the negative selected cells, 
which were transferred into a fresh 30ml universal tube. The cells were counted and resuspended in 
RPMI at a concentration of 1x106/ml. 
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2.2.3.3 T cell stimulation assays 
T cell stimulation assays were performed in 96-well flat bottom plates. 1x105 T cells were plated out per 
well in a total volume of 200µl. T cells were stimulated with CD3/CD28 T Cell Expander Dynabeads. 
0.5µl of the beads were added to each well to achieve a 1:4 bead to cell ratio.  
 
CD4+CD25+ T cells were supplemented with IL-2 (100U/ml).  
 
2.3 Molecular Biology 
2.3.1 Generation of CTLA-4-CD86 chimera 
Oligonucleotide primers were designed to fuse the extracellular domain of CTLA-4 and the 
transmembrane and cytoplasmic domain (TMCY) of CD86 by PCR amplification, using CTLA-4 
(5µg/ml) and CD86 (5µg/ml) plasmid DNA (Deoxyribonucleic acid) as templates (table 2.2). The 
volumes required for a single Pfu PCR are listed in table 2.3. PCR was performed by predenaturation at 
95°C for 5minutes followed by 25 cycles at 95°C for 1minute, annealing at 55°C for 1minute and 
extension at 72°C for 1minute 30seconds. The programme ended with a period of extension at 72°C for 
10minutes before cooling to 4°C for storage. Following amplification, 2µl of sample loading buffer was 
added to 10µl of digested samples to analyse product size by electrophoresis on 1% agarose TAE gel 
set with 10µl Sybr Safe DNA gel stain. 1kb DNA ladder was prepared by adding 1µl of DNA ladder to a 
microcentrifuge tube with 9µl of water and 2µl of loading buffer.  
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Table 2.2 Forward and reverse primer sequences used for the amplification of regions within the 
transcripts of CTLA-4 and CD86. [F], Forward; [R], Reverse; bp, base pair. 
 
Reagents Volume (µl) 
H2O 44 
dNTP (2.5mM) 10 
MgCl2 (5mM) 5 
10X Pfu buffer with MgSO4 10 
Forward primer (10µM) 10 
Reverse primer (10µM) 10 
Target DNA 10 
Pfu DNA polymerase 1 
Total 100 
 
Table 2.3 Volumes of reagents required for one Pfu reaction. 
Construct Plasmid DNA Primers Product 
length 
CTLA-4-CD86 CTLA-4 [F]ATGGCTTGCCTTGGATTTCAGCGG 509bp 
[R]GGAAGTACAGCTGTAATCCAAGGAATGTCAGAA
TCTGGGCACGGTTC 
CD86 [F]GAACCGTGCCCAGATTCTGACATTCCTTGGATTA
CAGCTGTACTTCC 
276bp 
[R]TTAAAAACATGTATCACTTTTGTCGC 
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The reverse primers used to amplify CTLA-4 protein was designed to recognise the 5’ transmembrane 
region of CD86 and the forward primer of CD86 was designed to recognise the 3’ extracellular domain 
of CTLA-4. 15µl of CTLA-4 extracellular domain and 15µl of CD86 TMCY were added to a 
microcentrifuge tube with 2.5µl MgCl2 and 17.5µl 10X Pfu buffer with MgSO4. The amplicons were 
heated to 100°C for 2minutes to denature the DNA, and cooled to 55°C on ice to anneal the target DNA. 
A PCR was setup to amplify the construct using 10µl of target DNA and using the oligonucleotides 
designed to recognise the 5’ extracellular domain of CTLA-4 and 3’ cytoplasmic domain of CD86 under 
standard PCR conditions. The size of the amplicons were analysed by TAE (Tris-acetate EDTA) gel 
electrophoresis and visualised by ultraviolet transillumination.  
 
2.3.2 Addition of 3’ A-Overhangs Post-Amplification 
Due to the proof reading capacity of Pfu, 3’A overhangs necessary for the direct cloning of the PCR 
fragments by the TOPO-TA method are not created. Prior to setting up the TOPO cloning reaction, 3’ A-
overhangs were added post-amplification. 1unit of Taq polymerase was added to each PCR tube and 
heated to 72°C for 10minutes. The DNA amplification product was used directly in the TOPO cloning 
reaction.  
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2.3.3 TOPO Cloning 
2µl of the PCR product from section 2.3.2 were mixed with 1µl salt solution, 1µl H2O and 1µl 
pcDNATM3.3 TOPO vector provided in the TOPO TA cloning kit from Invitrogen. The reaction mix was 
incubated at room temperature (25°C) for 10minutes, placed on ice and then used for the 
transformation of One Shot TOP10 Chemically Competent E.coli cells. 
 
2.3.4 Bacterial Transformation 
One vial of One Shot TOP10 Chemically Competent E.coli cells was thawed on ice. 2µl of the TOPO 
cloning reaction prepared in section 2.3.3 was added to the vial, mixed gently and incubated on ice for 
30minutes. The cells were then heat shocked at 42°C for exactly 30seconds, and transferred to ice for 
2minutes. 250µl of room temperature SOC medium was added to the vial, which was then shaken 
horizontally for 1hour at 37°C at 250RPM in a shaking incubator. 100µl of each transformation was 
spread onto a pre-warmed LB plate containing 50µg/ml ampicillin. Plates were inverted and incubated 
overnight at 37°C. The vectors contained an Ampicillin resistance gene and the presence of the 
antibiotic in the agar resulted in selective growth of transformed cells.  
 
2.3.5 Quik-change lightning site-directed mutagenesis  
Two complimentary oligonucleotides were synthesised for each desired mutation, flanked by unmodified 
nucleotide sequence and purified by HPLC (table 2.4). The volumes required for a single mutant strand 
synthesis reaction are listed in table 2.5. The control reaction was prepared as listed in table 2.6. PCR 
was performed by pre-denaturation at 95°C for 2minutes followed by 18 cycles at 95°C for 20seconds, 
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annealing at 60°C for 10seconds and extension at 68°C for 30seconds/kb of plasmid length. The 
programme ended with a period of extension at 68°C for 10minutes. The amplification products were 
mixed with 2µl of the Dpn I restriction enzyme. The reaction mixtures were gently vortexed and 
immediately incubated at 37°C for 5minutes to digest the parental supercoiled double stranded DNA. 
The reaction mixtures were transferred to ice and then used for transformation of XL-Gold 
ultracompetent cells. 
 
2.3.6 Transformation of XL-Gold Ultracompetent Cells 
The XL10-Gold ultracompetent cells were thawed on ice. 45µl of the ultracompetent cells were 
aliquoted into pre-chilled 15-ml BD Falcon polypropylene round-bottom tubes for each control and 
sample reaction. 2µl of the 2-Mercaptoethanol (β-ME) mix provided with the kit was added to the cells. 
The contents were swirled and the cells were incubated on ice for 2minutes. 2µl of the Dpn I-treated 
DNA from each control and sample reactions were added to the separate aliquots of the ultracompetent 
cells, gently mixed and the reactions were incubated on ice for 30minutes. The tubes were heat-pulsed 
in a 42°C water bath for 30seconds, and transferred to ice for 2minutes. 500µl of preheated (42°C) 
NZY+ broth was added to each tube, which was then shaken for 1hour at 37°C at 250 rotations per 
minute (RPM) in a shaking incubator. 100µl of each transformation was spread onto a pre-warmed LB 
plate containing 50µg/ml Ampicillin. 100µl of the control reaction was spread onto LB-ampicillin plate 
containing 80µg/ml 5-Bromo-4-chloro-3-indoyl β-D-galactopyranoside (X-gal) and 20mM Isopropyl β-D-
1-thiogalactopyranoside (IPTG). Plates were inverted and incubated overnight at 37°C. The vectors 
contained an Ampicillin resistance gene and the presence of the antibiotic in the agar resulted in 
selective growth of transformed cells.  
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Table 2.4 Forward and reverse primer sequences synthesised for each desired mutation. [F], 
Forward; [R], Reverse; bp, base pair. 
* X pmoles of oligo =  125ng of oligo   x 1000 
   330 x # of bases in oligo 
Plasmid 
DNA 
Construct Primer pmoles of oligo 
(125ng)* 
CTLA-4  ATEP [F]GTGAAAATGCCCGCAACAGAGCCAGAATGTGAA 
(33bp) 
11.5µl 
[R]TTCACATTCTGGCTCTGTTGCGGGCATTTTCAC  
(33bp) 
 
AVKM [F]CTTACAACAGGGGTCGCTGTGAAAATGCCCCCAACA  
(36bp) 
10.5µl 
[R]TGTTGGGGGCATTTTCACAGCGACCCCTGTTGTAAG  
(36bp) 
 
AFIP [F] GCAATTTCAGCCTGCTTTTATTCCCATCAATTGA  
(34bp) 
11.1µl 
[R]TCAATTGATGGGAATAAAAGCAGGCTGAAATTGC  
(34bp) 
 
AVKM AVKM-AFIP [F] GCAATTTCAGCCTGCTTTTATTCCCATCAATTGA  
(34bp) 
11.1µl 
[R]TCAATTGATGGGAATAAAAGCAGGCTGAAATTGC  
(34bp) 
 
CTLA-4  K191R [F]GAGCAAAATGCTAAGGAAAAGAAGCCCTC (29bp) 13.1µl 
[R]GAGGGCTTCTTTTCCTTAGCATTTTGCTC (29bp)  
K192R [F]GCAAAATGCTAAAGAGGAGAAGCCCTCTTAC (31bp) 12.2µl 
[R]GTAAGAGGGCTTCTCCTCTTTAGCATTTTGC (31bp)  
K203R [F]CAGGGGTCTATGTGAGGATGCCCCCAACAG (30bp) 12.6µl 
[R]CTGTTGGGGGCATCCTCACATAGACCCCTG (30bp)  
K213R [F]CCAGAATGTGAAAGGCAATTTCAGCC (26bp) 14.6µl 
[R]GGCTGAAATTGCCTTTCACATTCTGG (26bp)  
K203R K203,213R [F]CCAGAATGTGAAAGGCAATTTCAGCC (26bp) 14.6µl 
[R]GGCTGAAATTGCCTTTCACATTCTGG (26bp)  
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Reagents Volume (µl) 
10X reaction buffer 5 
dsDNA (5ng/ l) 5 
Oligonucleotide primer 1 125ng 
Oligonucleotide primer 2 125ng 
dNTP 1 
QuikSolution Reagent 1.5 
ddH2O To a final volume of 50µl 
QuikChange Lightning Enzyme 1 
Total 50 
 
Table 2.5 Volume of reagents required for 1 QuikChange Lightning Site-Directed Mutagenesis 
reaction. 
 
 
Reagents Volume (µl) 
10X reaction buffer 5 
pWhitescript 4.5kb control 
plasmid (5ng/ l) 
5 
Oligonucleotide primer 1 1.25 
Oligonucleotide primer 2 1.25 
dNTP 1 
QuikSolution Reagent 1.5 
ddH2O 34 
QuikChange Lightning Enzyme 1 
Total 50 
 
Table 2.6 Volume of reagents required for the control QuikChange Lightning Site-Directed 
Mutagenesis reaction. 
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2.3.7 Mini Plasmid Preparations  
Plates were analysed for the presence of bacterial colonies. Ten 5ml aliquots of Ampicillin broth 
(consisting of circle grow supplemented with 50µg/ml of Ampicillin) were each inoculated with one 
colony picked from the selection plates. The cultures were incubated for 8-12hours at 37°C under 
continual shaking at 250RPM in a shaking incubator. The QIAGEN plasmid mini kit was used to extract 
the plasmid from 2ml of the cultures for restriction digestion analysis prior to Maxi plasmid preparation. 
The bacterial pellet was resuspended in 250µl of Buffer P1 with RNAse, 250µl Buffer P2 to lyse the 
cells and inverted 6 times before the addition of Buffer N3 to precipitate proteins. The eppendorf was 
inverted 6 times and centrifuged for 10minutes. The supernatant was loaded onto the spin column, 
centrifuged for 1minute and supernatant discarded. The DNA was washed with 750µl of Wash Buffer 
with Ethanol for 1minute and to ensure removal of residual Ethanol, the column was centrifuged for a 
further minute. The collection tube was discarded and column transferred to a fresh eppendorf to elute 
the DNA with 30µl of Elution buffer. The column was left to stand for 1minute and centrifuged for a 
further minute. The concentration of plasmid was measured by a nanodrop using 1µl of the sample and 
using Elution buffer as the blank. Tubes were stored at 4°C. Unless otherwise indicated all centrifuge 
steps were carried out at 16.1 g. 
 
2.3.8 Restriction Digest Analysis of Plasmid Extracts 
To confirm the orientation of the chimera, restriction digest analysis was used as a screening method. 
The reactions were prepared by mixing 2µl of the plasmid DNA with 2µl of 10X restriction enzyme 
buffer, 2µl of restriction enzyme and 14µl of H2O, and incubated at 37°C for 1hour and 30minutes. The 
reaction was stopped by the addition of 4µl of 6X loading buffer and separation by gel electrophoresis 
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against a 1kb ladder. The culture for the hybrid in the correct orientation was transferred into a large 
conical flask containing 500ml of Ampicillin broth and left overnight to grow at 250RPM and 37°C. 
 
2.3.9 Maxi Plasmid Preparations 
Large-scale preparations of plasmid DNA were performed using the PureLinkTM HiPure Plasmid Filter 
DNA Purification Kit, according to the manufacturer’s protocol. Cultures set up for maxiprep were 
centrifuged for 10minutes at 5000 g and 17°C using a JLA 162.50 rotor to pellet the cells. The pellet 
was resuspended in 10ml Resuspension Buffer with RNase A and transferred to a 50ml centrifuge tube, 
followed by addition of 10ml Lysis buffer to lyse the cells. 10ml of Precipitation Buffer was added to 
precipitate proteins. The supernatant was loaded onto the equilibrated column, washed with 50ml of 
Wash buffer and the flow-through was discarded. 15ml of Elution buffer was added to the column to 
elute the DNA and the column was discarded.  
 
DNA was precipitated using the PureLinkTM HiPure Precipitator Module. 10.5ml of Isopropanol was 
added to the elution tube and mixed. The plunger of a 30ml syringe was removed, and a PureLink 
HighPureTM Precipitator Module was attached through the luer lock inlet of the syringe. The precipitated 
DNA mixture was loaded into the syringe, placed over a waste container and the plunger was re-
inserted into the syringe. A slow, constant force was used to push the plunger to pass the DNA mixture 
through the precipitator. The flow-through was discarded. The precipitator was detached from the 
syringe, the plunger removed and the precipitator was re-attached to the syringe. To wash the 
precipitated DNA, 5ml of 70% Ethanol was added to the syringe, plunger re-inserted and pushed to 
pass the Ethanol through the precipitator. The precipitator was detached from the syringe, the plunger 
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removed and the precipitator was re-attached to the syringe. To dry the precipitator membrane, the 
plunger was re-inserted and a slow, constant force was used to push the plunger to pass air through the 
precipitator. The precipitator was detached from the 30ml syringe. The plunger from a 5ml syringe was 
removed, and the precipitator module was attached to the syringe. To elute the DNA, 1ml TE buffer was 
added to the 5ml syringe. The plunger was reinserted and placed over a clean, sterile microcentrifuge 
tube. The plunger was pushed to elute the DNA into the new tube. The concentration of plasmid was 
measured by a nanodrop using 1µl of the sample and using TE buffer as the blank. Tubes were stored 
at 4°C. 
 
2.3.10 Sequencing of amplified fragments 
Following on plasmid preparation, samples of the DNA were then prepared for sequencing. Two 
reactions were prepared per DNA extract: one using the forward primer (CMV forward) and one using 
the reverse primer (BgH for pcDNATM3.1/V5-His vector and TKpolyA for pcDNATM3.3 vector). 500ng of 
DNA as determined by the Nanodrop were mixed with 1.5pmols of forward or reverse primer and H2O 
added to give a final volume of 15µl. The Value Read Sequencing Service offered by Eurofins MWG 
Operon was used to sequence the DNA. The returned sense and antisense sequences were aligned 
with the expected sequence adapted from the NCBI database using the program DNA strider for 
confirmation of mutant plasmid generation.  
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2.4 Transfection 
2.4.1 Transfection using the Amaxa Nucleofector 
Stable cultures of CHO cells were transfected transiently with the CTLA-4 constructs by electroporation 
using an Amaxa Nucleofector device for CHO cell transfections, according to the manufacturer’s 
protocol. Cells (1x106) were electroporated in 100µl of pre-warmed NucleofectorTM Solution T with 2µg 
of plasmid. The nucleofection sample was transferred into an amaxa certified cuvette. The program U-
23 (for high transfection efficiency) was selected. Plastic pipettes were used to transfer the sample into 
a 6-well plate containing 2ml DMEM and incubated in a humidified 37°C/5% CO2 incubator. Gene 
expression was analysed after 48-72hours.  
 
Untransfected CHO cells and CHO cells previously transfected with WT CTLA-4, KLESS CTLA-4 
(synthesised by Stratagene), green fluorescent protein (GFP) tagged CD80 and CD86 plasmid DNA 
were utilised in the experiments and maintained as described in section 2.2.1. 
 
2.4.2 Transfection using the Neon Transfection System 
Stable cultures of CHO cells expressing CTLA-4 constructs were transfected with CD63-GFP plasmid 
using the Neon Transfection System under the following conditions: 1600mV, 20ms, 1 pulse. Briefly, 
cells were counted, spun down (5minute at 490 g), and resuspended in DMEM (containing 10% FBS 
only) at a concentration of 1x106 cells/100µl. 10µg of plasmid DNA was transferred into a fresh 
eppendorf and combined with 100µl of cells. The cells and plasmid DNA was transferred into the Neon 
Pipette tip and the pipette was plugged into the pipette holder, which contained 3ml of DMEM alone. 
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The start button was selected. The transfected cells were transferred onto cover slips and left overnight 
in a 37°C incubator. 
  
2.4.3 Selection of transfected cells 
2.4.3.1 Antibiotic Resistance 
G418 was used to select transfected cells that expressed the required vectors. G418 was added to the 
medium of transfected CHO cells at a concentration of 500µg/ml each time the cells were passaged.  
 
2.4.3.2 Fluorescence Activated Cell Sorting (FACS) 
Following passage, 5ml of the transfected cells were centrifuged at 490 g for 5minutes, resuspended in 
100µl of DMEM and labelled with 3µl of PE-conjugated anti-CTLA-4 Ab at 4°C for 30minutes in a 
universal tube. Cells were washed in 5ml ice-cold DMEM at 870 g for 2minutes, filtered, and sorted 
using a MoFlo cell sorter to select cells expressing low levels of surface CTLA-4. Flow cytometry was 
used to screen the cells to obtain a clone of cells expressing the desired level of protein. 
 
2.5 Flow Cytometric Analysis 
2.5.1 Preparation for flow cytometric analysis 
Staining of cells was performed using PE-conjugated anti-CTLA-4 (primary Ab) for 30minutes and 
where indicated this was followed by detection using Alexa647 anti-mouse secondary Ab for 30minutes. 
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Unless otherwise indicated following the incubation with the primary Ab, cells were washed once in 2ml 
ice-cold DMEM and supernatant discarded. Where indicated following the incubation with the secondary 
Ab, cells were washed once in excess ice-cold DMEM and supernatant was discarded. Cells were 
resuspended in 200µl ice-cold PBS and kept on ice until FACs analysis. Unless otherwise indicated all 
washes were performed at 870 g for 2minutes. Control samples were stained using the same protocol 
using a PE-labelled isotype control Ab, PE-conjugated anti-CTLA-4 alone or Alexa647 anti-mouse 
secondary Ab alone. CHX was used at a final concentration of 10µg/ml, NH4Cl was used at a final 
concentration of 10mM, BafA was used at a final concentration of 50nM, MG132 was used at a final 
concentration of 5µM and UBEI-41 was used at a final concentration of 20µM.   
 
2.5.2 Staining different pools of CTLA-4 
A total of 2x105 cells suspended in 100µl of medium were incubated at 4°C (surface CTLA-4) or 37°C 
(endocytosed CTLA-4) with PE-conjugated anti-CTLA-4 Ab. Cells were washed, resuspended in ice-
cold PBS and kept on ice. 
 
Total CTLA-4 expression was determined by fixing cells in 500µl of 3% PFA for 10minutes at room 
temperature. Cells were washed in PFA, supernatant discarded, and cells were resuspended and 
washed in 500µl of 0.1% saponin (PBS/sap). Supernatant was discarded and the cells were incubated 
with PE-conjugated anti-CTLA-4 Ab at room temperature for 30minutes in the dark. Cells were washed 
in 500µl PBS/sap, resuspended in 200µl of PBS and kept on ice. All washes were performed at 490 g 
for 5minutes. 
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Where indicated, cells were pre-incubated with MG132 at 37°C before analysing the effect of this 
chemical on CTLA-4 localisation. 
 
2.5.3 CTLA-4 Internalisation 
A total of 2x105 cells suspended in 100µl of medium or 0.45M sucrose were incubated with PE-
conjugated anti-CTLA-4 Ab at 4°C. Cells were washed, resuspended and raised to 37°C for 1minute, 
5minutes, 15minutes, and 30minutes followed by incubation with Alexa647 anti-mouse secondary Ab at 
4°C. Cells were washed, resuspended in ice-cold PBS and kept on ice (figure 2.1A).  
 
2.5.4 CTLA-4 Recycling 
A total of 2x105 cells suspended in 100µl of medium were incubated with PE-conjugated anti-CTLA-4 
Ab at 37°C. Cells were washed, resuspended and incubated with Alexa647 anti-mouse secondary Ab at 
4°C or raised to 37°C for 2minutes, 4minutes, 8minutes, 16minutes and 30minutes. Cells were washed, 
resuspended in ice-cold PBS and kept on ice (figure 2.1B).  
 
Where indicated, cells were pre-incubated with MG132 or UBEI-41 for 2hours at 37°C before analysing 
the effect of these chemicals on CTLA-4 recycling. 
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Figure 2.1 Diagrammatic representations of the internalisation and recycling assay performed by 
FACs. (A) CHO cells expressing CTLA-4 were labelled at 4°C with PE-conjugated anti-CTLA-4 Ab to 
label surface CTLA-4. Cells were then warmed to 37°C to allow endocytosis. Cells were placed on ice 
and any remaining surface CTLA-4 detected with Alexa647 anti-mouse secondary Ab. In the case of an 
endocytic protein, the loss of the secondary Ab signal indicates protein endocytosis. In the case of a 
surface protein, little or no loss of secondary Ab should be observed. (B) CHO cells expressing CTLA-4 
were labelled with PE-conjugated anti-CTLA-4 Ab at 37°C to detect cycling CTLA-4, washed and any 
recycling primary Ab detected by addition of Alexa647 anti-mouse secondary Ab at either 4°C or 37°C.  
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There are two factors to consider when analysing the recycling FACs plots. Firstly how well the receptor 
internalises after the primary Ab label (figure 2.2A, orange line) and secondly the efficiency of 
recycling as determined by how fast the internalised receptor recycles back to the cell surface (figure 
2.2A, black line). For a highly endocytic receptor the control re-staining at 4°C with Alexa647 would 
reveal no signal, as all the PE-labelled receptor would have internalised. If the receptor recycles as 
efficiently as it internalises, incubation at 37°C with Alexa647 should result in a 1:1 relationship between 
the primary and secondary Ab indicating that all the internalised receptor has recycled back to the cell 
surface. For some receptors, complete endocytosis is not achieved but the internalised protein is able to 
recycle back to the cell surface producing a 1:1 relationship between the primary and secondary Ab 
(figure 2.2B). For other receptors, complete endocytosis is not achieved and not all of the internalised 
protein is able to recycle back to the cell surface (figure 2.2C). In the case of a surface receptor the 
amount of protein at the surface should remain the same after a 4°C or 37°C incubation with Alexa647 
(figure 2.2D). 
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Figure 2.2 Analysis of recycling FACs plots. FACS plots are shown for PE-label (cycling CTLA-4) vs 
Alexa647 label (recycling CTLA-4). (A) FACs plot for a typical endocytic protein. In the 4°C control, 
there is no CTLA-4 remaining at the surface to be detected by Alexa647. However after a 37°C 
incubation, all the internalised protein recycles back to the surface producing a 1:1 relationship between 
the primary and secondary Ab. (B) In the 4°C control, the endocytic protein does not clear all the protein 
from the cell surface, however after incubation at 37°C with Alexa647 all the internalised protein has 
efficiently recycled back to the cell surface. (C) In the 4°C control, the endocytic protein does not clear 
all the protein from the cell surface. After incubation at 37°C with Alexa647 not all of the internalised 
protein recycles back to the cell surface. (D) FACs plot for a typical surface protein. The level of protein 
at the surface remains the same in the 4°C control and after 37°C incubation with Alexa647. 
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2.5.5 CTLA-4 Degradation 
A total of 2x105 cells suspended in 200µl of medium alone or medium supplemented with CHX, BafA, 
NH4Cl, BafA and CHX or NH4Cl and CHX were incubated at 37°C for 3hours in a 96-well round bottom 
plate. Cells were fixed and permeabilsed as described in section 2.5.2 and stained for total CTLA-4 with 
PE-conjugated anti-CTLA-4 Ab for 1hour at room temperature in the dark.  
 
2.5.6 Transendocytosis assay 
A total of 5x106 CD80-GFP or CD86-GFP transfected CHO cells were violet labeled with CellTrace 
Violet in 1ml PBS for 10minutes at room temperature. Cells were washed in 5ml PBS at 490 g for 
5minutes and resuspended in DMEM at a concentration of 2x106/ml. CTLA-4 transfected CHO cells 
were counted and resuspended at a concentration of 2x106/ml.  CTLA-4 transfected CHO cells were 
then incubated with violet labeled CD80-GFP or CD86-GFP at a 1:1 ratio in the presence or absence of 
NH4Cl for 3hours at 37°C in a 96-well round bottom plate. Cells were washed in 2ml ice-cold PBS and 
kept on ice. GFP transfer was quantified by gating single expressing CTLA-4 cells that were negative for 
Violet dye staining. CTLA-4 expressing cells were stained for cycling CTLA-4 to quantify the efficiency 
of capture. To obtain capture efficiency the percentage of cells that have acquired GFP was multiplied 
by the mean fluorescence intensity (MFI) of this population. This was divided by the percentage of 
positive CTLA-4 expressing cells (cycling) by the MFI of this population. Cells were analysed on the 
Dako cyan as shown in figure 2.3. 
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Figure 2.3 Gating strategy used for GFP acquisition and efficiency of capture by CTLA-4 
expressing CHO cells. 1. FSC vs SSC was used to gate live cells. 2. A low pulse width was used to 
gate single cells. 3. Cell trace violet labelled CHO-CD80/CD86-GFP cells were excluded. 4A. 
Percentage of CTLA-4 expressing cells that have acquired GFP was multiplied by the MFI of this 
population. 4B. The MFI of CTLA-4 expressing cells (cycling) was multiplied by the percentage of 
CTLA-4 expressing cells that have acquired GFP shown in 4A. 
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2.5.7 Sample Acquisition and Analysis 
Flow cytometry was carried out using a FACSCalibur flow cytometer and acquired using CellQuest 
software. For each sample, data for 10,000 cells within a gated region was collected. For 
transendocytosis flow cytometry was carried out using a Dako Cyan flow cytometer and acquired using 
Summit software. Analysis was performed using FlowJo software.  
 
2.5.8 Statistical Analysis 
Significance was calculated by a two-tailed Mann Whitney U test, as indicated in the figure legends, 
using GraphPad Prism4 software. This test allows two groups or conditions to be compared without 
making the assumption that the values are normally distributed.   
 
2.6 Confocal Microscopy Analysis 
2.6.1 Preparation of Cells for confocal microscopy 
Cover slips were coated with an excess of poly-L-lysine for 1hour at room temperature, washed twice in 
excess PBS and plated into a 24-well plate. PBS was aspirated to allow the cover slips to dry 
completely. A total of 1.5x105 cells suspended in 1ml of medium were grown on cover slips overnight at 
37°C. Staining of cells was performed using unlabelled anti-CTLA-4 Ab for 1hour and an AlexaFluor 
secondary Ab for 1hour. Unless otherwise indicated Ab incubations were performed in the dark at room 
temperature. For live cells, Ab dilutions and washes were performed in 1ml ice-cold DMEM. For cells 
fixed and permeabilised in Methanol, Ab dilutions and washes were performed in PBS. For cells fixed 
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and permeabilised in 3% PFA and PBS/sap, Ab dilutions and washes were performed in PBS/sap. All 
washes were performed three times. Following staining, cover slips were removed and dried at 37°C for 
10minutes. Cover slips were inverted and mounted onto microscope slides containing 1.8µl of 
Vectashield (Vector Laboratories, CA) as a mounting medium. 
 
2.6.2 Staining different pools of CTLA-4 
Surface expression was detected by incubating cells in 200µl of unlabelled anti-CTLA-4 Ab at 4°C for 
1hour, and cycling CTLA-4 was detected by incubation at 37°C. Cells were fixed in 1ml 100% Methanol 
at -20°C for 30minutes. Cells were washed and incubated in 200µl Alexa555 anti-mouse secondary Ab. 
Cells were washed in PBS and cover slips mounted as described in section 2.6.1.  
 
Total CTLA-4 expression was determined by fixing cells in 100% Methanol at -20°C for 30minutes, prior 
to incubation in unlabelled anti-CTLA-4 Ab and Alexa555 anti-mouse secondary Ab. Untransfected CHO 
cells were stained using the same protocol and used as a negative control. 
 
2.6.3 CTLA-4 chimera localisation 
For analysis of localisation, CHO cells expressing CTLA-4 chimeras were plated overnight on a poly-L-
lysine coated coverslip in a 24-well plate. For surface expression, cells were incubated with WGA - 
tetramethylrhodamine conjugate at 4°C for 45minutes. Cells were fixed in 500µl of 3% PFA for 
15minutes in the dark at room temperature prior to incubation in 200µl of unlabelled anti-CTLA-4 Ab, 
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washed and then incubated in 200µl Alexa488 anti-human secondary Ab at room temperature. Cells 
were washed in PBS/sap and cover slips mounted as described in section 2.6.1. 
 
2.6.4 Surface vs Internalised CTLA-4 
For analysis of surface vs internalised CTLA-4, cells were incubated at 37°C with unlabelled anti-CTLA-
4 Ab for 1hour, washed and then placed on ice. Surface receptors were labeled with Alexa555 anti-
mouse secondary Ab. Cells were then washed and fixed in 100% Methanol at -20°C for 30minutes. 
Internalised receptors were then detected by incubation with Alexa488 anti-mouse secondary Ab. Cells 
were washed in PBS and cover slips mounted as described in section 2.6.1. 
 
2.6.5 CTLA-4 Recycling 
Cells suspended in 200µl and labelled with unlabelled anti-CTLA-4 Ab at 37°C for 1hour. Cells were 
washed and incubated at 4°C with Alexa488 anti-mouse secondary Ab to label surface CTLA-4 for 
1hour. Cells were washed and incubated at 37°C with Alexa555 anti-mouse secondary Ab to label 
recycled CTLA-4. To ensure surface receptors were completely blocked, Alexa555 anti-mouse 
secondary Ab was applied to the 4°C control. Cells were washed in PBS and cover slips mounted as 
described in section 2.6.1. 
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2.6.6 CTLA-4 Degradation 
A total of 2x105 cells suspended in 200µl of medium alone or medium supplemented with CHX, BafA, 
NH4Cl, BafA and CHX or NH4Cl and CHX were incubated at 37°C for 3hours. Cells were fixed in 500µl 
of 3% PFA for 15minutes in the dark at room temperature prior to incubation in 200µl of unlabelled anti-
CTLA-4 Ab, washed and then incubated in 200µl Alexa488 anti-mouse secondary Ab at room 
temperature. Cells were washed in PBS/sap and cover slips mounted as described in section 2.6.1. 
 
2.6.7 Transferrin Uptake 
A total of 2x105 cells were serum-starved at 37°C for 45minutes. Cells were resuspended in 250µl of 
serum-starved medium and labeled with transferrin AlexaFluor633 conjugate and PE-conjugated anti-
CTLA-4 at 37°C for 45minutes. Cells were fixed in 500µl of 3% PFA for 15minutes in the dark at room 
temperature. Cells were washed in PBS and cover slips mounted as described in section 2.6.1. 
 
2.6.8 Co-localisation with CD63-GFP 
CTLA-4 chimeras transiently transfected with CD63-GFP were suspended in 200µl of medium alone or 
medium supplemented with NH4Cl and incubated at 37°C for 3hours. Cells were fixed in 500µl of 3% 
PFA for 15minutes in the dark at room temperature prior to incubation in 200µl of unlabelled anti-CTLA-
4 Ab and Alexa555 anti-human secondary Ab. Cells were washed in PBS/sap and cover slips mounted 
as described in section 2.6.1. 
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2.6.9 Visualisation of fluorescence 
Imaging was carried out using a Zeiss Axiovert LSM510 confocal microscope and Zeiss LSM 780 
inverted laser scanning confocal microscope using a 100X oil-immersion objective with excitation at 
488nm, 543nm and 633nm. Constant laser powers and acquisition parameters were maintained 
throughout individual experiments for analysis. For quantitation, cells were outlined and MFI measured 
using ImageJ (Wayne Rasband, NIH). All confocal images shown are representative of at least 40 cells 
taken from at least three independent experiments. 
 
2.7 Protein Analysis 
2.7.1 Sodium-Dodecyl-Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins were analysed by SDS-PAGE. Briefly, protein was mixed with Protein Loading Buffer (2X) and 
samples were heat-denatured at 100°C for 5minutes prior to separation. 10% polyacrylamide gels were 
run in Tris-glycine-SDS electrophoresis buffer (230.3g Tris, 144g Glycine and 10g SDS) at a constant 
current of 125volts for 1hour 30minutes, alongside a protein marker. Precast gradient gels (4-20%) were 
used (Thermo Fisher Scientific, USA) to achieve better resolution of bands and samples were separated 
in Tris-HEPES-SDS electrophoresis buffer (100 mM Tris Base (pH 8.3), 100 mM HEPES 
(electrophoresis grade) and 3 mM SDS). 
 
Prior to casting the gel, glass plates were wiped down with 70% Ethanol and a glass plate sandwich 
was setup in a gel-casting stand (Bio-rad Mini PROTEAN 3 Electrophoresis System). The following 
components were mixed to make two 10% polyacrylamide gels: separating gel - 9.9ml distilled H2O, 
 77 
8.3ml Protogel 30%, 6.5ml Resolving buffer (2X), 100µl APS (0.1g/ml) and 20µl TEMED; stacking gel – 
6.3ml distilled H2O, 1.3ml Protogel 30%, 2.5ml Stacking buffer (2X), 50µl APS and 10µl TEMED. 
TEMED was added to the mix in the fume cupboard. The separating gel was pipetted into the glass 
sandwich until the solution was ¾ of the way to the top. This was overlayed with 1ml dH2O to allow 
polymerisation for 30minutes. After the gel had polymerised the water was removed by placing a paper 
towel in the corner of the sandwich. The stacking gel was pipetted into the glass sandwich until the gel 
reached the very top of the glass plate and a 1.5mm comb was inserted. The stacking gel was left to 
polymerise for 30minutes.  
 
2.7.2 CTLA-4 Immunoprecipitation 
Cells were pelleted and lysed in 1ml 1% Triton X-100 (1% Triton, 20mM Tris pH7.5, 150nM NaCl, 1mM 
EDTA and 0.02% Sodium azide) at 4°C for 30minutes containing protease cocktail inhibitor (1:100). 
Cells were centrifuged at 15.7 g for 10minutes at 4°C to remove cell debris. 50µl of cleared lysate was 
taken and added to an equal volume of Protein Loading buffer (2X) to make a whole cell lysate (WCL). 
For immunoprecipitation studies, 50µl of protein-G-sepharose beads were pre-coated with 2.5µg anti-
human CTLA-4 Ab suspended in 750µl of 1% Triton X-100 overnight at 4°C. The bead-Ab complex was 
pelleted by centrifugation at 2.3 g for 20seconds. The pellet was then washed three times in 1ml 1% 
Triton X-100. Prior to the final wash, the 1ml bead-Ab complex was divided into two clean, eppendorf 
tubes, centrifuged and supernatant aspirated. 925µl of the lysate was added to the complex, vortexed 
and incubated at 4°C for 1hour and 30minutes. Following this, the beads were pelleted by centrifugation 
at 2.3 g for 20seconds and washed four times in 1ml 1% Triton X-100. Prior to the final wash the beads 
resuspended in 1ml 1% Triton X-100 were transferred to a clean eppendorf tube and centrifuged at 2.3 
g for 10 seconds. Supernatant was aspirated leaving behind 50µl of 1% Triton X-100. The beads were 
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centrifuged for a further 10 seconds, supernatant was aspirated and the beads were resuspended in 
40µl Protein Loading Buffer (2X).   
 
2.7.3 Immunoblotting 
Immunoblot analysis was performed using 10% polyacrylamide gels or precast gradient gels. Proteins 
were electrophoretically transferred to Immobilon-FL PVDF transfer membranes in transfer buffer at 
350mA (100volts) for 1hour using a wet transfer system (Mini Trans-Blot Electrophoretic Transfer Cell, 
BIO-RAD). Membranes were activated for 1minute in Methanol. Gels and membranes were equilibrated 
in 1X transfer buffer (100ml Electroblotting Buffer Tris-glycine (10X), 200ml Methanol and 800ml dH2O) 
for 30minutes. A transfer sandwich was set up as follows: a cassette was placed on a clean surface with 
the gray side up, pre-wetted fiber pad, sheet of filter paper, equilibrated gel, pre-wetted membrane, 
sheet of filter paper and pre-wetted fiber pad. A glass roller was used to remove any air bubbles. 
Membranes were blocked for 1hour at room temperature in 50ml of 5% milk/TBS with gentle shaking. 
Membranes were incubated overnight at 4°C with the desired Ab (1µg/ml) diluted in Tris-buffered-saline 
with 0.1% Tween (TBST) containing 3% BSA and 0.1% Sodium azide. Membranes were then washed 
three times in high salt TBST over a 30minute period. Following this, membranes were incubated with 
IRDye 800 secondary Ab (goat anti-mouse 1:10000) diluted in TBST containing 3% BSA and 0.1% 
Sodium azide for 1hour. Membranes were subsequently washed five times in high salt TBST over a 
25minute period, followed by a final wash in Tris-buffered-saline (TBS) for 1minute. Membranes were 
then dried on filter paper and analysed using the Odyssey Infrared Imaging System (LI-COR 
Biosciences, Lincoln, NE). 
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For blots developed using the Pierce ECL Western Blotting Substrate, proteins were electrophoretically 
transferred to nitrocellulose membrane. The substrate solution was prepared by mixing equal parts of 
Detection Reagent 1 and 2. The membrane was transferred onto a clear plastic wrap and substrate 
solution applied. Following 1minute incubation, paper tissue was used to remove excess liquid and any 
bubbles present between the blot and membrane protector. The protected membrane was placed in a 
film cassette with the protein side facing up. X-ray film was placed on top of the membrane and film was 
developed in the dark room. Exposure time was varied to achieve optimal results.  
 
2.7.4 Biochemical quantification of CTLA-4 internalisation 
For analysis of internalisation, CTLA-4 transfected CHO cells were grown overnight in 6cm tissue 
culture petri dishes. Cells were transferred to ice and were surface labelled at 4°C with NHS-SS-biotin 
in PBS for 25minutes. Biotin was removed and cells re-labelled with NHS-SS-biotin for 25minutes. Cells 
were washed three times in ice-cold PBS and biotin quenched in 500µl Quenching solution at 4°C for 
10minutes. Cells were washed three times in ice-cold PBS and transferred immediately to pre-warmed 
medium at 37°C to allow internalisation. At the indicated times the cells were rapidly transferred to ice, 
medium aspirated and washed twice with ice-cold PBS. Biotin was removed from proteins remaining at 
the cell surface by Sodium 2-mercaptoethanesulphonate (MesNa) prepared in cell surface reduction 
buffer (50mM Tris and 100mM NaCl adjusted to pH8.6). Reduction proceeded for 25minutes at 4°C with 
gentle rocking. Cells were washed three times in ice-cold PBS before lysis in 150µl 1% Triton X-100 
(1% Triton, 20mM Tris pH7.5, 150nM NaCl, 1mM EDTA and 0.02% Sodium azide) at 4°C for 1hour 
containing protease cocktail inhibitor (1:100). 40µl of whole cell lysate (WCL) was removed prior to the 
addition of the sample to a neutravidin gel. Briefly, 100µl neutravidin gel was added to a column, 
centrifuged and supernatant discarded. The column was washed and then capped before addition of the 
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remaining sample for overnight end-to-end mixing at 4°C. Next day, the cap was removed, column 
centrifuged and supernatant discarded. 100µl Dithiothreitol (DTT) prepared in 2X Protein Loading 
Buffer (70mM) was added to the capped tube and the column was incubated at room temperature with 
end-to-end mixing for 1hour. The cap was removed and column transferred to an eppendorf before 
centrifuging for 2minutes. Proteins were analysed by SDS-PAGE and western blotting. Unless 
otherwise indicated all centrifuge washes were performed at 3.3 g. 
 
2.7.5 CTLA-4 Degradation 
A total of 4x106 cells suspended in 4ml of medium alone or medium supplemented with CHX, NH4Cl, or 
NH4Cl and CHX were incubated at 37°C for 3hours. Cells were lysed and immunoprecipitated as 
described in section 2.7.2. Immunoblotting was performed as described in section 2.7.3 using the 
Odyssey Infrared Imaging System. CTLA-4 was blotted using the C-19 C-terminus anti-CTLA-4 Ab. 
 
2.7.6 CTLA-4 Ubiquitination 
CTLA-4 transfected CHO were stained for total CTLA-4 expression as described in section 2.5.2. Cell 
numbers with equivalent CTLA-4 protein were suspended in 5ml of medium alone or medium 
supplemented with BafA and incubated at 37°C for 3hours in a universal tube. Cells were lysed and 
immunoprecipitated as described in section 2.7.2. Immunoblotting was performed as described in 
section 2.7.3 using ECL. CTLA-4 was blotted using the C-19 C-terminus anti-CTLA-4 Ab and ubiquitin 
was blotted using an anti-ubiquitin Ab.  
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3.0 CHARACTERISING THE CELL BIOLOGY OF THE CTLA-4 
RECEPTOR 
 
3.1 Introduction 
CTLA-4 surface expression has been difficult to demonstrate by flow cytometry. One model used to 
explain this lack of surface expression is the constitutive internalisation of CTLA-4 from the cell surface 
mediated by the YVKM motif located in the cytoplasmic tail associating with the clathrin adaptor AP-2 
(Chuang et al., 1997; Leung et al., 1995; Shiratori et al., 1997). Following T cell stimulation, however, 
CTLA-4 expression is upregulated and the receptor is trafficked to the cell surface. It has been 
proposed that this event is accompanied by tyrosine phosphorylation of the YVKM motif, which leads to 
CTLA-4 stabilisation at the plasma membrane (Miyatake et al., 1998; Shiratori et al., 1997). 
Theoretically tyrosine phosphorylation should block any association of YVKM with AP-2 and ultimately 
result in predominant cell surface accumulation of CTLA-4. However, when T cells are stained for total 
CTLA-4 expression there is predominant localisation of CTLA-4 in intracellular vesicles (Qureshi et al., 
2012; Walker and Sansom, 2011). This therefore suggests that CTLA-4 endocytosis is a more complex 
process than initially thought. Moreover little is known about how the receptor is sorted in intracellular 
compartments. In this chapter I have therefore investigated the mechanisms that regulate the trafficking 
of the CTLA-4 receptor.  
 
3.2 CTLA-4 is an endocytic receptor and is located in intracellular vesicles 
In our lab, stable lines of CTLA-4 transfected CHO cells were established previously as a manipulable 
model of how CTLA-4 expression is controlled in T cells. Such a model has overcome the potential 
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drawbacks of using T cells including the time-consuming purification from PBMCs, several hours of 
stimulation to induce CTLA-4 expression for detection at the cell surface, and the large cytoplasm of 
CHO cells has eased co-localisation studies. The levels of CTLA-4 can be monitored and adjusted 
using cell sorting, and further the genetic analyses of the role of candidate trafficking proteins can be 
determined by co-transfecting additional plasmids into these cell lines. CTLA-4 transfected CHO cells 
were therefore used to further elucidate the intracellular trafficking of CTLA-4 and establish whether 
findings from CHO model systems were valid in CTLA-4 transfected Jurkat T cells and activated T cells. 
 
To characterise the trafficking of CTLA-4 in CTLA-4 transfected CHO cells and activated T cells, CTLA-
4 expression was compared using three different staining protocols. CTLA-4 transfected CHO cells 
were labelled with PE-conjugated anti-CTLA-4 Ab at 4°C, 37°C or were fixed and permeabilised before 
analysis by flow cytometry. In live cells staining at 4°C labelled all surface expressed CTLA-4 since at 
this temperature all metabolic processes, including protein trafficking, was inhibited. Staining at 37°C 
labelled all surface expressed CTLA-4 that was present during Ab staining, as well as protein that had 
been endocytosed from the cell surface. Finally, in cells that were fixed and permeabilised the total pool 
of CTLA-4 protein was measured before Ab staining. This included CTLA-4 within the endocytic 
pathway, newly synthesised CTLA-4 within the secretory pathway, and CTLA-4 within storage 
compartments. As shown in figure 3.1A, CHO cells expressing human CTLA-4 had a 5-fold lower cell 
surface expression at 4°C compared to cells stained for endocytosed CTLA-4 at 37°C. Moreover, the 
level of CTLA-4 expression in fixed and permeabilised cells was comparable to that identified in cells 
stained at 37°C further suggesting CTLA-4 is predominantly located in endocytic compartments (figure 
3.1B).  
 
 83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Human CTLA-4 is located in punctate intracellular vesicles with limited cell surface 
expression. (A) CHO cells expressing human CTLA-4 were stained for surface CTLA-4 expression at 
4°C; endocytosed CTLA-4 expression at 37°C; or were fixed and permeabilised prior to staining for total 
CTLA-4 expression with PE-conjugated anti-CTLA-4 Ab. Cells were analysed by flow cytometry. 
Representative FACs plots of one independent experiment of n=7. (B) Horizontal lines indicate median 
values. Significance was tested by two-tailed Mann Whitney U test. (***, p<0.001). (C) CHO cells 
expressing human CTLA-4 were stained as described in A. with an unlabelled anti-CTLA-4 Ab and 
Alexa555 anti-mouse secondary Ab (n=5). Bar indicates scale of 10µm. 
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To validate CTLA-4 localisation in endocytic compartments as identified by flow cytometry, the staining 
of surface, cycling and total human CTLA-4 expression in CHO cells was repeated and analysed by 
confocal microscopy. Consistent with flow cytometry, staining at 4°C revealed little or no human CTLA-4 
at the plasma membrane, whilst staining at 37°C revealed CTLA-4 to be located predominantly in 
intracellular vesicles (figure 3.1C). This is consistent with the concept that CTLA-4 was being exported 
to the plasma membrane and then rapidly endocytosed, contributing to the low steady-state level seen 
at the cell surface. In fixed and permeabilised cells, a perinuclear compartment was observed 
containing high levels of CTLA-4, representing either newly synthesised protein or protein that had been 
endocytosed and targeted back to this compartment. 
 
The pattern of CTLA-4 expression was reproducible in CTLA-4 transfected Jurkat T cells where CTLA-4 
expression was higher at 37°C compared to 4°C (figure 3.2). However, total CTLA-4 expression in 
Jurkat T cells was higher than the combined surface and cycling pool of the receptor. To characterise 
CTLA-4 expression in human T cells, CD4+CD25- T-cells were stimulated with anti-CD3 and anti-CD28 
beads for 3 days or 5 days. In keeping with literature, CTLA-4 was upregulated in activated T cells and 
levels peaked after 3 days of stimulation (figure 3.3A and B). CTLA-4 expression decreased after 5 
days of stimulation but was still detectable (figure 3.3C and D). Importantly similar to CTLA-4 
transfected Jurkat T cells, total CTLA-4 expression in activated T cells was higher when compared to 
cells stained at 37°C. This data suggests that only a fraction of total CTLA-4 is trafficking at any given 
time and that the vast majority of the protein may be stored in a storage compartment as is described 
for Glucose transporter type 4 (GLUT4) (Slot et al., 1991a; Slot et al., 1991b).  
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Figure 3.2 The pattern of human CTLA-4 expression in CTLA-4 transfected Jurkat T cells is 
comparable to CTLA-4 transfected CHO cells. Jurkat T cells expressing human CTLA-4 were stained 
for surface CTLA-4 expression at 4°C; endocytosed CTLA-4 expression at 37°C; or were fixed and 
permeabilised prior to staining for total CTLA-4 expression at room temperature with PE-conjugated 
anti-CTLA-4 Ab. Cells were analysed by flow cytometry. Horizontal lines indicate median values. 
Significance was tested by two-tailed Mann Whitney U test (n=3). (n.s, not significant). 
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Figure 3.3 The pattern of human CTLA-4 expression in activated T cells is comparable to CTLA-4 
transfected CHO cells and Jurkat T cells. CD4+CD25- T cells were left untreated (unstimulated) or 
stimulated with anti-CD3/CD28 beads. At three days (A and B) and five days (C and D) cells were 
stained for surface CTLA-4 expression at 4°C; endocytosed CTLA-4 expression at 37°C; or were fixed 
and permeabilised prior to staining for total CTLA-4 expression at room temperature with PE-conjugated 
anti-CTLA-4 Ab. Cells were analysed by flow cytometry. Horizontal lines indicate median values. 
Significance was tested by two-tailed Mann Whitney U test (n≥3). (n.s, not significant; *, p<0.05). 
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In contrast to CD4+CD25- T cells, Tregs constitutively express CTLA-4, which raises questions as to 
whether there is a difference in the turnover and trafficking of the receptor in the two cell types. To 
address this, CD4+CD25+ T cells were stimulated with anti-CD3/CD28 beads and IL-2 prior to staining 
for CTLA-4 localisation. In contrast to CD4+CD25- T cells, total CTLA-4 expression was detectable in 
unstimulated Tregs (figure 3.3A and C vs 3.4A). Comparable to stimulated T cells however, CTLA-4 
expression in Tregs was upregulated after stimulation (figure 3.3B and D vs 3.4B). Importantly, a 3-fold 
increase was observed in total CTLA-4 (unstimulated Tregs vs stimulated Tregs), again suggesting at 
steady state CTLA-4 could be stored and mobilised from storage compartments (figure 3.4A vs 3.4B). 
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Figure 3.4 The pattern of CTLA-4 expression in CD4+CD25+ Tregs is comparable to CD4+CD25-
activated T cells. CD4+CD25+ T cells were unstimulated (A) or stimulated overnight with IL-2 and anti-
CD3/CD28 beads (B). Cells were stained for surface CTLA-4 expression at 4°C; endocytosed CTLA-4 
expression at 37°C; or were fixed and permeabilised prior to staining for total CTLA-4 expression at 
room temperature with PE-conjugated anti-CTLA-4 Ab. Cells were analysed by flow cytometry. Error 
bars show standard error (n=3).  
A B 
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3.3 CTLA-4 endocytosis is clathrin-dependent 
CTLA-4 localisation in intracellular vesicles questions the role of the tyrosine based hydrophobic motif 
(YVKM) located in the cytoplasmic tail driving its constitutive internalisation from the cell surface. To 
directly measure endocytosis CTLA-4 transfected CHO cells were stained for surface CTLA-4 
expression at 4°C with PE-conjugated anti-CTLA-4 Ab. Cells were warmed to 37°C for various times to 
allow any internalisation of surface CTLA-4 to take place. Cells were then placed on ice and any 
remaining CTLA-4 at the surface detected with Alexa647 anti-mouse secondary Ab. Accordingly in this 
assay loss of Alexa647 staining over time reflects endocytosis of CTLA-4. Figure 3.5A shows that in the 
4°C control there was a linear relationship between CTLA-4-PE (y-axis) and Alexa647 (x-axis). 
However after 30minute incubation at 37°C a curved plot was generated where the initial PE-labelled 
surface CTLA-4 internalised resulting in a minimal surface Alexa647 label, typical of an endocytic 
protein. Figure 3.5B shows that human CTLA-4 has a fast rate of endocytosis with 50% of the protein 
internalising within 5minutes. Since internalisation of CTLA-4 occurs in an AP-2 mediated, clathrin-
dependent manner (Chuang et al., 1997; Shiratori et al., 1997), treatment with sucrose can be used to 
inhibit the formation of CCVs (Heuser and Anderson, 1989). Accordingly the rapid internalisation of 
human CTLA-4 was prevented by sucrose treatment (figure 3.5B).  
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Figure 3.5 Human CTLA-4 has a fast rate of internalisation. (A) CHO cells expressing human CTLA-
4 were labelled at 4°C with PE-conjugated anti-CTLA-4 Ab. Cells were then warmed to 37°C to allow 
endocytosis for the times indicated. Cells were then placed on ice and any remaining surface CTLA-4 
detected with Alexa647 anti-mouse secondary Ab. Representative FACs plot of one experiment 
showing remaining surface CTLA-4 after maximum 37°C incubation (red) compared to 4°C (black). (B) 
The 647 signal was plotted against time as a fraction remaining compared to 4°C in medium or medium 
supplemented with sucrose. Error bars show standard error (n≥3).  
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To confirm that antibody binding is not inducing receptor endocytosis, CTLA-4 internalisation was 
measured by western blotting. Cell surface CTLA-4 was biotinylated at 4°C. Cells were then either kept 
on ice or warmed to 37°C for the indicated time-points and any remaining surface biotin was cleaved off 
by reducing agent. Cells were lysed and internalised CTLA-4 was concentrated by immunoprecipitating 
biotin using a neutravidin gel. Membranes were then probed for CTLA-4 using a C-19 C-terminus anti-
CTLA-4 Ab. For human CTLA-4 maximal protection of biotinylated protein was seen after 15minutes 
(figure 3.6). However after 30minutes this protected pool of internalised CTLA-4 decreased, which 
could be suggestive of degradation. The difference in internalisation rate as detected by flow cytometry 
and western blotting could be due to the sensitivity of the assays.   
 
The TfR is well characterised and internalises by clathrin-dependent endocytosis using signals encoded 
in the cytoplasmic tail (Iacopetta et al., 1988). Using transferrin as a marker for the clathrin pathway, the 
co-localisation of CTLA-4 with transferrin was compared. Cells were incubated with transferrin 
AlexaFluor633 and PE-conjugated anti-CTLA-4 Ab at 37°C for 45minutes and subsequently fixed and 
analysed by confocal microscopy. This revealed that human CTLA-4 co-localised with transferrin in 
intracellular vesicles suggesting that the internalisation pathway used by CTLA-4 overlaps with the 
pathway used by the TfR (figure 3.7). Taken together, this data confirms that CTLA-4 internalisation is 
clathrin-dependent and is not induced by Ab binding. 
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Figure 3.6 Antibody binding does not induce human CTLA-4 endocytosis. Cell surface CTLA-4 
was biotinylated at 4°C. Cells were then either kept on ice or warmed to 37°C for the indicated time-
points and any remaining surface biotin was reduced. Cells were lysed and internalised CTLA-4 was 
concentrated by immunoprecipitating biotin using a neutravidin gel. Membranes were then probed for 
CTLA-4 using a C-19 C-terminus anti-CTLA-4 Ab. CTLA-4 has a molecular weight of ~ 30kDa. IP, 
immunoprecipitated CTLA-4 - bands represent CTLA-4 that was internalised and protected. WCL, whole 
cell lysate - bands represent total amount of CTLA-4 protein present in each condition. This is 
representative of 3 independent experiments.  
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Figure 3.7 Human CTLA-4 co-localises with TfR. CTLA-4 transfected CHO cells were incubated with 
a transferrin AlexaFluor633 conjugate and PE-conjugated anti-CTLA-4 Ab at 37°C for 45minutes. Cells 
were subsequently fixed and analysed by confocal microscopy. The red arrows indicate co-localisation. 
This is representative of 3 independent experiments. Bar indicates scale of 10µm. 
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3.4 CTLA-4 is recycled back to the cell surface 
The path taken by CTLA-4 post-internalisation is poorly understood. Despite studies suggesting that 
CTLA-4 co-localises with TfR in murine splenocytes and activated human T cells (Chuang et al., 1997; 
Leung et al., 1995), it is not clear if CTLA-4 like TfR also recycles back to the cell surface. To address 
CTLA-4 recycling, cells were incubated with an unlabelled anti-CTLA-4 Ab at 37°C for 1hour to label the 
cycling pool of CTLA-4. Cells were then placed on ice and any remaining cell surface CTLA-4 labelled 
with Alexa488 anti-mouse secondary Ab. Cells were then further stained at 37°C with Alexa555 anti-
mouse secondary Ab. This detects any internalised receptor that subsequently recycled back to the 
plasma membrane. Labeling at 37°C with the Alexa555 anti-mouse secondary Ab revealed a clear 
population of recycling CTLA-4 receptor (figure 3.8A top panel). In contrast, control staining at 4°C did 
not show any additional red surface labeling with the Alexa555 anti-mouse secondary Ab (figure 3.8A 
bottom panel).  
 
To validate that the CTLA-4 receptor does indeed recycle as identified by confocal microscopy, the 
assay was repeated using flow cytometry. Cells were incubated at 37°C with a PE-conjugated anti-
CTLA-4 Ab for 30 minutes to label the cycling pool of CTLA-4. Cells were then incubated further at 37°C 
for various times with an Alexa647 anti-mouse secondary Ab to label any of the primary Ab recycling 
back to the cell surface. Accordingly, recycling CTLA-4 is seen as an increase in the Alexa647 signal 
over time. As shown in figure 3.8B and C, after 30minute incubation at 37°C the control re-staining at 
4°C revealed only in a small percentage of cells does CTLA-4 protein remain at the surface to be 
detected by Alexa647. However, when cells are stained at 37°C with Alexa647, a greater pool of CTLA-
4 was seen. This data suggests the Alexa647 signal could only increase if the internalised PE-labelled 
CTLA-4 recycled back to the plasma membrane (figure 3.8C). Data was reproducible in CTLA-4 
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transfected Jurkat T cells further verifying the reliability of this assay (figure 3.9). Taken together this 
data suggests one path taken by CTLA-4 post-internalisation is to be recycled back to the cell surface. 
 
3.5 CTLA-4 is degraded in lysosomes 
CTLA-4 has been reported to interact with the lysosomal adaptor AP-1 and undergo degradation in a 
lysosomal compartment (Iida et al., 2000; Schneider et al., 1999). To measure the stability of the CTLA-
4 protein, CTLA-4 transfected CHO cells were incubated in medium or medium supplemented with CHX, 
NH4Cl or BafA, at 37°C for 3hours. CHX is an inhibitor of new protein synthesis and NH4Cl and BafA 
are inhibitors of lysosomal degradation. After treatment, cells were fixed and permeabilised prior to 
staining for total CTLA-4 expression. Degradation was analysed by both confocal microscopy and flow 
cytometry (figure 3.10 and 3.11A-B). In the absence of new protein synthesis, rapid loss of human 
CTLA-4 was observed indicating that CTLA-4 was degraded rapidly. Moreover, NH4Cl and BafA 
resulted in an accumulation of CTLA-4 suggesting that blocking lysosomal function prevents CTLA-4 
degradation. These results were also consistent with biochemical analysis of CTLA-4 by western 
blotting, indicating that CTLA-4 protein was indeed degraded rather than a loss of signal being due to 
loss of fluorescence (figure 3.11C). To validate the findings in CHO cells, the assay was repeated in 
CTLA-4 transfected Jurkat T cells and in activated T cells. The analysis in these cells revealed strong 
similarities in the pattern of CTLA-4 degradation observed in CHO cells (figure 3.12 and 3.13).  
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Figure 3.8 Human CTLA-4 recycles back to the cell surface after internalisation. (A) CHO cells 
expressing human CTLA-4 were labeled at 37°C with unlabelled anti-CTLA-4 Ab and then placed on ice 
to label surface CTLA-4 with Alexa488 anti-mouse secondary Ab (green). To observe recycling 
receptors, cells were labeled with Alexa555 anti-mouse secondary Ab (red) at 37°C and fixed before 
confocal analysis. Control conditions are shown where the Alexa555 Ab was incubated at 37°C (top) 
compared with incubation at 4°C (bottom). This is representative of 3 independent experiments. Bar 
indicates scale of 10µm. (B) CHO cells expressing human CTLA-4 were labeled with PE-conjugated 
anti-CTLA-4 Ab at 37°C to detect cycling CTLA-4, washed and any recycling primary Ab detected by 
addition of Alexa647 anti-mouse secondary Ab at either 4°C or 37°C. Representative FACS plots are 
shown for PE-label (cycling CTLA-4) vs Alexa647 label (recycling CTLA-4) at the indicated time points. 
(C) Recycling rates are plotted for human CTLA-4 as normalised to the 4°C control. Error bars show 
standard error (n=3).   
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Figure 3.9 Human CTLA-4 recycling in CTLA-4 transfected Jurkat T cells is comparable to CTLA-
4 transfected CHO cells. Jurkat T cells expressing human CTLA-4 were labelled with PE-conjugated 
anti-CTLA-4 Ab at 37°C to detect cycling CTLA-4, washed and any recycling primary Ab detected by 
addition of Alexa647 anti-mouse secondary Ab at either 4°C or 37°C. Recycling rates are plotted for 
human CTLA-4 as normalised to the 4°C control. Error bars show standard error (n=3). 
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Figure 3.10 Human CTLA-4 is degraded in lysosomal compartments. (A) CHO cells expressing 
human CTLA-4 were incubated in medium or medium supplemented with CHX, NH4Cl or BafA at 37°C 
for 3hours. Cells were stained for total CTLA-4 expression with an unlabelled anti-CTLA-4 Ab and 
Alexa488 anti-mouse secondary Ab and analysed by confocal microscopy. Bar indicates scale of 10µm. 
(B) Total CTLA-4 was quantified by outlining cells in ImageJ and MFI plotted. Error bars show standard 
error (n>3). MFI, mean fluorescence intensity. 
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Figure 3.11 Flow cytometry and western blotting verify that human CTLA-4 degradation takes 
place in lysosomal compartments. (A) CHO cells expressing human CTLA-4 were incubated in 
medium or medium supplemented with CHX, NH4Cl or BafA at 37°C for 3hours. Cells were stained for 
total CTLA-4 expression with a PE-conjugated anti-CTLA-4 Ab and analysed by flow cytometry. 
Representative FACs plots of one experiment. (B) The is MFI plotted as a percentage of initial 
fluorescence. Error bars show standard error (n>3). (C) Cells were treated as shown and CTLA-4 was 
then immunoprecipitated using an Ab binding to the extracellular region of CTLA-4. Expression of 
CTLA-4 was analysed by western blotting using a C-19 C-terminal anti-CTLA-4 Ab. This is 
representative of one independent experiment of n>3.  
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Figure 3.12 Human CTLA-4 degradation in CTLA-4 transfected Jurkat T cells is comparable to 
CTLA-4 transfected CHO cells. Jurkat T cells expressing CTLA-4 were incubated in medium or 
medium supplemented with CHX, NH4Cl or BafA at 37°C for 3hours. Cells were stained for total CTLA-4 
expression with a PE-conjugated anti-CTLA-4 Ab and analysed by flow cytometry. The MFI is plotted as 
a percentage of initial fluorescence. Error bars show standard error (n=3). 
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Figure 3.13 Human CTLA-4 degradation in activated T cells is comparable to CTLA-4 transfected 
CHO and Jurkat T cells. CD4+CD25- T cells were left untreated (unstimulated) or stimulated with anti-
CD3/CD28 beads. At three days (A and B) and five days (C and D) cells were incubated in medium or 
medium supplemented with CHX, NH4Cl or BafA at 37°C for 3hours. Cells were stained for total CTLA-4 
expression with a PE-conjugated anti-CTLA-4 Ab and analysed by flow cytometry. Error bars show 
standard error (n=3).   
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To determine if CTLA-4 co-localised with markers of late endosomes, CTLA-4 transfected CHO cells 
were transfected with CD63, fused to GFP, in the presence of NH4Cl. Notably, human CTLA-4 
demonstrated substantial co-localisation with CD63-GFP, suggesting traffic to late endosomes (figure 
3.14). Collectively these data suggest that degradation in lysosomal compartments may be one 
mechanism used to regulate the surface expression of CTLA-4 and could explain the decrease seen in 
the internalised biotinylated CTLA-4 protein in figure 3.6.  
 
3.6 CTLA-4 degradation is ubiquitin-dependent 
Ubiquitin has long been recognised as an important signal for targeting membrane proteins for 
destruction in proteasomes and lysosomes (Myung et al., 2001). Intracellular lysine residues serve as 
targets of ubiquitin attachment in receptor proteins. CTLA-4 has five lysine residues encoded in the 
cytoplasmic domain. To examine whether ubiquitin regulated CTLA-4 degradation, CTLA-4 was 
incubated in medium or medium supplemented with NH4Cl or BafA at 37°C for 3hours. CTLA-4 was 
then immunoprecipitated from CTLA-4 transfected CHO cells using an antibody binding the extracellular 
region of CTLA-4. Membranes were then probed for CTLA-4 with a C-19 C-terminus anti-CTLA-4 Ab 
and for ubiquitin with an anti-ubiquitin Ab, which binds both mono- and polyubiquitin. Figure 3.15 shows 
that treatment with NH4Cl and BafA resulted in an accumulation of CTLA-4, which suggests that by 
blocking lysosomal function the degradation of CTLA-4 is prevented. Moreover ubiquitinated proteins 
with molecular masses of ~ 46-58kDa were only detectable after BafA treatment and not with NH4Cl or 
the media control. This result could be explained by the fact that NH4Cl and BafA act at different sites 
within the cell. NH4Cl acts to inhibit the acidification of endosomes (Ohkuma and Poole, 1978) whereas 
BafA is a specific inhibitor of V-type H+-ATPase, which is required for lysosomal function (Yasir et al., 
2011). This data therefore suggests that NH4Cl accumulates CTLA-4 prior to the ubiquitination of the 
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receptor but BafA accumulates CTLA-4 after receptor ubiquitination. Taken together this data confirms 
that CTLA-4 degradation in lysosomes is ubiquitin-dependent. 
 
MG132 is an inhibitor of proteasomal degradation but can function to deplete free ubiquitin (Melikova et 
al., 2006). If CTLA-4 is degraded in lysosomes and this requires ubiquitin CTLA-4 levels should 
increase in the presence of MG132. To address the requirement of ubiquitin in CTLA-4 trafficking, CHO 
cells transfected with CTLA-4 were incubated in medium or medium supplemented with MG132 for 
2hours at 37°C. Cells were then stained for CTLA-4 expression using a PE-conjugated anti-CTLA-4 Ab 
at 4°C, 37°C or were fixed and permeabilised for total expression. Figure 3.16 shows an increase in 
surface, cycling and total CTLA-4 expression in the presence of MG132. This data suggests that by 
inhibiting CTLA-4 ubiquitination and degradation, the steady state is altered resulting in an increase of 
CTLA-4 receptor in the different locations. 
 
In order to maintain steady state when CTLA-4 degradation is blocked, a default pathway could be for 
the receptor to recycle back to the cell surface. In order to address if CTLA-4 recycling is enhanced after 
blocking degradation, CHO cells transfected with CTLA-4 were incubated in medium or medium 
supplemented with MG132 for 2hours at 37°C and the recycling assay as described in section 3.4 was 
repeated. To quantify any differences in recycling, the fraction of recycled protein was expressed as a 
percentage of labelled protein. Figure 3.17A shows that by depleting free ubiquitin and thereby blocking 
degradation CTLA-4 recycling is increased. 
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Figure 3.14 Human CTLA-4 co-localises with markers of late endosomes. CHO cells expressing 
human CTLA-4 were transfected with CD63-GFP. Cells were incubated in medium supplemented with 
NH4Cl at 37°C for 3hours. Cells were fixed, permeabilised, and stained with an unlabelled anti-CTLA-4 
Ab and Alexa565 anti-human secondary Ab (red) to stain total CTLA-4 protein and analysed by confocal 
microscopy. The red arrows indicate co-localisation. This is representative of one independent 
experiment of n=3. Bar indicates scale of 10µm. 
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Figure 3.15 Ubiquitination of the CTLA-4 receptor is revealed by blocking lysosomal degradation 
with BafA. CHO cells transfected with CTLA-4 were incubated in medium or medium supplemented 
with NH4Cl or BafA at 37°C for 3hours. CTLA-4 was then immunoprecipitated using an Ab binding to the 
extracellular region of CTLA-4. Expression of CTLA-4 was analysed by western blotting using a C-19 C-
terminal anti-CTLA-4 Ab and an anti-ubiquitin Ab.  
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Figure 3.16 The level of surface, cycling and total CTLA-4 expression increases when ubiquitin 
is depleted. CHO cells transfected with CTLA-4 were incubated with medium or medium supplemented 
with MG132 for 2hours at 37°C. Cells were then stained for surface, cycling or total CTLA-4 expression 
using a PE-conjugated anti-CTLA-4 Ab and analysed by flow cytometry. Representative FACs plots of 
one independent experiment of n=3.   
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Ubiquitin is attached to intracellular lysine residues via the ubiquitin conjugation cascade. UBEI-41 is an 
inhibitor of the E1-activating enzyme, which is required to start the cascade (Balut et al., 2011). If this 
enzyme is inhibited ubiquitin cannot be attached to intracellular lysine residues and this could inhibit 
CTLA-4 targeting to lysosomes. To address the effect of UBEI-41 on CTLA-4 trafficking, CHO cells 
transfected with CTLA-4 were incubated in medium or medium supplemented with UBEI-41 for 2hours 
at 37°C and the recycling assay as described in section 3.4 was repeated. To quantify any differences 
in recycling, the fraction of recycled protein was expressed as a percentage of labelled protein. Figure 
3.17B shows a steady increase in CTLA-4 recycling when treated with UBEI-41, further supporting a 
role for ubiquitin in regulating CTLA-4 degradation.  
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Figure 3.17 Inhibiting CTLA-4 degradation results in an increase in CTLA-4 recycling. CHO cells 
transfected with CTLA-4 were incubated with medium or medium supplemented with MG132 (A) or 
UBEI-41 (B) for 2hours at 37°C. Cells were then labeled with PE-conjugated anti-CTLA-4 Ab at 37°C to 
detect cycling CTLA-4, washed and any recycling CTLA-4-PE antibody detected by addition of 
Alexa647 anti-mouse secondary Ab at either 4°C or 37°C. The fraction of recycled protein was 
expressed as a percentage of labelled protein. (A) Data shown from two independent experiments. (B) 
Error bars show standard error (n=3). 
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3.7 CTLA-4 removes ligand from APCs 
The importance of CTLA-4 in regulating T cell activation is established but the mechanism under which 
CTLA-4 inhibition becomes dominant is debatable. As a lab, we have identified a further function for 
CTLA-4 termed transendocytosis where CTLA-4 binds its ligand at the cell surface, internalises the 
whole molecule and targets the ligand for degradation in lysosomes (Qureshi et al., 2011). To 
investigate this CHO cells expressing CTLA-4 were co-cultured with CHO cells stably expressing either 
CD80 or CD86, fused to GFP, for 3hours at 37°C in medium alone or medium supplemented with NH4Cl. 
CD80 or CD86-GFP cells were labelled with CellTrace Violet and accordingly GFP transfer could be 
quantified by gating CTLA-4 expressing cells that were negative for Violet dye staining. Using flow 
cytometry, transfer of CD80 and CD86 into CTLA-4-positive cells was observed (figure 3.18A and B). 
This transfer was further enhanced after incubation with the lysosomal inhibitor NH4Cl, which suggests 
that the ligand is being degraded in the CTLA-4-positive cell. Importantly the capture efficiency of CD80 
was greater than CD86, which could relate to the higher affinity of CTLA-4 for CD80 (figure 3.18C). 
Taken together, this data supports the concept that CTLA-4 regulates T cell activation by removing 
ligand from the surface of APCs and targets the ligand for degradation in lysosomes as reported 
previously.  
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Figure 3.18 CTLA-4 removes CD80 and CD86 and targets the ligand for lysosomal degradation. 
CD80 and CD86-GFP acquisition by CHO-cells expressing CTLA-4 was determined by flow cytometry. 
(A) Representative FACs plots showing percentage of acquired GFP by CTLA-4 in medium or medium 
supplemented with NH4Cl. Data are from a single experiment representative of three performed. (B) 
Error bars show standard error (n=3). (C) The capture efficiency was calculated as described in 
Materials and Methods. 
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3.8 Discussion 
In this chapter the general cell biology of the CTLA-4 receptor was investigated. It is well established 
that CTLA-4 internalisation from the cell surface is clathrin-mediated following the association of the 
YVKM motif located in its C-terminus, which associates with the clathrin adaptor AP-2. However the 
path taken by CTLA-4 post-internalisation and the ultimate fate of the receptor is not well understood. 
Moreover, how the intracellular trafficking of CTLA-4 and its predominant localisation in intracellular 
vesicles acts to regulate T cell activation by binding ligands at the cell surface remains controversial. I 
observed that at steady state CTLA-4 resides in intracellular vesicles in both CTLA-4 transfected cells 
and in T cells. Following the internalisation of CTLA-4 via clathrin, CTLA-4 either recycled back to the 
cell surface or was degraded in lysosomes. Importantly both pathways could serve a role in regulating T 
cell activation by the newly identified function of transendocytosis where CTLA-4 could target the ligand 
for degradation in lysosomes and recycle back to the surface to further inhibit CD28 co-stimulation. 
 
Using CTLA-4 transfected CHO cells as a model system, work in this thesis has demonstrated that 
human CTLA-4 is largely located in intracellular vesicles with little surface CTLA-4 expression. Findings 
were reproducible in transfected Jurkat T cells, activated T cells and in Tregs but the level of total 
CTLA-4 expression were higher in these cell types when compared to the combined surface and cycling 
pool. It is interesting to speculate whether once synthesised the CTLA-4 receptor in T cells is stored in a 
storage compartment and mobilised from these compartments once the T cell encounters antigen. 
Moreover, although Tregs constitutively express CTLA-4, data presented in this thesis reveals no 
difference in the localisation and trafficking of CTLA-4 in CD4+ CD25- T cells or Tregs.  
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The YVKM motif associates with the µ2 subunit of the AP-2 complex for subsequent inclusion into 
clathrin-coated pits (Chuang et al., 1997; Shiratori et al., 1997). In our experimental conditions, human 
CTLA-4 demonstrates rapid internalisation kinetics, where 50% of the surface receptor internalised 
within 5minutes. Moreover, following internalisation CTLA-4 co-localised with transferrin in intracellular 
vesicles suggesting that CTLA-4 uses the same pathway as TfR for internalisation. The importance of 
the YVKM motif in CTLA-4 endocytosis was determined in a previous study by mutating the tyrosine 
residue in the YVKM motif (Y→F) (Mead et al., 2005). This data revealed that the mutant had increased 
surface expression, and a slow endocytic rate, but internalisation was only partially inhibited. A likely 
hypothesis is other residues within the cytoplasmic tail may contribute to inclusion into clathrin pits, and 
subsequent internalisation (Chuang et al., 1997; Shiratori et al., 1997; Zhang and Allison, 1997). 
 
CTLA-4 trafficking may resemble that of other receptors. For example Protease-activated receptor 1 
(PAR1), a GPCR, has a C-tail sequence containing tyrosine-based motifs that appear to mediate 
distinct trafficking events. The proximal Y383SIL386 motif regulates lysosomal sorting whereas the distal 
Y420KKL423 motif controls internalisation (Marchese et al., 2008). Such findings suggest that within the 
cytoplasmic domain multiple motifs of the same sorting signal may confer distinct endocytic and sorting 
functions. Interestingly human CTLA-4 contains two tyrosine residues at positions 201 and 218. The 
proximal Y201VKM motif controls internalisation, whilst to date no functional significance has been 
identified for tyrosine 218. Thus, it is interesting to hypothesise whether the distal motif, like in PAR1, 
may have a role that contributes to endocytosis. Furthermore, this could explain the partial 
internalisation seen with the Y→F mutation in human CTLA-4. 
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Following internalisation, some internalised receptors are delivered to an early or sorting endosome 
(Hare and Taylor, 1991). Trafficking receptors such as TfR and EGFR have two fates: to recycle back to 
the membrane or to be targeted for degradation in lysosomes. Thus, in the absence of specific targeting, 
one possible route for internalised receptors is recycling back to the cell surface (Hare and Taylor, 
1991). The observation of CTLA-4 co-localisation with the TfR raises questions as to whether CTLA-4 
can also recycle constitutively back to the plasma membrane (Chuang et al., 1997; Leung et al., 1995). 
A two-step Ab staining assay revealed that CTLA-4 recycles back to the plasma membrane within a 
30minute time period, which was further verified by confocal microscopy. But why does CTLA-4 need to 
recycle? In the case of EGFR the requirement for recycling can be explained by the requirement for 
continued signalling by the receptor. If the receptor is degraded, the signal is diminished and the 
signalling pathway cannot be activated until the number of EGFRs at the surface is re-established by 
protein synthesis (Roepstorff et al., 2009).  
 
The pH sensitivity of ligand binding further regulates whether EGFR is recycled or degraded. For 
example TGF-α binding to EGFR is not stable at the pH of endosomes. The receptor dissociates from 
the ligand, is deubiquitinated and recycled back to the surface. In contrast, EGF binding to EGFR is 
stable at the endosomal pH, remains ubiquitinated and is targeted for degradation (Roepstorff et al., 
2009). Our data has consistently demonstrated that CTLA-4 rips CD80 more efficiently than CD86. This 
could be explained by the higher affinity of CTLA-4 for CD80 as opposed to CD86. It can therefore be 
postulated that the lower affinity of CTLA-4 for CD86 could result in CD86 dissociating from CTLA-4 at 
sorting endosomes, thus allowing the receptor to recycle back to the surface. However our assays have 
shown that both receptor-ligand pairs are targeted for degradation arguing against the hypothesis that 
ligands direct CTLA-4 recycling. It is interesting to speculate that the need for CTLA-4 to recycle is to 
remove ligand from APCs through transendocytosis. In this way, CTLA-4 would be readily available and 
 114 
the cell-cell contact between the T cell and APC would still be intact for CTLA-4 to remove ligand at the 
synapse.  
 
The pool of internalised CTLA-4 that does not recycle back to the plasma membrane is targeted to 
lysosomes for degradation. The rapid turnover rate of CTLA-4 suggests the lysosomal degradation 
pathway may control CTLA-4 expression and downregulation, and in fact such studies argue against the 
existence of a recycling pool (Egen and Allison, 2002; Iida et al., 2000). In accordance with Egen & 
Allison, (2002), a rapid loss of CTLA-4 levels was observed in the absence of new protein translation 
suggestive of degradation. Moreover the accumulation of CTLA-4 in the presence of lysosomal 
inhibitors and co-localisation with lysosomal markers suggests trafficking to lysosomes. Again, like 
recycling it is not completely understood why CTLA-4 needs to be degraded. Receptors involved in 
signalling are degraded in order to regulate the signalling pathway. Despite earlier studies arguing that 
CTLA-4 delivers an inhibitory signal, no such signalling pathway has been identified ruling out the 
possibility that degradation is required to regulate the CTLA-4 negative signal. However, the targeting of 
ligand for lysosomal degradation provides support for the requirement of this trafficking pathway and 
further fits the model of CTLA-4 transendocytosis. Moreover if CTLA-4 dissociates from ligand, the 
receptor could recycle back to the membrane to bind and remove more ligand. 
 
Proteins targeted for lysosomal degradation such as EGFR and PAR2 are ubiquitinated at lysine 
residues by E3 ligases, where ubiquitin serves as the signal to traffic cargo to lysosomes (Jacob et al., 
2005; Levkowitz et al., 1998). Using western blotting and a range of chemical inhibitors the data 
presented here confirm that CTLA-4 is ubiquitinated. However what needs to be addressed is the site of 
CTLA-4 ubiquitination. Ubiquitin is now emerging as a potential signal required for internalisation. In fact 
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in order for Interferon-α receptor 1 subunit (IFNAR1) to undergo efficient internalisation it must be 
polyubiquitinated (Kumar et al., 2007). The cell surface could therefore serve as the potential site for 
CTLA-4 ubiquitination, since it is at the cell surface where the receptor binds its ligands, which are 
targeted for degradation in lysosomes. However in the case of EGFR, ubiquitination is only essential for 
lysosomal degradation but it is not a requirement for its endocytosis (Huang et al., 2006), which 
suggests the ubiquitination of CTLA-4 could occur downstream of internalisation.  
 
A question that still needs to be addressed is what are the sorting motifs encoded in CTLA-4 that 
regulate receptor recycling and degradation? Presumably the YVKM motif plays an important role since 
CTLA-4 must be internalised first before it is sorted in early endosomes. Moreover, the data shown here 
reveal a role for lysine residues and ubiquitin in regulating CTLA-4 recycling and degradation. These 
observations could be confirmed using a lysine-less CTLA-4 mutant. Such a mutant could be used to 
determine the requirement of lysine residues in internalisation, recycling, degradation and in 
transendocytosis. Additionally by creating single lysine point mutants of CTLA-4, the lysine residue/s 
that serve as targets for ubiquitination could be determined. An interesting motif encoded in the CTLA-4 
cytoplasmic domain is the proline-based motif PTEP. This motif resembles the PT/SAP motif encoded in 
viruses required to recruit the ESCRT-I component TSG101 (Dilley et al., 2010). It is interesting to 
speculate that the PTEP motif in CTLA-4 could be involved in MVB formation prior to the delivery of the 
receptor to lysosomes.  
 
Central to the role of membrane protein trafficking and degradation are E3 ubiquitin ligases. Two 
primary classes of E3 ligases have been identified, distinguished by a homologous to E6-AP carboxyl 
terminus (HECT) domain, and a really interesting new gene (RING) finger domain. The potential 
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involvement of a HECT type E3 ligase in CTLA-4 ubiquitination arises from the presence of a series of 
WW domains that recognise proline-rich PPxY motifs (d'Azzo et al., 2005). Such a motif is present in the 
CTLA-4 extracellular domain. However this would present a problem, as this is same motif required for 
ligand binding suggesting that if a HECT type E3 ligase was involved in CTLA-4 ubiquitination, ligand 
must be displaced. Thus it is not yet possible to rule out a role for a HECT type E3 ligase in this process, 
as the effect of ligand binding on CTLA-4 ubiquitination is not yet clear. 
 
Overall, understanding the localisation, trafficking and function of CTLA-4 could highlight areas that 
could be manipulated for the treatment of autoimmunity and cancer. I have addressed the mechanisms 
and pathways required for CTLA-4 intracellular trafficking that could directly impact the function of 
CTLA-4 as a negative regulator of T cell activation.   
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4.0 REGULATION OF CTLA-4 RECYCLING AND 
DEGRADATION 
 
4.1 Introduction 
The findings of chapter 3 of this thesis reveal that post-internalisation CTLA-4 either recycles back to 
the surface or is degraded in lysosomes, a mechanism that involves the ubiquitination of intracellular 
lysine residues. However other sorting motifs important for such trafficking remain to be identified. Of 
importance are the two tyrosine-based motifs, the lysine residues and a proline-based motif. By 
mutating such motifs I considered whether the regulation of CTLA-4 recycling and degradation could be 
unmasked. In this chapter I have therefore investigated the mechanisms regulating the post-endocytic 
fate of CTLA-4. 
 
4.2 CTLA-4 localisation in intracellular vesicles is regulated by the YVKM motif 
To identify the motifs encoded in the cytoplasmic domain that regulate CTLA-4 localisation in 
intracellular vesicles, site-directed mutagenesis was used to generate single or multiple point mutants of 
CTLA-4 as outlined in figure 4.1. CHO cells were transfected with the CTLA-4 mutants and expression 
was compared at 4°C, 37°C or cells were fixed and permeabilised before analysis by confocal 
microscopy or flow cytometry. KLESS, ATEP and AFIP CTLA-4 showed a comparable localisation to 
WT CTLA-4 with little or no surface CTLA-4 expression and predominant distribution in intracellular 
vesicles (figure 4.2 and 4.3). In contrast, AVKM and AVKM-AFIP demonstrated predominant surface 
CTLA-4 expression with far more limited intracellular vesicles (figure 4.3). This difference in the amount 
of surface CTLA-4 relative to the total was quantified by flow cytometry and is shown in figure 4.4. 
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Figure 4.1 Generation of CTLA-4 mutants. (A) C-terminal sequence alignments of human CTLA-4. 
Lysine residues mutated to arginine are shown in blue. Proline and tyrosine mutations to alanine are 
shown in green. (B) Brief description of the CTLA-4 mutants.   
! ! 190       200       210 ! 220!
WT ! !SKMLKKRSPLTTGVYVKMPPTEPECEKQFQPYFIPIN!
KLESS! !SRMLRRRSPLTTGVYVRMPPTEPECERQFQPYFIPIN!
ATEP ! !SKMLKKRSPLTTGVYVKMPATEPECEKQFQPYFIPIN!
AVKM ! !SKMLKKRSPLTTGVAVKMPPTEPECEKQFQPYFIPIN!
AFIP ! !SKMLKKRSPLTTGVYVKMPPTEPECEKQFQPAFIPIN!
AVKM-AFIP !SKMLKKRSPLTTGVAVKMPPTEPECEKQFQPAFIPIN!
!
A 
B 
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Figure 4.2 Phenotype of CTLA-4 mutants. CHO cells expressing CTLA-4 mutants were stained for 
surface CTLA-4 expression at 4°C; endocytosed CTLA-4 expression at 37°C; or were fixed and 
permeabilised prior to staining for total CTLA-4 expression with an unlabelled anti-CTLA-4 Ab and 
Alexa555 anti-mouse secondary Ab (n≥3). Bar indicates scale of 10µm. 
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Figure 4.3 Phenotype of CTLA-4 mutants. CHO cells expressing CTLA-4 mutants were stained for 
surface CTLA-4 expression at 4°C; endocytosed CTLA-4 expression at 37°C; or were fixed and 
permeabilised prior to staining for total CTLA-4 expression with an unlabelled anti-CTLA-4 Ab and 
Alexa555 anti-mouse secondary Ab (n≥3). Bar indicates scale of 10µm. 
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Figure 4.4 Surface to Total ratio of CTLA-4 mutants. CHO cells expressing CTLA-4 mutants were 
stained for surface CTLA-4 expression at 4°C or were fixed and permeabilised prior to staining for total 
CTLA-4 expression with PE-conjugated anti-CTLA-4 Ab. Cells were analysed by flow cytometry. The 
ratio of surface to total CTLA-4 for each mutant is plotted as determined by flow cytometry. Error bars 
show standard error (n>3).  
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4.3 CTLA-4 endocytosis is regulated by the YVKM motif 
The increased surface expression observed in CTLA-4 mutants deficient in YVKM suggested that the 
absence of this motif might confer less efficient internalisation. Moreover, although mutations in the 
lysine residues and in the proline-based motif do not have an effect on CTLA-4 localisation, such 
mutations could affect the rate of CTLA-4 internalisation from the cell surface. Moreover, it is now 
emerging that ubiquitination of intracellular lysine residues could serve as an internalisation signal 
(Kumar et al., 2007). To investigate the importance of these motifs in CTLA-4 internalisation, the cell 
surface pool of CTLA-4 was stained on ice with a PE-conjugated anti-CTLA-4 Ab. Cells were then 
warmed to 37°C for the indicated time-points to allow any internalisation of surface CTLA-4 to take 
place. Cells were then placed on ice, and any CTLA-4 remaining at the cell surface detected with an 
Alexa647 anti-mouse secondary Ab. Accordingly in this assay loss of Alexa647 staining over time 
reflects endocytosis of CTLA-4. In the 4°C control, a linear relationship was observed between CTLA-4-
PE (y-axis) and Alexa647 (x-axis) for all CTLA-4 mutants (figure 4.5). However after 30minute 
incubation at 37°C a curved plot was generated for WT, KLESS, ATEP and AFIP CTLA-4 where the 
initial PE-labelled surface CTLA-4 internalised resulting in a minimal surface Alexa647 label, typical of 
an endocytic protein. In contrast AVKM and AVKM-AFIP showed a more linear relationship between 
internalised and surface CTLA-4 in the 4°C control and at 37°C suggesting impaired endocytosis. 
 
To quantify this data, the 647 signal was plotted against time as the fraction remaining compared to 4°C. 
Using this assay WT CTLA-4 showed a comparable rate of endocytosis to KLESS, ATEP and AFIP, 
internalising 50% or more protein within 15minutes (figure 4.6A). In contrast CTLA-4 mutants deficient 
in YVKM demonstrated a reduced ability to internalise (figure 4.6B). Interestingly, AVKM-AFIP was 
more stable than AVKM suggesting a more stable surface CTLA-4 protein requires both tyrosine 
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residues to be absent. Taken together, this data suggests CTLA-4 internalisation is regulated by the 
YVKM motif and is not dependent on lysine residues, the proline-based motif or the YFIP motif.  
 
To confirm the findings identified by flow cytometry, CTLA-4 internalisation in the various mutants was 
measured by western blotting. Cell surface CTLA-4 was biotinylated at 4°C. Cells were then either kept 
on ice or warmed to 37°C for the indicated time-points and any remaining surface biotin was reduced. 
Cells were lysed and internalised CTLA-4 was concentrated by immunoprecipitating biotin using a 
neutravidin gel. Membranes were then probed for CTLA-4 using a C-19 C-terminus anti-CTLA-4 Ab. For 
WT CTLA-4 maximal internalisation was seen within 15minutes but after 30minutes this pool decreased 
over time. Comparable to WT CTLA-4, maximal protection of KLESS and ATEP was seen within 
15minutes but the biotinylated pool appeared to be stable throughout the course of the experiment 
(figure 4.7). This data suggests any differences between the trafficking of WT, KLESS and ATEP 
CTLA-4 are related to their post-endocytic fate. AVKM CTLA-4 was used as a surface control 
considering the high surface vs. total ratio and impaired endocytosis (figure 4.4). However using 
western blotting it can be confirmed that a fraction of AVKM CTLA-4 internalises and the fate of the 
internalised pool is comparable to WT (figure 4.8).  
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Figure 4.5 CTLA-4 mutants have different endocytic efficiencies. CHO cells expressing CTLA-4 
mutants were labelled at 4°C with PE-conjugated anti-CTLA-4 Ab to label surface CTLA-4. Cells were 
then warmed to 37°C to allow endocytosis. Cells were placed on ice and any remaining surface CTLA-4 
detected with Alexa647 anti-mouse secondary Ab. Representative FACs plot of one experiment 
showing remaining surface CTLA-4 after maximum 37°C incubation (red) compared to 4°C (black).  
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Figure 4.6 CTLA-4 mutants have different endocytic efficiencies. (A and B) CHO cells expressing 
CTLA-4 mutants were labelled at 4°C with PE-conjugated anti-CTLA-4 Ab to label surface CTLA-4. 
Cells were then warmed to 37°C to allow endocytosis. Cells were placed on ice and any remaining 
surface CTLA-4 detected with Alexa647 anti-mouse secondary Ab. The 647 signal was plotted against 
time as a fraction remaining compared to 4°C. Error bars show standard error (n≥3). 
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Figure 4.7 Western blotting reveals that KLESS and ATEP CTLA-4 mutants have a different post-
endocytic fate to WT CTLA-4. Cell surface CTLA-4 was biotinylated at 4°C. Cells were then either 
kept on ice or warmed to 37°C for the indicated time-points and any remaining surface biotin was 
reduced. Cells were lysed and internalised CTLA-4 was concentrated by immunoprecipitating biotin 
using a neutravidin gel. Membranes were then probed for CTLA-4 using a C-19 C-terminus anti-CTLA-4 
Ab. CTLA-4 has a molecular weight of ~ 30kDa. IP, immunoprecipitated CTLA-4 - bands represent 
CTLA-4 that was internalised and protected. WCL, whole cell lysate - bands represent total amount of 
CTLA-4 protein present in each condition. This is representative of 3 independent experiments.  
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Figure 4.8 Western blotting reveals that AVKM CTLA-4 internalises. Cell surface CTLA-4 was 
biotinylated at 4°C. Cells were then either kept on ice or warmed to 37°C for the indicated time-points 
and any remaining surface biotin was reduced. Cells were lysed and internalised CTLA-4 was 
concentrated by immunoprecipitating biotin using a neutravidin gel. Membranes were then probed for 
CTLA-4 using a C-19 C-terminus anti-CTLA-4 Ab. CTLA-4 has a molecular weight of ~ 30kDa. IP, 
immunoprecipitated CTLA-4 - bands represent CTLA-4 that was internalised and protected. WCL, whole 
cell lysate - bands represent total amount of CTLA-4 protein present in each condition. This is 
representative of 3 independent experiments.  
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4.4 CTLA-4 recycling is regulated by lysine residues and a proline motif  
We have previously shown that in order to maintain a steady state pool of CTLA-4, a fraction of the 
internalised receptor either recycles back to the surface or is targeted for degradation (Qureshi et al., 
2012). To further address the role of the two tyrosine-based motifs, the lysine residues and the proline-
based motif in CTLA-4 intracellular trafficking, CTLA-4 recycling was assayed using flow cytometry. 
Cells were incubated at 37°C with a PE-conjugated anti-CTLA-4 Ab for 30minutes to label the cycling 
pool of CTLA-4. Cells were then incubated further at 37°C for various times with an Alexa647 anti-
mouse secondary Ab to label any of the primary Ab recycling back to the cell surface. Accordingly, 
recycling CTLA-4 is seen as an increase in the Alexa647 signal over time.  
 
For WT, KLESS, ATEP and AFIP, after 30minute incubation at 37°C the control re-staining at 4°C 
revealed that only in a small percentage of cells does CTLA-4 protein remain at the surface to be 
detected by Alexa647 (figure 4.9 red). When cells were stained at 37°C with Alexa647, a greater pool 
of CTLA-4 for WT, KLESS, ATEP and AFIP was seen (figure 4.9 black). This suggests the Alexa647 
signal could only have increased if the internalised PE-labelled CTLA-4 recycled back to the plasma 
membrane. Of note, there were differences in the efficiency of internalisation and recycling of the 
endocytic mutants as judged by the gradient of the red and black population of cells. KLESS and ATEP 
internalised and recycled more efficiently than WT and AFIP CTLA-4. In contrast, for AVKM and AVKM-
AFIP the control re-staining at 4°C and staining at 37°C revealed a 1:1 relationship between the primary 
and secondary Ab suggestive of impaired endocytosis and recycling (figure 4.9).  
 
To quantify this data, the 647 signal was plotted against time as the fraction recycled compared to 4°C. 
Using this assay, KLESS and ATEP CTLA-4 recycled more efficiently than WT and AFIP CTLA-4 
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(figure 4.10A-D). In contrast AVKM and AVKM-AFIP demonstrated little or no recycling (figure 4.10E-
F). Taken together this data suggests that the YVKM motif, lysine residues and a proline motif regulate 
CTLA-4 recycling, where the absence of YVKM impairs CTLA-4 recycling whilst the absence of lysine 
residues and PTEP enhances CTLA-4 recycling.  
 
4.5 CTLA-4 degradation is regulated by lysine residues and a proline motif 
The increase in CTLA-4 recycling observed for KLESS and the ATEP mutant questions the role of 
lysine residues and the proline-based motif in regulating CTLA-4 degradation. To address the stability of 
the CTLA-4 point mutants, new protein synthesis was blocked using CHX to monitor the decay of 
existing CTLA-4. Moreover, if CTLA-4 was being degraded in lysosomes NH4Cl or BafA should prevent 
degradation. After 3hour incubation at 37°C, cells were fixed and permeabilised prior to staining for total 
CTLA-4 expression and analysed by confocal microscopy. In the absence of new protein synthesis, 
whilst WT CTLA-4 levels decreased, KLESS and ATEP levels remained relatively constant (figure 4.11). 
Moreover, no accumulation of KLESS or ATEP was seen in the presence of NH4Cl or BafA but a 
marked upregulation in the level of WT CTLA-4 was observed, again confirming lysosomes as the site 
of CTLA-4 degradation. These findings were verified using flow cytometry and a time course revealed 
that whereas KLESS and ATEP CTLA-4 were stable for up to 5hours, WT CTLA-4 had a half-life of 
around 2-3hours, in keeping with previous studies (figure 4.13A-C and 4.14A-C). In contrast AVKM and 
AVKM-AFIP revealed subtle changes in protein expression in the presence of the inhibitors, typical of a 
surface protein (figure 4.12, 4.13E-F and 4.14E-F). Interestingly, AVKM was less stable than AVKM-
AFIP suggesting a more stable surface CTLA-4 protein requires both tyrosine residues to be absent. 
Collectively this data suggests that intracellular lysine residues and a proline motif regulate CTLA-4 
degradation.   
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Figure 4.9 CTLA-4 mutants have different recycling efficiencies. CHO cells expressing CTLA-4 
mutants were labelled with PE-conjugated anti-CTLA-4 Ab at 37°C to detect cycling CTLA-4, washed 
and any recycling primary Ab detected by addition of Alexa647 anti-mouse secondary Ab at either 4°C 
or 37°C. Representative FACS plots are shown for PE-label (cycling CTLA-4) vs Alexa647 label 
(recycling CTLA-4) of n≥3. 
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Figure 4.10 CTLA-4 mutants have different recycling efficiencies. CHO cells expressing CTLA-4 
mutants were labelled with PE-conjugated anti-CTLA-4 Ab at 37°C to detect cycling CTLA-4, washed 
and any recycling primary Ab detected by addition of Alexa647 anti-mouse secondary Ab at either 4°C 
or 37°C. Recycling rates are plotted for CTLA-4 mutants as normalised to the 4°C control. Error bars 
show standard error (n≥3).     
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Figure 4.11 CTLA-4 mutants have different degradation efficiencies. (A) CHO cells expressing 
CTLA-4 mutants were incubated in medium or medium supplemented with CHX, NH4Cl or NH4Cl and 
CHX at 37°C for 3hours. Cells were stained for total CTLA-4 expression with an unlabelled anti-CTLA-4 
Ab and Alexa488 anti-mouse secondary Ab and analysed by confocal microscopy. Bar indicates scale 
of 10µm. (B) Total CTLA-4 was quantified by outlining cells in ImageJ and MFI plotted. Error bars show 
standard error (n≥3).  
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Figure 4.12 CTLA-4 mutants have different degradation efficiencies. (A) CHO cells expressing 
CTLA-4 mutants were incubated in medium or medium supplemented with CHX, NH4Cl or NH4Cl and 
CHX at 37°C for 3hours. Cells were stained for total CTLA-4 expression with an unlabelled anti-CTLA-4 
Ab and Alexa488 anti-mouse secondary Ab and analysed by confocal microscopy. Bar indicates scale 
of 10µm. (B) Total CTLA-4 was quantified by outlining cells in ImageJ and MFI plotted. Error bars show 
standard error (n≥3). 
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Figure 4.13 Flow cytometry verifies that the CTLA-4 mutants have different degradation 
efficiencies. CHO cells expressing CTLA-4 mutants were incubated in medium or medium 
supplemented with CHX, NH4Cl or NH4Cl and CHX at 37°C for 1-5hours. Cells were fixed, 
permeabilised and stained for total CTLA-4 with a PE-conjugated anti-CTLA-4 Ab. Cells were analysed 
by flow cytometry. The MFI is plotted as a percentage of initial fluorescence (n=1). 
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Figure 4.14 Flow cytometry verifies that the CTLA-4 mutants have different degradation 
efficiencies. CHO cells expressing CTLA-4 mutants were incubated in medium or medium 
supplemented with CHX, BafA or BafA and CHX at 37°C for 1-5hours. Cells were fixed, permeabilised 
and stained for total CTLA-4 with a PE-conjugated anti-CTLA-4 Ab. Cells were analysed by flow 
cytometry. The MFI is plotted as a percentage of initial fluorescence (n=1). 
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4.6 CTLA-4 ubiquitination is regulated by lysine residues and a proline motif 
The increased recycling and stability of KLESS and ATEP CTLA-4 mutants suggests the protein is not 
being degraded. Receptors such as PAR2 and IFNAR1 have intracellular lysine residues that serve as 
targets for ubiquitin attachment and thus facilitate their degradation in lysosomes (Jacob et al., 2005; 
Kumar et al., 2007). Moreover, prior to entry into lysosomes proteins are sorted into MVBs, which 
requires the ESCRT machinery. Interestingly, the PTEP motif in CTLA-4 cytoplasmic domain could 
serve as a target site for TSG101 or other components of the ubiquitin conjugation cascade (Dilley et al., 
2010).  
 
To address the ubiquitination status of the CTLA-4 mutants, CHO cells transfected with the CTLA-4 
mutants were stained for total CTLA-4 expression and analysed by flow cytometry. Cells with 
approximately equal levels of total protein were incubated in medium or medium supplemented with 
BafA for 3hours at 37°C. CTLA-4 was then immunoprecipitated using an antibody binding the 
extracellular region of CTLA-4 and membranes were probed for CTLA-4 with a C-19 C-terminus anti-
CTLA-4 Ab and for ubiquitin with an anti-ubiquitin Ab. WT CTLA-4 was accumulated in the presence of 
BafA, which further revealed ubiquitinated species with molecular masses of ~ 46-58kDa (figure 4.15). 
In contrast, no accumulation of KLESS and ATEP CTLA-4 was observed in the presence of BafA and 
the two CTLA-4 mutants were not ubiquitinated. AVKM CTLA-4 mutant was accumulated in the 
presence of BafA, however no ubiquitinated species were detected. This could be explained by the fact 
that since only a fraction of the protein undergoes internalisation and is targeted for degradation, the 
ubiquitin signal could be too low for detection. The CTLA-4 signal for the AVKM-AFIP mutant was low 
most probably due to changes in the site recognised by the C-19 C-terminus anti-CTLA-4 Ab in the 
cytoplasmic domain. Taken together this data suggests lysine residues and the proline-based motif play 
a role in the ubiquitination of the CTLA-4 receptor.   
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Figure 4.15 CTLA-4 mutants are not ubiquitinated. CHO cells transfected with CTLA-4 mutants were 
incubated in medium or medium supplemented with BafA at 37°C for 3hours. CTLA-4 was then 
immunoprecipitated using an Ab binding to the extracellular region of CTLA-4. Expression of CTLA-4 
was analysed by western blotting using a C-19 C-terminal anti-CTLA-4 Ab and an anti-ubiquitin Ab. 
Representative data of one independent experiment of n≥3. 
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4.7 Inhibition of CTLA-4 ubiquitination affects recycling and degradation 
The increased recycling of KLESS and ATEP CTLA-4 mutants suggested that this increase could be 
due to the lack of receptor ubiquitination, which allows the receptor to escape degradation. To address 
the effect of inhibiting ubiquitination on CTLA-4 intracellular trafficking, CHO cells transfected with WT 
and KLESS CTLA-4 were incubated in the presence of MG132 at 37°C, a chemical that depletes free 
ubiquitin (Melikova et al., 2006). Cells were then stained for surface, cycling and total CTLA-4 with a 
PE-conjugated anti-CTLA-4 Ab and analysed by flow cytometry. All three pools were increased in WT 
CTLA-4 following MG132 treatment, which is in keeping with the lack of degradation (figure 4.16). 
However, this effect was not seen for KLESS CTLA-4 consistent with the absence of ubiquitin. To 
address whether the increase in CTLA-4 protein results in an increase in recycling, cells were pre-
incubated with MG132 or UBEI-41, an inhibitor of the E1 enzyme, for 2hours prior to performing the 
recycling assay described in section 4.4. To quantify any differences in recycling, the fraction of 
recycled protein was expressed as a percentage of labelled protein. WT CTLA-4 recycled more 
efficiently after both MG132 and UBEI-41 treatment when compared to the media control (figure 4.17A 
and C). Again, this effect was not observed for KLESS CTLA-4 (figure 4.17B and D). Taken together 
this data confirms a role for lysine residues and ubiquitin in regulating CTLA-4 recycling and 
degradation.  
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Figure 4.16 Effect of MG132 on WT and KLESS CTLA-4 localisation. CHO cells transfected with WT 
and KLESS CTLA-4 were incubated with medium or medium supplemented with MG132 for 2hours at 
37°C. Cells were then stained for surface, cycling or total CTLA-4 expression and analysed by flow 
cytometry. Representative FACs plots of one independent experiment of n=3. 
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Figure 4.17 MG132 and UBEI-41 have different effects on WT and KLESS CTLA-4 recycling. CHO 
cells transfected with WT or KLESS CTLA-4 were incubated with medium or medium supplemented 
with MG132 (A and B) or UBEI-41 (C and D) for 2hours at 37°C. Cells were then labelled with PE-
conjugated anti-CTLA-4 Ab at 37°C to detect cycling CTLA-4, washed and any recycling CTLA-4-PE 
antibody detected by addition of Alexa647 anti-mouse secondary Ab at either 4°C or 37°C. The fraction 
of recycled protein was expressed as a percentage of labelled protein. Data shown from two 
independent experiments.  
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4.8 All lysine residues influence CTLA-4 recycling and degradation 
Throughout this chapter it is clear that lysine residues regulate CTLA-4 recycling and degradation. 
However in the case of some receptors such as EGFR and INFAR-1 not all the lysine residues are 
targets of ubiquitination (Huang et al., 2006; Kumar et al., 2007). In order to address which lysine 
residues are important for CTLA-4 degradation, single lysine point mutants were generated using site-
directed mutagenesis and transfected into CHO cells (figure 4.18A). CTLA-4 single lysine point mutants 
were then characterised to determine their role in the intracellular trafficking of the receptor.  
 
To assess localisation, CHO cells expressing the various CTLA-4 mutants cells were stained for total 
CTLA-4 expression using an antibody to the human CTLA-4 ectodomain and analysed by confocal 
microscopy. The data showed that the CTLA-4 single lysine point mutants were predominantly located 
in intracellular vesicles (figure 4.18B). The difference in the amount of surface CTLA-4 relative to 
cycling CTLA-4 was also quantified by flow cytometry and is shown in figure 4.19, further verifying the 
predominant intracellular localisation of the lysine mutants. To assay internalisation, cells were 
incubated at 4°C with PE-conjugated anti-CTLA-4 Ab for 30minutes to label the surface pool. Cells were 
then incubated at 37°C for the indicated time points and remaining surface CTLA-4 was then labelled 
with Alexa647 anti-mouse secondary Ab. Again this revealed no difference between the internalisation 
rate of WT CTLA-4, KLESS and the single lysine point mutants (figure 4.20A). Taken together this data 
suggests that the lysine residues do not regulate CTLA-4 localisation and internalisation. 
 
To address which lysine residues are important for regulating CTLA-4 recycling, cells were incubated at 
37°C with PE-conjugated anti-CTLA-4 Ab for 30minutes to label the cycling pool. Cells were then either 
kept on ice or incubated at 37°C for various time points with Alexa647 anti-mouse secondary Ab to label 
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any of the primary Ab recycling back to the surface. To quantify any differences in recycling, the fraction 
of recycled protein was expressed as a percentage of labelled protein. An increase in labelled protein 
that recycled back to the surface was seen for the various CTLA-4 mutants. However, KLESS CTLA-4 
recycled more efficiently than any other single lysine point mutant whilst K191R and K192R recycled as 
efficiently as WT CTLA-4. Importantly a mutation of either one of the two distal lysine residues, K203R 
or K213R, showed a recycling efficiency that was greater than WT but did not reach the potential of 
KLESS (figure 4.20B). This suggests that both distal lysine residues in the CTLA-4 cytoplasmic domain 
could regulate the recycling of the CTLA-4 receptor. 
 
To address whether both K203 and K213 residues regulate CTLA-4 recycling, a mutant was generated 
lacking both of these lysine residues, K203,213R. Again, this mutant was located in intracellular vesicles, 
internalised as efficiently as WT but the mutant does not recycle as efficiently as KLESS (figure 4.21). 
Collectively, this data therefore suggests all of the lysine residues in the CTLA-4 cytoplasmic domain 
could regulate recycling.  
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Figure 4.18 Generation and localisation of CTLA-4 single lysine point mutants. (A) C-terminal 
sequence alignments of human CTLA-4. Lysine residues mutated to arginine are shown in blue. (B) 
CHO cells expressing CTLA-4 lysine mutants were fixed and permeabilised prior to staining for total 
CTLA-4 expression with an unlabelled anti-CTLA-4 Ab and Alexa555 anti-mouse secondary Ab and 
analysed by confocal microscopy (n≥ 3). Bar indicates scale of 10µm.  
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Figure 4.19 Phenotype of CTLA-4 lysine mutants. CHO cells expressing CTLA-4 mutants were 
stained for surface CTLA-4 expression at 4°C or were fixed and permeabilised prior to staining for total 
CTLA-4 expression with PE-conjugated anti-CTLA-4 Ab. Cells were analysed by flow cytometry. Error 
bars show standard error (n>3).  
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Figure 4.20 CTLA-4 lysine mutants have a comparable internalisation rate to WT but have 
different recycling efficiencies. (A) CHO cells expressing CTLA-4 lysine mutants were labelled at 4°C 
with PE-conjugated anti-CTLA-4 Ab. Cells were then warmed to 37°C to allow endocytosis for the times 
indicated. Cells were then placed on ice and any remaining surface CTLA-4 detected with Alexa647 
anti-mouse secondary Ab. The 647 signal was plotted against time as a fraction remaining compared to 
4°C. Error bars show standard error (n≥3). (B) CHO cells expressing CTLA-4 lysine mutants were 
labelled with PE-conjugated anti-CTLA-4 Ab at 37°C to detect cycling CTLA-4, washed and any 
recycling primary Ab detected by addition of Alexa647 anti-mouse secondary Ab at either 4°C or 37°C. 
The fraction of recycled protein was expressed as a percentage of labelled protein. Error bars show 
standard error (n≥3). 
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Figure 4.21 K203,213R does not recycle as efficiently as KLESS CTLA-4. (A) CHO cells expressing 
K203,213R were stained for surface CTLA-4 expression at 4°C; endocytosed CTLA-4 expression at 
37°C; or were fixed and permeabilised prior to staining for total CTLA-4 expression with an unlabelled 
anti-CTLA-4 Ab and Alexa555 anti-mouse secondary Ab and analysed by confocal microscopy (n≥3). 
Bar indicates scale of 10µm. (B) CHO cells expressing WT, KLESS and K203,213R CTLA-4 were 
labelled at 4°C with PE-conjugated anti-CTLA-4 Ab. Cells were then warmed to 37°C to allow 
endocytosis for the times indicated. Cells were then placed on ice and any remaining surface CTLA-4 
detected with Alexa647 anti-mouse secondary Ab. The 647 signal was plotted against time as a fraction 
remaining compared to 4°C (n≥3). (C) CHO cells expressing WT, KLESS and K203,213R CTLA-4 were 
labelled with PE-conjugated anti-CTLA-4 Ab at 37°C to detect cycling CTLA-4, washed and any 
recycling primary Ab detected by addition of Alexa647 anti-mouse secondary Ab at either 4°C or 37°C. 
The fraction of recycled protein was expressed as a percentage of labelled protein. Error bars show 
standard error (n≥3). 
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To address which lysine residues are important for regulating CTLA-4 degradation, CHO cells 
expressing the lysine mutants were incubated in CHX or NH4Cl for 3hours at 37°C. Cells were then 
stained for total CTLA-4 expression and analysed by confocal microscopy or flow cytometry. All single 
lysine point mutants showed a pattern comparable to WT CTLA-4 with a rapid loss of protein 
demonstrated in the absence of new protein synthesis and accumulation of protein observed in the 
presence of NH4Cl (figure 4.22-4.24). K203,213R was much less sensitive to CHX treatment although 
compared to KLESS CTLA-4 some degradation was still evident (figure 4.24B vs 4.24G). Taken 
together this data suggests that all lysine residues need to be absent in order for CTLA-4 to escape 
degradation.  
 
To address the ubiquitination status of CTLA-4 when one or more lysine residues are mutated, CHO 
cells transfected with the CTLA-4 lysine mutants were stained for total CTLA-4 expression and analysed 
by flow cytometry. Cells with approximately equal levels of total protein were incubated in medium or 
medium supplemented with BafA for 3hours at 37°C. CTLA-4 was then immunoprecipitated using an 
antibody binding the extracellular region of CTLA-4 and membranes were probed for CTLA-4 with a C-
19 C-terminus antibody and for ubiquitin with an anti-ubiquitin Ab. The single and double lysine point 
mutants showed a comparable pattern to WT CTLA-4 where protein was accumulated in the presence 
of BafA, which further revealed ubiquitinated species with molecular masses of ~ 46-58kDa (figure 4.25 
and 4.26). This is in contrast to KLESS CTLA-4 where no protein accumulation or ubiquitinated species 
were detected after BafA incubation. Taken together, this data suggests that all lysine residues in the 
CTLA-4 cytoplasmic domain serve as targets for ubiquitination.  
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Figure 4.22 CTLA-4 lysine mutants have different degradation efficiencies. (A) CHO cells 
expressing CTLA-4 lysine mutants were incubated in medium or medium supplemented with CHX, 
NH4Cl or NH4C l and CHX at 37°C for 3hours. Cells were stained for total CTLA-4 expression with an 
unlabelled anti-CTLA-4 Ab and Alexa488 anti-mouse secondary Ab and analysed by confocal 
microscopy. Bar indicates scale of 10µm. (B) Total CTLA-4 was quantified by outlining cells in ImageJ 
and MFI plotted. Error bars show standard error (n≥3).  
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Figure 4.23 CTLA-4 lysine mutants have different degradation efficiencies. (A) CHO cells 
expressing CTLA-4 lysine mutants were incubated in medium or medium supplemented with CHX, 
NH4Cl or NH4Cl and CHX at 37°C for 3hours. Cells were stained for total CTLA-4 expression with an 
unlabelled anti-CTLA-4 Ab and Alexa488 anti-mouse secondary Ab and analysed by confocal 
microscopy. Bar indicates scale of 10µm. (B) Total CTLA-4 was quantified by outlining cells in ImageJ 
and MFI plotted. Error bars show standard error (n≥3).  
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Figure 4.24 Flow cytometry verifies that CTLA-4 lysine mutants have different degradation 
efficiencies. CHO cells expressing CTLA-4 lysine mutants were incubated in medium or medium 
supplemented with CHX, NH4Cl or NH4Cl and CHX at 37°C for 3hours. Cells were stained for total 
CTLA-4 expression with a PE-conjugated anti-CTLA-4 Ab and analysed by flow cytometry. The MFI is 
plotted as a percentage of initial fluorescence. Error bars show standard error (n≥3). 
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Figure 4.25 CTLA-4 single lysine point mutants are not ubiquitinated. CHO cells transfected with 
CTLA-4 mutants were incubated in medium or medium supplemented with BafA at 37°C for 3hours. 
Expression of CTLA-4 was analysed by western blotting using a C-19 C-terminal anti-CTLA-4 Ab and 
an anti-ubiquitin Ab. Representative data of one independent experiment of n≥3 
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Figure 4.26 CTLA-4 single or double lysine mutants are not ubiquitinated. CHO cells transfected 
with CTLA-4 mutants were incubated in medium or medium supplemented with BafA at 37°C for 3hours. 
Expression of CTLA-4 was analysed by western blotting using a C-19 C-terminal anti-CTLA-4 Ab and 
an anti-ubiquitin Ab. Representative data of one independent experiment of n≥3 
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4.9 CTLA-4 mutants can transendocytose ligand 
Central to the biology of the CTLA-4 receptor is how the receptor functions. Chapter 3 demonstrated 
that CTLA-4 can transendocytose CD80 or CD86 and then targets the ligand for degradation in 
lysosomes. Despite CTLA-4 encoding the YVKM motif in the cytoplasmic domain that is important for 
internalisation, just like CTLA-4 recycling and degradation, the sorting motifs required for 
transendocytosis are yet unclear. To address the requirements for CTLA-4 transendocytosis CHO cells 
expressing CTLA-4 mutants were co-cultured with CHO cells stably expressing either CD80 or CD86, 
fused to GFP, for 3hours at 37°C in medium alone or medium supplemented with NH4Cl. CD80 or 
CD86-GFP cells were labelled with CellTrace Violet and accordingly GFP transfer could be quantified 
by gating CTLA-4 expressing cells that were negative for Violet dye staining. Using flow cytometry, the 
CTLA-4 mutants demonstrated the ability to capture CD80 or CD86 but the efficiency was lower than 
WT (figure 4.27). Moreover, the capture of CD80 was far greater than CD86. Surprisingly, the CTLA-4 
mutant receptors that escaped degradation (KLESS, ATEP and AVKM-AFIP) possessed the ability to 
target the ligand for lysosomal degradation as revealed by NH4Cl. Taken together this data suggests the 
mechanism required for CTLA-4 transendocytosis differs from the mechanism of conventional 
endocytosis, which is exclusively dependent on a tyrosine-based hydrophobic motif.  
  
 154 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27 CTLA-4 mutants remove CD80 and CD86 and target the ligand for lysosomal 
degradation. CD80 and CD86-GFP acquisition by CHO-cells expressing CTLA-4 mutants in medium or 
medium supplemented with NH4Cl was determined by flow cytometry. Error bars show standard error 
(n=3). The capture efficiency was calculated as described in Materials and Methods. 
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4.10 Discussion 
The mechanism regulating CTLA-4 internalisation via the clathrin pathway is well described (Chuang et 
al., 1997; Shiratori et al., 1997). However, despite increased speculation that CTLA-4 can recycle and 
that it is targeted for lysosomal degradation, the pathways associated with sorting of the receptor to 
these destinations remains unclear (Chuang et al., 1997; Iida et al., 2000; Leung et al., 1995). Moreover, 
the uncertainty of the post-endocytic sorting of CTLA-4 adds to the complexity of how a receptor that is 
predominantly located in intracellular vesicles removes surface transmembrane proteins, internalises 
them and targets them for degradation. However transendocytosis does provide an answer for some of 
the unexplained features of the CD28/CTLA-4 system including why CTLA-4 is located in intracellular 
vesicles and why CD28 and CTLA-4 share ligands.  
 
The CTLA-4 cytoplasmic domain is conserved in mammalian species suggesting there is selective 
pressure to maintain this region (Bernard et al., 2007; Teft et al., 2006). Multiple motifs are and could be 
encoded in this region but the precise function of these motifs in CTLA-4 intracellular trafficking remains 
to be identified. Data presented in this thesis revealed that CTLA-4 internalisation is regulated by the 
YVKM motif and in keeping with previous studies a Y→A mutation abolished the efficiency of 
internalisation. Moreover, the YVKM motif appears to be an absolute requirement for CTLA-4 recycling 
since the receptor must first be internalised prior to being sorted in an intracellular compartment. 
However this motif does not appear to be an absolute requirement for receptor degradation since the 
AVKM mutant (where a fraction of receptor is internalised) was susceptible for degradation. This slow 
turnover rate could explain how stable surface proteins are internalised over time and degraded.  
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CTLA-4 has five lysine residues in the cytoplasmic domain and the suggestion that the receptor is 
degraded in lysosomes raised the possibility of ubiquitination being the signal directing the receptor to 
lysosomes. Although ubiquitination is now emerging as a signal for internalisation (Kumar et al., 2007), 
the data presented here shows that CTLA-4 internalisation is not ubiquitin-dependent using a lysine-less 
mutant of CTLA-4 (KLESS). However, lysine residues do regulate CTLA-4 recycling and degradation 
and this regulation resembles that of other receptors such as PAR2 (Jacob et al., 2005) and Neurokinin-
1 receptor (Cottrell et al., 2006) where enhanced recycling is observed in the absence of lysine residues. 
This suggests that the mutation of intracellular lysine residues allows CTLA-4 to escape from lysosomal 
degradation and return to the plasma membrane. Moreover, in the presence of lysosomal inhibitors no 
accumulation of KLESS CTLA-4 was observed and no ubiquitinated species were detected. The lack of 
KLESS targeting to lysosomes suggests the step at which ubiquitination is essential for post-
internalisation sorting could be absent. The size of ubiquitinated CTLA-4 indicates that the receptor is 
mono- or multi-ubiquitinated thus resulting in molecular sizes of 46-58kDa. Such a finding could prove to 
be significant when developing therapeutic vaccines for the treatment of autoimmune disease or 
cancers. The ubiquitin attachment checkpoint could be manipulated so as to increase CTLA-4 levels by 
preventing ubiquitination or decreasing CTLA-4 levels by promoting ubiquitination accordingly. However, 
further work is required to address what effect ligand binding has on CTLA-4 ubiquitination. It is also 
interesting to speculate whether the CTLA-4 receptor undergoes deubiquitination after disposing of 
ligand in lysosomes, a process that should free up the receptor to recycle back to the cell surface. Such 
a process has been described for EGFR (Berlin et al., 2010) and thus further work could help us identify 
the deubiquitinating enzyme responsible for this activity.  
 
Work in this thesis concluded that all five lysine residues play a role in CTLA-4 recycling and 
degradation and in the absence of one or more of these residues other lysines could compensate for 
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the loss. This was surprising considering how for other receptors such as EGFR (Huang et al., 2006) 
and IFNAR1 (Kumar et al., 2004) not all lysine residues are targets of ubiquitination. Importantly further 
work is required to address which E3 ligase is responsible for attaching ubiquitin molecules to the 
intracellular lysine residues in CTLA-4. Focus on T cell specific E3 ligases places GRAIL (gene related 
to anergy in lymphocytes) (Anandasabapathy et al., 2003), Cbl-b (Bachmaier et al., 2000) and Itch 
(Perry et al., 1998) as possible candidates. Previous studies have shown that all three E3 ligases are 
upregulated in anergic CD4+ CD25- T cells during ionomycin-induced anergy (Heissmeyer et al., 2004), 
a phenotype that often results when a T cell is activated via the TCR without appropriate co-stimulatory 
signals. In particular the hyperproliferative and activated phenotype of T cells deficient in Cbl-b and Itch 
resembles the phenotype seen in CTLA-4 knockout mice, further questioning whether these ligases 
have a role in CTLA-4 ubiquitination.  
 
A role for lysine residues in CTLA-4 degradation could be explained by a requirement for the receptor to 
undergo ubiquitination prior to lysosomal degradation. However the phenotype of the CTLA-4 receptor 
where the proline residue in a PTEP motif was mutated was surprising. By removing the candidate 
lysine residues, ubiquitin can no longer be attached to the CTLA-4 receptor and enhanced recycling of 
the KLESS mutant was observed. But what role does the proline-based motif play in this process? In 
the ATEP mutant, the targets of ubiquitin are still intact yet the receptor escapes ubiquitination and 
degradation. Thus, it is interesting to speculate whether the step prior to ubiquitin attachment could be 
blocked. This particular motif could be the binding site of the E3 ligase mediating ubiquitin attachment to 
lysine residues or of an intermediate protein that recruits the ligase. Of interest is TSG101, which is part 
of the ESCRT complex and co-ordinates MVB formation (Dilley et al., 2010). TSG101 binds to PT/SAP 
motifs similar to the PTEP motif in CTLA-4 and could facilitate its recruitment into MVBs prior to receptor 
degradation in lysosomes. Further work is required to identify the specific role of TSG101 in CTLA-4 
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intracellular trafficking possibly through knockdown or overexpression of this protein.  In fact, this would 
fill in the missing blanks as to how CTLA-4 is trafficking from sorting endosomes to lysosomes.  
 
The range of CTLA-4 mutants generated allowed a differentiation to be made between the sorting motifs 
important for internalisation, recycling and degradation. However for transendocytosis, all CTLA-4 
mutants captured ligand albeit less efficiently than WT. Although transendocytosis has been reported for 
other receptor-ligand pairs (Cagan et al., 1992; Klueg et al., 1998; Kusakari et al., 2008), a detailed 
mechanistic pathway for the requirements of such a pathway remains to be identified. Recent data in 
our lab suggests that the actin machinery is important in clustering the receptor and ligand, leading to 
membrane deformation and subsequent endocytosis (Omar Qureshi; personal communication). Such a 
mechanism could therefore bypass the endocytosis machinery and could explain how surface CTLA-4 
mutants AVKM and AVKM-AFIP capture and degrade ligand. 
 
Taken together, this chapter details the mechanisms regulating CTLA-4 intracellular trafficking; in 
particular highlighting the sorting motifs encoded in the cytoplasmic domain important for CTLA-4 
recycling and degradation. Such data could help our understanding when therapies are being 
developed in controlling autoimmune disease and conditions where the CD28/CTLA-4 pathway plays a 
key role.  
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5.0 COMPARISON OF THE INTRACELLULAR TRAFFICKING 
ITINERARY OF CTLA-4 ORTHOLOGUES  
 
5.1 Introduction 
The CD28/CTLA-4 pathway has been well characterised in mammals and is vital for regulating effective 
T cell responses. Interestingly, the CTLA-4 receptor has been identified in rainbow trout, amphibians 
and birds, that although require functional characterisation, could provide an insight into the evolution of 
the CTLA-4 receptor (Bernard et al., 2007; Bernard et al., 2006; Teft et al., 2006). Sequence alignments 
of the CTLA-4 extracellular domain reveal that the proline-based motif required for ligand binding, 
M(L)YPPPY, is well conserved across species. In contrast, whilst the cytoplasmic domain shows a 
striking degree of conservation in mammals, it is much less well conserved in non-mammals.  
 
In mammals, CTLA-4 is constitutively internalised from the plasma membrane, which is dependent on 
the association of the YVKM motif encoded in the CTLA-4 cytoplasmic domain associating with the 
clathrin adaptor AP-2 (Chuang et al., 1997; Shiratori et al., 1997). At steady state, the receptor is 
predominantly located in intracellular compartments raising the question of how intracellular trafficking 
may affect the function of CTLA-4. Our lab has recently proposed a model that this endocytic ability may 
play an important role in CTLA-4 function by facilitating the capture of its transmembrane co-stimulatory 
ligands from opposing cells by a process of transendocytosis (Qureshi et al., 2011). This chapter 
therefore addressed whether CTLA-4 intracellular trafficking is conserved during evolution and if any 
differences in receptor trafficking affect CTLA-4 function across species. 
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5.2 Comparison of the intracellular distribution of CTLA-4 orthologues  
In mammals, there is essentially 100% amino acid sequence conservation of the CTLA-4 cytoplasmic 
tail (figure 5.1A) (Bernard et al., 2007; Bernard et al., 2006; Teft et al., 2006). This supports the view 
that any protein sorting signals encoded within this region are likely to be of functional importance. In 
contrast, in species such as chicken, xenopus and trout, there is considerable variation in this region 
(figure 5.1A), which may provide insights into CTLA-4 trafficking and the regulation of co-stimulation. 
Chimeric versions of human CTLA-4 were therefore generated where the C-terminus was replaced with 
that of chicken, xenopus, or trout CTLA-4 (figure 5.1B). Chinese hamster ovary (CHO) cell lines were 
transfected with the CTLA-4 chimeras, the cell surface was labelled with wheat germ agglutinin (WGA) 
at 4°C and then cells were stained for total CTLA-4 expression using an Ab to the human CTLA-4 
ectodomain to assess localisation (figure 5.2A). Xenopus and chicken chimeras revealed a pattern 
similar to human CTLA-4 with a punctate intracellular distribution. In contrast, the chimera with the trout 
C-terminus showed robust surface expression with far more limited intracellular vesicles. This difference 
in the amount of surface CTLA-4 relative to the total was quantified by flow cytometry and is shown in 
figure 5.2B. 
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Figure 5.1 Generation of CTLA-4 chimeras. (A) C-terminal sequence alignments of selected 
mammalian CTLA-4 based on sequence data from Ensembl and in reference Bernard et al., (1997). (B) 
Diagram of human CTLA-4 chimeras containing the extracellular and transmembrane domain of human 
CTLA-4 and the C-terminus of species shown. C-terminal amino acid sequence alignments of human, 
chicken, xenopus and trout CTLA-4 are shown below, based on alignments using Clustal W. 
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Figure 5.2 Localisation of CTLA-4 chimeras. (A) CHO cells expressing CTLA-4 chimeras were 
incubated with WGA-tetramethylrhodamine at 4°C. Cells were subsequently fixed, permeabilised, and 
stained with an unconjugated anti-CTLA-4 Ab followed by Alexa488 anti-human secondary Ab (green) 
to stain total CTLA-4 protein. Cells were analysed by confocal microscopy. Confocal images shown are 
representative of at least 40 cells taken from one independent experiment of n=3. Bar indicates scale of 
10µm. (B) Relative expression of surface (4°C) and total CTLA-4 for each chimera as determined by 
flow cytometry. Error bars show standard error (n>3).   
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5.3 Comparison of the endocytic ability of CTLA-4 orthologues 
The increased surface expression observed with chimeric trout CTLA-4 suggested that the C-terminus 
of trout CTLA-4 might confer less efficient internalisation consistent with its lack of a YXKM motif. To 
assay internalisation directly, cells were labelled at 37°C with an unlabelled anti-CTLA-4 Ab so as to 
label CTLA-4 protein cycling from the plasma membrane. Cells were subsequently placed on ice to 
prevent further trafficking and receptors remaining at the cell surface labeled with Alexa555 anti-mouse 
secondary Ab (red). Cells were then fixed and permeabilised and internalised CTLA-4 protein detected 
with Alexa488 anti-mouse secondary Ab (green) before analysing cells by confocal microscopy (figure 
5.3A). To quantify these differences, internalisation was also measured as a ratio of surface (red) to 
internalised (green) CTLA-4 (figure 5.3B). Human CTLA-4 possessed the lowest surface to internalised 
ratio reflecting that CTLA-4 is predominantly localised in intracellular vesicles, which was similar to 
chimeric constructs from xenopus and chicken CTLA-4. In contrast, the C-terminus of trout CTLA-4 
showed a greater surface to internalised ratio suggesting relatively poor endocytosis consistent with its 
more obvious surface phenotype.  
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Figure 5.3 Cellular localisation of CTLA-4 chimeras. (A) CHO cells expressing CTLA-4 chimeras 
were incubated with unconjugated anti-CTLA-4 Ab at 37°C for 1hour, cooled to 4°C and surface CTLA-
4 stained red with Alexa555 anti-mouse secondary Ab. Cells were subsequently fixed, permeabilised 
and stained with Alexa488 anti-mouse secondary Ab (green) and imaged by confocal microscopy. 
Confocal images shown are representative of at least 40 cells taken from one independent experiment 
of n=3. Bar indicates scale of 10µm. (B) The ratio of surface to internalised CTLA-4 fluorescence was 
calculated by outlining cells in ImageJ. Error bars show standard error. Representative data of one 
independent experiment of n=3.  
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To assay the efficiency of CTLA-4 internalisation more quantitatively in multiple cells, a flow cytometric 
approach was used. Cycling CTLA-4 was labelled with a PE-conjugated anti-CTLA-4 Ab at 37°C. Cells 
were subsequently washed and placed on ice and any residual surface primary antibody was detected 
using an Alexa647 anti-mouse secondary Ab (figure 5.4A). For WT CTLA-4 this generates a curved 
plot where the extensive cycling label at 37°C (Y-axis) is greater than the minimal surface label (x-axis), 
typical of an endocytic protein. Whilst both chicken and xenopus CTLA-4 chimeras showed a similar 
pattern to human the chimeric trout CTLA-4 displayed an almost linear relationship between cycling and 
surface CTLA-4 (figure 5.4B) typical of a cell surface protein, again suggesting impaired CTLA-4 
endocytosis in trout. 
 
To directly measure the rates of endocytosis the cell surface pool of CTLA-4 was stained on ice with an 
unlabelled anti-CTLA-4 Ab. Cells were then warmed to 37ºC for the indicated time-points to allow any 
internalisation of surface CTLA-4 to take place. Cells were then placed on ice, and any CTLA-4 
remaining at the cell surface detected with an Alexa647 anti-mouse secondary Ab. Accordingly, in this 
assay the loss of Alexa647 staining over time reflects endocytosis of CTLA-4. Using this assay, human 
CTLA-4 showed a comparable rate of endocytosis to the chimeric xenopus and chicken constructs 
(figure 5.5A), internalising 50% or more within 5minutes. In contrast, chimeric trout CTLA-4 showed a 
much slower rate of endocytosis taking at least 30minutes to achieve 50% internalisation. Nevertheless, 
chimeric trout CTLA-4 did internalise compared to a control CTLA-4 chimera with a cytoplasmic domain 
from CD86, which is a plasma membrane resident in CHO cells (figure 5.5A). However, it was clear 
that even for surface proteins (CTLA-4-CD86) there was a small decrease in signal over time in this 
assay, which was not due to endocytosis, further emphasising the much reduced endocytic nature of 
the trout chimera. 
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Figure 5.4 Flow cytometry identifies different cellular trafficking in the CTLA-4 chimeras. (A) 
CHO cells expressing human CTLA-4 were labelled with PE-conjugated anto-CTLA-4 Ab at 37°C for 30 
minutes followed by labelling surface CTLA-4 on ice (4°C) with Alexa647 anti-mouse secondary Ab. 
Cells were analysed by flow cytometry and data are plotted as cycling CTLA-4 (37°C label) vs surface 
CTLA-4 (4°C label). (B) CHO cells expressing the CTLA-4 chimeras were labelled as described in A. 
and analysed by flow cytometry. Dotted line provides a standard gradient for reference purposes. 
Representative FACS plots are shown of one independent experiment of n≥3. 
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Experiments in chapter 3 revealed that in the presence of hypertonic sucrose CTLA-4 internalisation is 
inhibited. The effect of sucrose treatment was therefore tested on the chimeric constructs to determine 
their clathrin dependence. As shown in figure 5.5B sucrose treatment inhibited the endocytosis of 
CTLA-4 molecules. In particular the more rapid endocytosis seen in chicken, xenopus and human 
CTLA-4 chimeras (relative to trout) was prevented by sucrose treatment. Overall, this data suggests that 
the chimeras internalise via a clathrin dependent pathway. 
 
To further verify that the chimeras internalise using clathrin, the co-localisation of the CTLA-4 chimeras 
with transferrin was compared. Cells were incubated with transferrin AlexaFluor633 and PE-conjugated 
anti-CTLA-4 Ab at 37°C for 45minutes and subsequently fixed and analysed by confocal microscopy. 
This revealed that human, chicken and xenopus CTLA-4 co-localised with transferrin in intracellular 
vesicles, suggesting internalisation in the chimeras is clathrin-dependent (figure 5.6). Additionally, this 
assay revealed limited but detectable co-localisation between trout CTLA-4 and transferrin, further 
suggesting that trout CTLA-4 does internalise via clathrin albeit at a reduced rate.  
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Figure 5.5 CTLA-4 chimeras show different endocytic efficiencies. (A) CHO cells expressing CTLA-
4 chimeras were labeled at 4°C with an unlabelled anti-CTLA-4 Ab to label surface CTLA-4. Cells were 
then warmed to 37°C to allow endocytosis for the times indicated. Cells were then placed on ice and 
any remaining surface CTLA-4 detected with Alexa647 anti-mouse secondary Ab. The 647 signal was 
plotted against time as the fraction remaining compared to 4°C. (B) CHO cells expressing CTLA-4 
chimeras were labeled as in A. but in medium supplemented with sucrose (0.45M) to prevent 
endocytosis. Error bars show standard error (n≥3). 
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Figure 5.6 CTLA-4 chimeras internalise using a clathrin-dependent pathway. CHO cells expressing 
the chimeric CTLA-4 constructs were incubated with a transferrin AlexaFluor633 and PE-conjugated 
anti-CTLA-4 at 37°C for 45minutes. Cells were subsequently fixed and analysed by confocal 
microscopy. The red arrows indicate co-localisation. Confocal images shown are representative of at 
least 40 cells taken from one independent experiment of n=3. Bar indicates scale of 10µm. 
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Whilst trout CTLA-4 lacked the conserved YVKM internalisation motif found in mammals, it did appear 
to have a putative YxxF motif (Bernard et al., 2007), which could possibly mediate endocytosis. To 
address whether this motif contributed to the internalisation observed with the chimeric trout CTLA-4, 
the tyrosine residue was mutated to a valine and the behaviour of this mutant was monitored in CHO 
cells. A comparison of internalisation rates indicated the VGNF mutant had further impaired endocytosis 
compared to the YGNF control and now resembled the behavior of non-endocytic proteins seen using 
sucrose or with the surface CD86 chimera (figure 5.7A). In contrast to chimeric trout CTLA-4 containing 
YGNF, the VGNF mutant demonstrated no co-localisation with transferrin (figure 5.7B). Together, these 
results confirmed the presence of a functional tyrosine-based endocytic motif in trout CTLA-4 albeit one 
that functions with reduced efficiency. 
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Figure 5.7 Trout CTLA-4 has a rudimentary endocytic motif. (A) CHO cells expressing CTLA-4 
chimeras were labeled at 4°C with an unlabelled anti-CTLA-4 Ab to label surface CTLA-4. Cells were 
then warmed to 37°C to allow endocytosis for the times indicated. Cells were then placed on ice and 
any remaining surface CTLA-4 detected with Alexa647 anti-mouse secondary Ab. The 647 signal was 
plotted against time as the fraction remaining compared to 4°C. Error bars show standard error (n≥3). 
(B) CHO cells expressing the chimeric CTLA-4 constructs were incubated with a transferrin 
AlexaFluor633 and PE-conjugated anti-CTLA-4 at 37°C for 45minutes. Cells were subsequently fixed 
and analysed by confocal microscopy. Confocal image shown is representative of at least 40 cells taken 
from one independent experiment of n=3. Bar indicates scale of 10µm. 
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5.4 Degradation of CTLA-4 orthologues correlates with endocytic ability 
Chapter 3 revealed that human CTLA-4 is degraded in lysosomes. To address the stability of the CTLA-
4 chimeras, new protein synthesis was blocked using CHX and the decay of existing CTLA-4 was 
monitored. In addition, if CTLA-4 was being degraded via a lysosomal pathway then NH4Cl should 
prevent degradation. CTLA-4 protein stability was therefore monitored in the presence of CHX or NH4Cl 
for 3hours at 37°C. After treatment, cells were fixed and permeabilised prior to staining for total CTLA-4 
expression and analysed by confocal microscopy or flow cytometry. In the absence of new protein 
synthesis, rapid loss of human, chicken and xenopus CTLA-4 was observed (figure 5.8A) indicating 
that CTLA-4 was degraded rapidly. Degradation was quantified by both confocal analysis (figure 5.8B) 
and by flow cytometry (figure 5.9). Moreover, NH4Cl resulted in an accumulation of CTLA-4 
(predominantly in human, xenopus and chicken chimeras) suggesting that blocking lysosomal function 
prevents CTLA-4 degradation. Whilst human CTLA-4, chimeric xenopus and chicken showed 
comparable degradation, the trout CTLA-4 chimera was much less affected by CHX although compared 
to the non-endocytic variants (trout VGNF and CTLA-4-CD86 chimera) some degradation was still 
evident (figure 5.8 and 5.9E-F).  
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Figure 5.8 Degradation efficiency of the CTLA-4 chimeras correlates with their endocytic 
potential. (A) CHO cells expressing CTLA-4 chimeras were incubated in medium or medium 
supplemented with CHX, NH4Cl or NH4Cl and CHX at 37°C for 3hours. Cells were fixed, permeabilised 
and stained for total CTLA-4 with an unlabelled anti-CTLA-4 Ab followed by Alexa488 anti-mouse 
secondary Ab (green) and nuclei counterstained using DAPI (blue). Cells were analysed by confocal 
microscopy. Bar indicates scale of 10µm. (B) Total CTLA-4 was quantified by outlining cells in ImageJ 
and MFI plotted. Error bars shows standard error (n≥3). 
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Figure 5.9 Flow cytometry verifies the degradation efficiency of the CTLA-4 chimeras correlates 
with their endocytic potential. CHO cells expressing CTLA-4 chimeras were incubated in medium or 
medium supplemented with CHX, NH4Cl or NH4Cl and CHX at 37°C for 3hours. Cells were fixed, 
permeabilised and stained for total CTLA-4 with a PE-conjugated anti-CTLA-4 Ab. Cells were analysed 
by flow cytometry. The MFI is plotted as a percentage of initial fluorescence. Error bars show standard 
error (n≥3).  
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To determine if CTLA-4 co-localised with markers of late endosomes, the CTLA-4 chimeras were 
transfected with CD63, fused to GFP, in the presence of NH4Cl. Notably, human, chicken and xenopus 
CTLA-4 all demonstrated substantial co-localisation with CD63-GFP, suggesting traffic to late 
endosomes (figure 5.10). In contrast, the non-endocytic trout VGNF mutant and the cell surface CTLA-
4-CD86 chimera demonstrated no obvious co-localisation with CD63. Collectively these data suggest 
that degradation of CTLA-4 is related to its endocytic capacity and that the presence of YV/EKM motif 
promotes both internalisation and sensitivity to lysosomal degradation. Moreover, trout CTLA-4 contains 
an alternate tyrosine-based motif that has a reduced efficiency of endocytosis and has a more stable 
cell surface phenotype when compared to CTLA-4 from human, chicken and xenopus.  
 
5.5 CTLA-4 orthologues differ in their ability to recycle 
Chapter 3 revealed that once internalised a proportion of human CTLA-4 molecules recycle back to the 
plasma membrane. Since variation in endocytic motifs may also affect recycling, this property was 
assessed in the chimeras (Obermuller et al., 2002). To assay CTLA-4 recycling, cells were incubated at 
37°C with a PE-conjugated anti-CTLA-4 Ab for 30 minutes to label the cycling pool of CTLA-4. Cells 
were then incubated further at 37°C for various times with an Alexa647 anti-mouse secondary Ab to 
label any of the primary antibody recycling back to the cell surface. Accordingly, recycling CTLA-4 is 
seen as an increase in the Alexa647 signal over time. Notably, human CTLA-4 and chimeric chicken 
CTLA-4 (YVKM containing proteins) showed a comparable rate of recycling (figure 5.11) whereas 
chimeric xenopus and trout CTLA-4, which lacked YVKM motif were notably less efficient.  
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Figure 5.10 CTLA-4 chimeras co-localise with markers of late endosomes. CHO cells expressing 
CTLA-4 chimeras were transfected with CD63-GFP. Cells were incubated in medium supplemented 
with NH4Cl at 37°C for 3 hours. Cells were fixed, permeabilised, and stained with an unconjugated anti-
CTLA-4 Ab and Alexa565 anti-human secondary Ab (red) to stain total CTLA-4 protein and analysed by 
confocal microscopy. The red arrows indicate co-localisation. Confocal images shown are 
representative of at least 40 cells taken from one independent experiment of n=3. Bar indicates scale of 
10µm. 
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Figure 5.11 CTLA-4 chimeras differ in their ability to recycle. CHO cells expressing CTLA-4 
chimeras were labeled with PE-conjugated anti-CTLA-4 Ab at 37°C to detect cycling CTLA-4, washed 
and any recycling CTLA-4-PE antibody detected by addition of Alexa647 anti-mouse secondary Ab at 
either 4°C or 37°C. Recycling rates are plotted for the chimeras as normalised to the 4°C control (A and 
B).  Error bars shown standard error (n=3). 
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Since an acidic residue (E) at the +1 position of YxxM has been suggested to favour an interaction with 
the lysosomal sorting adaptor AP-3 (Ohno et al., 1998), the YVKM motif in human CTLA-4 was mutated 
to YEKM and assayed for the efficiency of internalisation and recycling. The CTLA-4 YEKM construct 
remained endocytic albeit with slightly reduced efficiency compared to CTLA-4 YVKM (figure 5.12A). 
However, recycling by CTLA-4 YEKM was impaired (figure 5.12B), which was reminiscent of the lower 
recycling observed for the xenopus CTLA-4 chimera (figure 5.12C). Taken together these data suggest 
that the YVKM motif found in mammalian CTLA-4 is optimised for both endocytosis and recycling of 
CTLA-4 and that even relatively subtle variations as found in xenopus CTLA-4 can compromise these 
functions. 
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Figure 5.12 Recycling efficiency is regulated by the YVKM motif. (A) CHO cells expressing WT 
human CTLA-4 YVKM or YEKM motif were labelled at 4°C with anti-CTLA-4 to label surface CTLA-4. 
Cells were warmed to 37°C for the time indicated. Cells were then placed on ice and the remaining 
surface CTLA-4 detected with Alexa647 anti-mouse secondary Ab and plotted over time. Error bars 
show standard error (n=3). (B) CHO cells expressing WT human CTLA-4 YVKM or a point mutant 
YEKM motif were labelled with PE-conjugated anti-CTLA-4 Ab at 37°C to detect cycling CTLA-4. 
Recycling protein was detected with Alexa647 anti-mouse secondary Ab at 37°C for the indicated time 
points. Recycling rates are plotted for the CTLA-4 variants normalised to the 4°C control. Error bars 
show standard error (n=3). (C) Representative data comparing human and xenopus CTLA-4 recycling 
after 30minutes is shown (n≥3). 
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5.6 CTLA-4 orthologues can transendocytose ligand 
The significant variation in the CTLA-4 cytoplasmic domain between species suggests there could be a 
difference in the function and the ability of the CTLA-4 in these species to transendocytose ligand. To 
address transendocytosis, CHO cells expressing CTLA-4 chimeras were co-cultured with CHO cells 
stably expressing either CD80 or CD86, fused to GFP, for 3hours at 37°C in medium alone or medium 
supplemented with NH4Cl. CD80 or CD86-GFP cells were labelled with CellTrace Violet and accordingly 
GFP transfer could be quantified by gating CTLA-4 expressing cells that were negative for Violet dye 
staining. Using flow cytometry, the CTLA-4 chimeras demonstrated the ability to capture CD80 or CD86 
albeit at a reduced efficiency when compared to human CTLA-4 (figure 5.13). The ability to capture 
CD80 was higher for all chimeras when compared to the capture of CD86. Importantly, this ability was 
diminished in the trout VGNF mutant, suggesting the YxxF motif could direct transendocytosis in trout 
CTLA-4. Importantly, the trend in the pattern of ligand capture, (human>chicken>xenopus>trout) 
demonstrates that the efficiency of ligand capture has improved as a result of evolution but may also 
require other sorting motifs encoded within the CTLA-4 cytoplasmic domain. 
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Figure 5.13 CTLA-4 chimeras show a difference in their ability to capture ligand. CD80-GFP (A) 
and CD86-GFP (B) acquisition by CHO cells expressing CTLA-4 chimeras was determined by flow 
cytometry. The capture efficiency of ligand by the CTLA-4 chimeras was calculated as described in 
Materials and Methods in medium or medium supplemented with NH4Cl. Error bars show standard error 
(n=3). 
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5.7 Discussion 
The high degree of conservation in the CTLA-4 cytoplasmic domain amongst mammalian species 
suggests there is selective pressure to maintain the functional regulation mediated via motifs encoded in 
this region (Bernard et al., 2007; Teft et al., 2006). As a lab we have identified a new function of CTLA-4 
termed transendocytosis that takes its highly endocytic nature into account (Qureshi et al., 2011). 
Moreover after binding and internalising ligand, CTLA-4 disposes of the ligand in lysosomal 
compartments. However in non-mammals the CTLA-4 cytoplasmic domain varies considerably from that 
encoded in mammals. This therefore raises questions as to whether the intracellular trafficking of CTLA-
4 is conserved through evolution and whether these differences impact CTLA-4 function. In this chapter 
I found that the location of the tyrosine-based hydrophobic motif in the CTLA-4 cytoplasmic domain 
contributes greatly to localisation, endocytosis and recycling across species. Moreover, the sensitivity to 
lysosomal degradation correlates with the endocytic potential of the CTLA-4 receptor and is conserved 
through evolution evident since the emergence of fish.  
 
The YVKM motif in human CTLA-4 is important in regulating the internalising of the receptor from the 
cell surface. Chicken and xenopus CTLA-4 encode a tyrosine-based hydrophobic motif that align well 
with the mammalian YVKM motif and both chimeras demonstrated comparable characteristics to human 
CTLA-4 being present in intracellular vesicles. The absence of a conserved YXXM motif in trout CTLA-4 
is interesting since without this motif some of the specialised trafficking features we observe in human 
CTLA-4 should be absent. However, emphasis has been placed on YxxF motif located further 
downstream in the trout CTLA-4 cytoplasmic domain (Bernard et al., 2007). Work in this thesis 
confirmed that despite the trout CTLA-4 chimera exhibiting a greater surface to internalised ratio when 
compared to other endocytic chimeras, internalisation was taking place but at a reduced rate. 
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Mutagenesis of the YxxF motif in trout CTLA-4 did in fact confirm that this motif was regulating its 
internalisation. This was surprising and not only from the point of view of the CTLA-4 receptor. Work in 
other receptors has demonstrated that location of the tyrosine residue in the cytoplasmic tail of 
receptors is critical to the movement of a receptor into coated pits (Lazarovits and Roth, 1988). Likewise, 
CD28 has YMNM motif similar to the YVKM motif in CTLA-4. However whereas CTLA-4 is endocytic 
CD28 is a surface resident receptor. Alignment of the cytoplasmic domain sequences reveals that the 
YMNM motif in CD28 is located further downstream of the YVKM motif in CTLA-4. Moreover transfer of 
the YVKM motif in CTLA-4 to CD28 does not trigger endocytosis but endocytosis is preserved in a 
CTLA-4 mutant encoding the YMNM motif of CD28 (Omar Qureshi; personal communication). Thus, it 
appears that the location of the tyrosine-based hydrophobic motif in the cytoplasmic domain is key to 
the efficiency of CTLA-4 endocytosis. In the case of trout CTLA-4 the location of the YxxF motif further 
downstream could prevent rapid and efficient internalisation but the presence of this motif in trout CTLA-
4 suggests that this could represent the initial emergence of CTLA-4 endocytosis.  
 
The degradation of CTLA-4 in lysosomal compartments has been suggested to be a mechanism used 
to regulate the expression of the receptor at the cell surface (Iida et al., 2000). Work in this thesis 
demonstrates that the sensitivity to lysosomal degradation in the various CTLA-4 chimeras correlates 
with their endocytic potential and in the ability to transendocytose ligand. Although these features were 
less well developed in trout CTLA-4 they do exist. It is therefore interesting to speculate whether the 
specialised intracellular trafficking of mammalian CTLA-4 and the transendocytosis function is the direct 
result of mutation and selection of cytoplasmic domain variants. The greater surface expression of trout 
CTLA-4 suggests that the receptor could largely function at the cell surface. Once the receptor binds 
ligand only does it then internalise and dispose of the ligand in lysosomes. This would explain the slow 
internalisation rate of trout CTLA-4 and little sensitivity to degradation. In the case of the endocytic 
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chimeras since internalisation from the cell surface is constitutive, the chance of interacting with 
components regulating lysosomal degradation is increased and thus the receptor undergoes 
degradation in the presence or absence of ligand.  
 
Work in this thesis has confirmed that once internalised a fraction of the CTLA-4 receptor is recycled 
back to the cell surface. The C-terminus of chicken CTLA-4 demonstrated a comparable rate of 
recycling as human CTLA-4 suggesting that the recycling function is regulated by the YVKM motif. 
Importantly the residue in the +1 position of the YXXM motif also plays a role in regulating recycling as 
demonstrated by the lack of recycling seen for xenopus CTLA-4 that encodes a YEKM motif. This 
finding is consistent with the trafficking of other membrane receptors. The lysosomal membrane 
proteins LAMP1 and LAP (lysosomal acid phosphatase) are both trafficked to lysosomes from the TGN 
(Honing et al., 1996; Peters et al., 1990). However the route taken to lysosomes is determined by the 
tyrosine based hydrophobic motifs encoded in the cytoplasmic domain (Obermuller et al., 2002). LAP 
encodes a YRHV motif which regulates recycling of the protein between endosomes and the plasma 
membrane and is delivered via an indirect route to lysosomes. LAMP1 however encodes a YQTI motif 
which delivers the protein directly from the TGN to lysosomes. These may represent subtle differences 
in the tyrosine-based hydrophobic motif but these changes have a direct effect on which clathrin adaptor 
protein binds to the motif and thus the trafficking pathway in which the receptor is sorted. In the case of 
human CTLA-4, the recycling efficiency was reduced when the valine residue in the YVKM motif was 
mutated to glutaminc acid further demonstrating the tight regulation of this mechanism. 
 
Taken together data in this chapter has demonstrated that CTLA-4 function as a cell-extrinsic regulator 
of the immune system is conserved through evolution. However, the CTLA-4 cytoplasmic domain has 
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undergone major changes since the emergence of fish. Fish have a simple immune system and do not 
require the specialised immune features present in mammals. Thus it is interesting to speculate that 
CTLA-4 in fish could function as a cell-extrinsic regulator and remove ligand efficiently by predominantly 
remaining at the cell surface. In the case of mammals, the cell-extrinsic function of CTLA-4 in Tregs 
requires CTLA-4 to traffic continuously to the plasma membrane and remove ligand from the surface of 
APCs.  
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6.0 GENERAL DISCUSSION 
 
The regulation of T cell activation is vital for controlling immune responses against foreign pathogens 
and in preventing the development of autoimmune disease (Murphy, 2008). To control this on/off switch 
T cells require two signals for activation. Of importance is the second co-stimulatory signal provided by 
the CD28 receptor or the CTLA-4 receptor. Both receptors share 30% homology at the amino acid level 
and bind the same ligands expressed on APCs but the outcome of ligand engagement leads to different 
outcomes (Carreno and Collins, 2002; Sharpe and Freeman, 2002). CD28 binding to CD80 or CD86 
drives T cell activation, proliferation and differentiation (Carreno and Collins, 2002; Lenschow et al., 
1996). However, once T cells are activated they upregulate CTLA-4, which acts to compete with CD28 
to bind the ligands and inhibit T cell activation. Over the years there has been a long-standing debate as 
to how CTLA-4 functions and importantly how this function is related to its predominant localisation in 
intracellular vesicles (Rudd, 2008; Walker and Sansom, 2011). CTLA-4 endocytosis via the clathrin-
pathway has been well described (Chuang et al., 1997; Shiratori et al., 1997). However our 
understanding of the intracellular trafficking pathways used by CTLA-4 is not complete. This thesis 
therefore set out to identify the post-internalisation fate of CTLA-4 with particular emphasis in identifying 
the sorting signals encoded in the cytoplasmic domain important for trafficking. 
 
The location of CTLA-4 in intracellular vesicles has been the most dominating aspect of its biology yet 
the receptor functions at the cell surface. One aim of this PhD was to address the localisation of the 
CTLA-4 receptor at steady state in activated T cells and Tregs. Most trafficking receptors are 
predominantly located at the cell surface and only once the receptor binds ligand does the receptor 
internalise. CTLA-4 is unusual as its internalisation is constitutive and ligand binding is not an absolute 
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requirement for its internalisation. As such we found that in both activated T cells and Tregs CTLA-4 
was located in intracellular compartments with minimal cell surface expression. Previous studies 
suggest that T cell activation by Src kinases results in the stabilisation of the CTLA-4 receptor at the 
plasma membrane (Bradshaw et al., 1997; Chuang et al., 1997; Hu et al., 2001; Shiratori et al., 1997). 
For this to occur the tyrosine residue of the YVKM motif encoded the CTLA-4 cytoplasmic domain is 
phosphorylated and can no longer associate with the clathrin adaptor AP-2 therefore preventing 
endocytosis. However, recent findings in our lab have shown that after T cell activation, CTLA-4 is 
mobilised to the plasma membrane but the receptor is not stabilised at the surface and continues to 
undergo endocytosis (Qureshi et al., 2012).  
 
Work in this thesis shows that in activated T cells and regulatory T cells the total CTLA-4 expression is 
greater than the pool of surface and cycling CTLA-4. This indicates that CTLA-4 like GLUT4 could be 
stored in a storage compartment and could be mobilised from these compartments once the T cell 
encounters antigen (Slot et al., 1991). This could explain how effector T cells in the periphery are able to 
regulate the immune response with limited damage to self. In this instance, CTLA-4 is already available 
in a T cell ready to be trafficked to the surface and bind ligand. 
 
The mechanism for CTLA-4 internalisation was first investigated when it was identified that following T 
cell activation most of the receptor resides in intracellular compartments and that any surface CTLA-4 is 
rapidly re-internalised (Chuang et al., 1997; Shiratori et al., 1997). It was concluded that CTLA-4 
internalises via the clathrin pathway and relies on a tyrosine-based hydrophobic motif encoded in the 
cytoplasmic domain associating with the clathrin adaptor AP-2 (Chuang et al., 1997). The work in this 
thesis confirmed these findings where a mutation of the YVKM motif to AVKM abolished CTLA-4 
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internalisation providing evidence that this motif is directing endocytosis of CTLA-4 from the cell surface. 
Moreover, a transferrin uptake assay confirmed that CTLA-4 utilises the same internalisation pathway 
as TfR, a well-established receptor that uses clathrin. Importantly, the ability of CTLA-4 to endocytose 
appears to be evolutionary conserved evident since the emergence of fish, however the efficiency to 
internalise was greater in humans and least efficient in fish. The YxxF motif in trout CTLA-4 aligns well 
with the second tyrosine based motif YFIP in human CTLA-4 and the finding that some human CTLA-4 
can internalise in the absence of YVKM could indicate that YFIP is mediating this poor and less efficient 
internalisation. Taken together this data could therefore suggest that the complex intracellular trafficking 
itinerary of mammalian CTLA-4 may have resulted from mutation and selection of cytoplasmic domain 
variants.  
 
Another aim of this thesis was to address the post-internalisation fate of the CTLA-4 receptor. Once 
endocytic receptors are internalised they are sorted in intracellular compartments, where receptors are 
first delivered to early endosomes and from here a decision is made about whether the receptor will be 
recycled back to the surface or targeted for degradation (Trowbridge et al., 1993). We have previously 
shown that fraction of internalised CTLA-4 is recycled back to the cell surface and co-localises with 
Rab11 positive compartments (Qureshi et al., 2012). Work in this thesis confirms that CTLA-4 does 
recycle and that recycling is driven by the YVKM motif, which appears to be optimised for this function. 
Moreover even subtle changes in the YVKM motif as identified in xenopus CTLA-4, which encodes a 
YEKM motif, can impair recycling. An acidic residue in the +1 position of YXXM has been suggested to 
favor interaction with the lysosomal sorting adaptor AP-3 (Ohno et al., 1998) and this could explain the 
reduced receptor recycling we observed in human CTLA-4 when the YVKM motif was mutated to YEKM.  
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Most trafficking receptors such as EGFR are recycled back to the surface so as to maintain the signal 
transmitted by the receptor (Roepstorff et al., 2009; Waterman et al., 1998). The requirement for 
recycling would fit in well with the model of CTLA-4 function where the receptor has been suggested to 
deliver an inhibitory signal in T cells, as similar to EGFR, recycling would be the mechanism by which 
CTLA-4 prolongs its signal. However despite years of research, no such signalling cascade for CTLA-4 
has been identified and it has now been suggested that CTLA-4 actually functions in a cell-extrinsic 
manner as opposed to a cell-intrinsic manner (Walker and Sansom, 2011). It is therefore interesting to 
speculate whether for the newly identified function of CTLA-4, transendocytosis, recycling is required to 
continuously remove ligand from the surface of APCs. CTLA-4 would therefore act like a pump to 
internalise ligand from the synapse between a T cell and an APC, target the ligand for degradation and 
recycle back to the cell surface to remove more ligand. 
 
In keeping with previous findings, work in this thesis confirms that CTLA-4 is degraded in lysosomes. 
CTLA-4 co-localised with lysosomal markers in the presence of NH4Cl. Moreover a rapid loss of protein 
was detected in the presence of CHX, which could explain why co-localisation of CTLA-4 with markers 
of lysosomal compartments has been difficult to detect in other studies. Previous studies suggest that 
degradation could be used as a mechanism to regulate the surface expression of CTLA-4 (Iida et al., 
2000; Schneider et al., 1999), but the exact requirement for degradation remains to be identified. Work 
in this thesis has confirmed that the sensitivity to degradation is related to the endocytic potential of the 
receptor. However it is interesting to speculate whether for transendocytosis trafficking to lysosomal 
compartments could be used to dispose of ligand allowing CTLA-4 to recycle back to the cell surface.  
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EGFR like CTLA-4 binds to more than one ligand, each of which has a different affinity for the receptor 
(Henriksen et al., 2013; Roepstorff et al., 2009). As such depending on which ligand binds EGFR, the 
receptor undergoes a different fate. For instance TGF-α binding to EGFR results in receptor recycling 
because the receptor-ligand binding is not stable at the endosomal pH and so become dissociated. This 
frees up EGFR to recycle back to the surface whilst targeting TGF-α for degradation. In contrast, EGF 
binding to EGFR is stable at the endosomal pH and so both receptor and ligand are degraded (Hu et al., 
2001). CD80 has a higher affinity for CTLA-4 compared to CD86 thus raising speculation that CTLA-4 
fate could also be determined by ligand binding. However work in this thesis has shown that CTLA-4 
can target both ligands for lysosomal degradation and the endocytic machinery may not solely be 
responsible for this function (Omar Qureshi; personal communication). Despite considerable variation 
between the cytoplasmic domain of human and trout CTLA-4, the trout CTLA-4 chimera could also 
transendocytose ligand further suggesting that other mechanisms contribute to this function of CTLA-4. 
Thus it appears that the function of transendocytosis appears to be evolutionary conserved, which could 
partly explain why the ligand-binding site is also conserved across species (Bernard et al., 2007; Teft et 
al., 2006). 
 
Finally the work in this thesis addressed the mechanism regulating CTLA-4 recycling and the 
degradation of the receptor in lysosomes. Ubiquitination is recognised as an important signal for 
targeting trafficking receptors to lysosomes (Kumar et al., 2007). The process involves the attachment 
of ubiquitin to intracellular lysine residues of the receptor (Myung et al., 2001). CTLA-4 encodes five 
lysine residues in the cytoplasmic domain and the mutation of these residues to arginine (KLESS) 
produced a stable trafficking receptor that was resistant to lysosomal degradation. Moreover 
assessment of the ubiquitination status revealed that human CTLA-4 is ubiquitinated and the loss of 
ubiquitination in the KLESS mutant confirmed that the lysine residues are targets of ubiquitin attachment. 
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The lack of degradation resulted in an increase in CTLA-4 recycling as has been described for other 
trafficking receptors such as PAR2 (Jacob et al., 2005). The point at which ubiquitin is attached to 
CTLA-4 could be used as a checkpoint to vary CTLA-4 levels in Tregs depending on whether 
expression needs to be increased or decreased. By modulating CTLA-4 levels there could be a 
possibility to enhance the weak immune responses against tumor antigens in cancer or decrease the 
strong immune responses observed in graft rejection. Thus, targeting CTLA-4 in Tregs could prove 
pivotal when designing vaccines and treatment for autoimmune disease, cancers and in facilitating 
organ transplantation. Further work however is required to determine the effect ligand binding has on 
CTLA-4 ubiquitination. However, it is interesting to speculate whether after CTLA-4 targets the ligand for 
degradation, the receptor itself becomes deubiquitinated and recycles back to the plasma membrane to 
remove more ligand. Such a mechanism has been described for EGFR (Berlin et al., 2010) and 
moreover provides an additional explanation for why CTLA-4 would need to recycle.   
 
More importantly further work is required to identify the E3 ligase responsible for ubiquitin attachment. 
Cbl-b is a candidate E3 ligase for TCR ubiquitination, which raises speculation if the same ligases could 
be associated with CTLA-4 downregulation and degradation in lysosomes. Moreover, the upregulation 
of Cbl-b in anergic CD4+ CD25+ T cells, a phenotype resulting from a lack of appropriate T cell co-
stimulation, and the marked similarity between the phenotype of Cbl-b deficient and CTLA-4 deficient 
mice makes this E3 ligase an ideal candidate. Other candidates include GRAIL and Itch. Again both 
these ligases are upregulated in anergic T cells and in particular Itch, a HECT type E3 ligase, binds to 
PPxY motifs via WW domains (Ishihara et al., 2011). Thus it is interesting to speculate whether Itch 
binds to the PPPY motif encoded in the CTLA-4 extracellular domain and thereby regulates CTLA-4 
ubiquitination. However, in order to facilitate ubiquitin attachment the E3 ubiquitin ligase should be 
recruited close to the intracellular lysine residues. Thus, the distance between the PPPY motif in the 
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CTLA-4 extracellular domain and the cytoplasmic lysine residues may rule out the involvement of a 
HECT type E3 ligase. 
 
Most trafficking receptors targeted for lysosomal degradation are ubiquitinated and subsequently sorted 
into MVBs (Wollert and Hurley, 2010). CTLA-4 has been reported to be present in non-lysosomal, 
perinuclear vesicles, which could represent MVBs or late endosomes (Mead et al., 2005). Interestingly 
TSG101, a component of the ESCRT complex that regulates MVB formation binds to ubiquitinated 
cargo and to PT/SAP motifs (Dilley et al., 2010). CTLA-4 encodes a PTEP motif the significance of 
which remains to be identified. However, work in this thesis has shown that a mutation of the proline 
residue to arginine resulted in a stable CTLA-4 receptor that exhibited the same characteristics as 
KLESS. The fact that the ubiquitin targets are still intact in the ATEP mutant suggests this could be the 
binding site for a protein required prior to the attachment of ubiquitin to the lysine residues. This protein 
could either act as an intermediate recruiting the E3 ubiquitin ligase or could be the binding site for the 
E3 ubiquitin ligase. Moreover the close proximity of the PTEP motif to the cytoplasmic lysine residues 
makes this site a more ideal candidate to recruit or bind an E3 ubiquitin ligase than the PPPY motif 
located in the extracellular domain. 
 
In summary, the work in this thesis has provided further insight into the intracellular trafficking of the 
CTLA-4 receptor demonstrating in particular how the receptors ability to undergo constitutive 
internalisation and how its post-endocytic sorting could be related to the recently identified function of 
transendocytosis. The findings are novel and exciting since by increasing our understanding on how 
CTLA-4 traffics in activated T cells or Tregs provides us with the opportunity to possibly manipulate 
CTLA-4 levels in certain intracellular compartments, which could prove to be invaluable therapeutically.  
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Work in this thesis also investigated the mechanisms responsible for CTLA-4 recycling and degradation 
with a particular emphasis on the sorting motifs encoded in the cytoplasmic domain. Since single or 
double point lysine mutants could not identify which lysine residue/s are targets of ubiquitination, it is 
concluded that in the absence of one or more lysine residues, other lysine residues could compensate. 
To strengthen this conclusion, more work would be required and the most obvious step to take would be 
to perform mass spectrometry. This technique has been used successfully to identify lysine residues 
that serve as targets of ubiquitin attachment for other receptors such as EGFR. Moreover, a second 
advantage of using mass spectrometry would be to identify the E3 ligase responsible for ubiquitin 
attachment. This would be more difficult as the E3 ligase would bind to the receptor transiently but 
nevertheless this is not impossible. Moreover, it would be worthwhile investigating if ligand binding has 
an effect on CTLA-4 receptor ubiquitination to see if the susceptibility of CTLA-4 towards lysosomal 
degradation is increased or decreased.    
 
The vertebrate immune system has evolved considerably with the development of lymph nodes (Boehm 
et al., 2012) and the emergence of a specialised subset of T cells, Tregs, which regulate enhanced 
effector functions (Sansom and Walker, 2006). Clearing up longstanding issues of how the biology of 
the CTLA-4 receptor and its function are related could prove crucial in the treatment of autoimmune 
disease and cancers where Tregs are known to play an important role. Moreover, further detailed 
mechanisms into how CTLA-4 is sorted into various intracellular compartments could be used as 
checkpoints in regulating the level of CTLA-4 when designing vaccines.  
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Availability of 25-hydroxyvitamin D3 to antigen presenting cells
controls the balance between regulatory and inflammatory T cell
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Abstract
1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the active form of vitamin D, exerts potent effects on
several tissues including cells of the immune system, where it affects T cell activation,
differentiation and migration. The circulating, inactive form of vitamin D, 25(OH)D3, is generally
used as an indication of “vitamin D status”. However, utilization of this precursor depends on its
uptake by cells and subsequent conversion by the enzyme 25(OH)D3-1α-hydroxylase (CYP27B1)
into active 1,25(OH)2D3. Using human T cells, we now show that addition of inactive 25(OH)D3
is sufficient to alter T cell responses only when dendritic cells (DCs) are present. Mechanistically,
CYP27B1 is induced in DCs upon maturation with LPS or upon T cell contact resulting in the
generation and release of 1,25(OH)2D3 which subsequently affects T cell responses. In most
tissues, vitamin D binding protein (DBP) acts as a carrier to enhance the utilization of vitamin D.
However, we show that DBP modulates T cell responses by restricting the availability of inactive
25(OH)D3 to DC. These data indicate that the level of “free” 25(OH)D3 available to DCs
determines the inflammatory/regulatory balance of ensuing T cell responses.
Introduction
Besides its longstanding association with calcium regulation and bone density, more
widespread physiological roles for vitamin D are now acknowledged. This is consistent with
the broad distribution of the vitamin D receptor throughout the body1 and the association of
low vitamin D status with numerous diseases in epidemiological studies2. Interestingly, low
vitamin D appears to increase the risk of immune related diseases, including multiple
sclerosis3,4, rheumatoid arthritis (RA)5, type 1 diabetes6 and inflammatory bowel disease7.
Thus, vitamin D appears to have an important immune-regulatory function, which may have
implications for the treatment of many conditions. Consistent with this, vitamin D
supplementation in mouse models of autoimmunity has been demonstrated to have
prophylactic and therapeutic benefit8-13. In-vitro studies have also identified profound
immunological effects of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the biologically active
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Trans-endocytosis of CD80 and CD86: a molecular basis for the
cell extrinsic function of CTLA-4 **
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Abstract
CTLA-4 is an essential negative regulator of T cell immune responses whose mechanism of action
is the subject of debate. CTLA-4 also shares two ligands (CD80 and CD86) with a stimulatory
receptor, CD28. Here we show that CTLA-4 can capture its ligands from opposing cells by a
process of trans-endocytosis. Following removal, these costimulatory ligands are degraded inside
CTLA-4-expressing cells resulting in impaired costimulation via CD28. Acquisition of CD86
from antigen presenting cells is stimulated by TCR engagement and observed in vitro and in vivo.
These data reveal a mechanism of immune regulation whereby CTLA-4 acts as an effector
molecule to inhibit CD28 costimulation by the cell-extrinsic depletion of ligands, accounting for
many of the known features of the CD28-CTLA-4 system.
Keywords
CTLA-4; CD86; T cell; dendritic cell; suppression
The T cell protein CTLA-4 is essential to the prevention of autoimmune disease (1-3).
Although the molecular basis for CTLA-4 action has been suggested to be a cell-intrinsic
inhibitory signal(4) possibly mediated by the cytoplasmic domain (5), a cell-extrinsic
function for CTLA-4 is clearly evident from in vivo models (6-13). Therefore a molecular
explanation of CTLA-4 function compatible with such a cell-extrinsic mechanism is needed.
The intercellular transfer of a ligand from one cell to its receptor on a different cell is
observed in both immune settings and elsewhere (14-19). Because of its highly endocytic
behaviour, we tested whether CTLA-4 could potentially act in such a manner in order to
deplete its ligands and thereby extrinsically inhibit T cell activation via CD28. We cultured
CTLA-4-expressing (CTLA-4+) CHO cells with donor CHO cells expressing a C-terminally
tagged CD86 protein (CD86-GFP). Using a flow cytometric assay we observed substantial
transfer of CD86 into CTLA-4+ cells (Fig. 1A and fig. S1). This finding was confirmed by
confocal microscopy where acquisition of ligand by CTLA-4 caused the appearance of
CD86 containing vesicles within the CTLA-4+ cell (Fig. 1B). Treatment with the lysosomal
inhibitor bafilomycin A caused an increase in detectable CD86-GFP after transfer (Fig 1A),
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